


The Journal of the American Diabetes Association

# diabetes

Volume 25 • 1976

## INDEX

*By Subject and Author*



**Copyright 1977, by American Diabetes Association, Inc.**

# DIABETES®

## The Journal of the American Diabetes Association

EDITOR, DAVID M. KIPNIS, M.D., *St. Louis*

ASSOCIATE EDITORS: PAUL E. LACY, M.D., *St. Louis* • FRANZ M. MATSCHINSKY, M.D., *St. Louis*

ADVISORY EDITORS: CHARLES H. BEST, M.D., *Toronto* • FRANK N. ALLAN, M.D., *Boston*

ABSTRACTS EDITOR, ANTHONY S. PAGLIARA, M.D., *St. Louis* • MANAGING EDITOR, LOUIS DOYLE, *New York*

### EDITORIAL BOARD

TERM EXPIRING JUNE 1977

LESTER BAKER, M.D., *Philadelphia*

REX S. CLEMENTS, JR., M.D., *Birmingham, Alabama*

R. PHILIP EATON, M.D., *Albuquerque*

PHILIP FELIG, M.D., *New Haven*

DONALD B. MARTIN, M.D., *Boston*

GERALD M. REAVEN, M.D., *Palo Alto*

TERM EXPIRING JUNE 1978

JEROME M. FELDMAN, M.D., *Durham*

RONALD K. KALKHOFF, M.D., *Milwaukee*

JOHN H. KARAM, M.D., *San Francisco*

ARTHUR A. LIKE, M.D., *Worcester*

THOMAS J. MERIMEE, M.D., *Gainesville, Fla.*

ARTHUR H. RUBENSTEIN, M.D., *Chicago*

GEORGE STEINER, M.D., *Toronto*

TERM EXPIRING JUNE 1979

WILLIAM L. CHICK, M.D., *Wellesley*

ALLAN L. DRASH, M.D., *Pittsburgh*

CHARLES J. GOODNER, M.D., *Seattle*

LEONARD S. JEFFERSON, JR., Ph.D., *Hershey, Pa.*

BOYD E. METZGER, M.D., *Chicago*

SUMER PEK, M.D., *Ann Arbor*

DANIEL PORTE, JR., M.D., *Seattle*

ROSALYN S. YALOW, Ph.D., *New York*

DIABETES is published by the American Diabetes Association, Inc., to provide an official Journal for the Association and to furnish the medical profession with information concerning diabetes and related fields of medicine. Manuscripts received after April 1, 1977 and subsequently accepted will incur a charge of \$25. per printed page, which may be waived under special conditions at the discretion of the Editor.

Contributions are invited from practicing physicians, clinical and laboratory investigators, and others who have data of importance to offer in these fields. Manuscripts, if suitable, will be accepted providing that the text has not been printed elsewhere.

Matter appearing in DIABETES is copyrighted by the American Diabetes Association, Inc. Permission to reproduce all or parts of papers appearing in it may be granted under appropriate conditions and if proper credit is given. Such requests should be addressed in writing to the Secretary of the Association, accompanied by a letter of permission from the senior author.

All signed articles and editorials are the responsibility of the author(s) and not that of the American Diabetes Association. The Editors will be pleased to consider for publication papers presented at the Annual Meeting of the Association. *Manuscript Specifications:* The length of manuscripts (not including special articles or letters) should be limited to 5,000 words, exclusive of illustrations, etc. Exceptions to this limitation will be made at the discretion of the Editors.

Communications for the "Brief Notes and Comments" department should not exceed 1,000 words except in unusual circumstances. Figures and tables in these brief communications should be limited to one of each, and references should not exceed twenty in number.

Manuscripts should be typewritten, with double spacing, and if possible, submitted in triplicate together with three copies of figures and photomicrographs. Authors' and coauthors' degrees should be cited.

References should be presented in the style of the following examples: For

Periodicals—Banting, F. G., and Best, C. H.: The internal secretion of the pancreas. *J. Lab. Clin. Med.* 7:251-66, Feb. 1922. For Books—Allen, Frederick M.: *Studies Concerning Glycosuria and Diabetes*. Cambridge, Harvard University Press, 1913, p. 461.

An abstract or summary of the content of the paper in not more than 250 words should usually appear at the beginning. This should be self-contained and understandable without reference to the text.

Photographs, drawings, and figures should be suitable for reproduction. Photographs should be unmounted, untrimmed glossy prints. The names of authors should appear on the back. The tops of photographs and figures should be indicated.

Galley proofs are sent to the principal author of each paper, with a price list and order blank for reprints.

All manuscripts and editorial correspondence should be addressed to the Editorial Office, DIABETES, American Diabetes Association, Inc., 600 Fifth Avenue, New York, New York 10020.

### Subscription and Advertising Information

DIABETES *The Journal of the American Diabetes Association* is published every month by the Association at 600 Fifth Avenue, New York, New York 10020. © American Diabetes Association, Inc., 1977. All rights reserved under International and Pan-American Copyright Convention.

Professional Members receive the Journal as part of their membership privileges. The annual subscription rates for nonmembers are as follows: \$40.00 for one year; \$70.00 for two years; \$100.00 for three years.

Individual copies \$3.50. Foreign postage at \$4.00 per year applies to all foreign countries, including Canada, Mexico, and other countries in the Postal Union of the Americas and Spain.

Subscriptions for medical students and physicians within five years after completion of medical school and bioscientists who are predoctoral or not more than two years postdoctoral are \$20.00 per year plus foreign postage where applicable. Subscriptions in this category may be entered or renewed for only one-year terms.

Correspondence concerning subscriptions should be addressed to the Subscription Department, DIABETES.

Checks, money orders, and drafts for subscriptions should be made payable to the American Diabetes Association, Inc., and sent to the aforementioned address.

Information concerning the microfilm edition of this Journal may be obtained from the offices of University Microfilms, P. O. Box 1346, Ann Arbor, Michigan 48106.

All inquiries about advertising and other business matters should be addressed to the Managing Editor of the American Diabetes Association. The publishers reserve in their full discretion the right to accept or reject any proposed advertisement and the right to cancel any advertising contract.





# SUBJECT INDEX 1976

This index covers all reading matter in Volume 25 of **DIABETES**. Entries marked with an asterisk (\*) indicate material that appeared in the Abstracts only. The Author Index begins on page 47.

## A

### ABDOMEN

- acute
- in juvenile diabetics, \*474

### ABSCCESS

- disc space, in insulin-dependent diabetics with vertebral osteomyelitis, \*359

### ACANTHOSIS NIGRICANS

- and insulin resistance, \*636, \*1165

### ACCELERATORY FACTOR FROM GROWTH HORMONE.

See AcG

### ACETOACETATE

- and inhibition of ketogenesis in fasting humans, \*534
- utilization in sheep hind limb, \*635

### ACETONE

- release
- in obese and diabetic mice, \*374

### B-N-ACETYLHEXOSAMINIDASE

- assays
- in juvenile diabetics, 420-426

### AcG

- and glycogen synthesis, 413-418

### ACID ETHANOL

- extracts of parotid glands
- and insulin, \*328

### $\alpha^1$ -ACID GLYCOPROTEIN SYNTHESIS

- in isolated perfused rat liver
- glucagon and, 867

### ACIDOSIS, DIABETIC

- and continuous low-dose insulin infusion, \*537

### ACIDOSIS, LACTIC

- induced in alloxan-diabetic rabbits, \*534
- phenformin associated, \*328
- and serum phenformin levels, \*359
- and vasodilator therapy, \*58

### ACIDOSIS, METABOLIC

- and phenformin therapy, 292-296

### ACIDS

- arachidonic
- and platelet function in diabetics, 826-830
- beta-hydroxybutyric
- and-induced lactic acidosis in alloxan-diabetic rabbits, \*534

### EDTA

- and insulin degradation, 174, 176-178

### tannic

- and pancreatic islet cell membranes, \*376

### ACTH

- degradation by neutral peptidase, \*387

### ADDIS COUNTS

- in juvenile diabetics, \*370

### ADENOMAS

- islet cell
- and serum insulin suppressibility by somatostatin, diazoxide and phenytoin, \*354

### ADENYLATE CYCLASE

- assays
- in isolated rat islets in vitro, 486
- hepatic
- and somatostatin, \*387

### ADIPOCYTES

- of hyperobese subjects, \*357
- insulin binding to
- and age and obesity, \*76
- glucose metabolism and, \*368
- obesity and, \*1163
- insulin receptors
- hormonal regulation of, \*360
- metabolism
- and endogenous hypertriglyceridemia, \*236
- plasma membrane sulphydryl groups
- modification by insulin, \*382
- protein phosphorylation in
- and insulin, epinephrine, and propranolol, \*337
- rat
- and anti-insulin receptor antibodies, \*322
- and insulin binding, glucose transport and glucose oxidation, obesity and, \*1163
- insulin insensitivity in, \*1164-1165
- insulin receptors and glucose metabolism during fasting and \*321

### ADIPOSE TISSUE

- cyclic AMP
- activation and purification of, \*386
- diabetic and normal rat
- and insulin and lipolytic hormone effects on cyclic AMP phosphodiesterase activity, \*77
- lipogenesis and enzymes
- obesity and, \*634
- metabolism
- and hyperobesity, \*357
- rat
- glucose uptake and protein synthesis in, \*366

### ADOLESCENTS

- oral glucose loading in
- and insulin response to intravenous glucagon, \*537

## DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
February, 81-160  
March, 161-240  
April, 241-320  
Supplement 1, 321-396

May, 397-476  
June, 477-544  
July, 545-644  
August, 645-740

September, 741-804  
Supplement 2, 805-930  
October, 931-1010  
November, 1011-1090  
December, 1091-1170

- ADP  
and platelet aggregation  
and diabetes, 826-830
- ADRENAL MEDULLA  
and neurotensin-induced hyperglycemia, \*337
- ADRENALECTOMY  
and glucagon response to insulin-induced hypoglycemia, \*315  
in rats  
and skeletal muscle amino acid release and protein turnover, \*333
- ADRENERGIC BLOCKADE  
and smoking  
and norepinephrine and epinephrine release, \*1083
- ADRENERGIC BLOCKING AGENTS  
and scorpion-toxin-induced glucagon release, 647
- ADRENERGIC MECHANISMS  
and insulin-induced hypoglycemia, \*1083-1084
- ADRENERGIC RECEPTORS  
and hyperobesity, \*357  
and insulin secretion, \*384
- $\beta$  ADRENORECEPTOR STIMULANTS  
intrapaneatic infusion of  
and glucagon and insulin secretion, \*155-156
- AGE  
and diabetes control  
and growth hormone levels, 168-172  
at diabetes diagnosis  
in retinopathy study, 554-560  
and diabetes prevalence in Greek rural population by sex, \*358  
in diabetes prevalence study of Michigan school-age children, 124-126  
of fetal pancreatic transplants  
and streptozotocin diabetes, 59  
and gastric inhibitory polypeptide in maturity-onset diabetes, 933  
and glucose tolerance relationship to time of day and time since last meal, 937, 938
- and insulin binding to isolated adipocytes, \*76  
and insulin and free fatty acid levels during oral glucose tolerance tests in healthy children, 505-508  
and insulin response of gestational diabetics, \*324  
of islets of Langerhans donor and transplantability in rats, \*338  
of onset of hyperinsulinism in Pima Indians, \*384  
and pancreatic beta-cell stimulation studies, 11-14
- AGING  
and biphasic insulin release, \*324  
in diabetic and nondiabetic Chinese hamsters  
and changes in intervertebral discs and spondylosis, 477-483
- ALANINE  
and amino acids, \*317  
infusions  
in alloxan-diabetic dogs, \*236  
and growth hormone, insulin and glucose in protein-calorie malnutrition, \*75  
metabolism  
diabetes and, \*333  
fasting and, \*358
- ALANINE- $I-C^{14}$   
 $C^{14}$  transfer to hepatic and blood glucose from  
in diabetic rats, \*381
- L-ALANINE- $U-^{14}C$   
and insulin infusion study in dogs, 284-285
- ALBUMIN  
excretion  
and diabetes control, 874  
and insulin adsorbance to polyvinyl-chloride surfaces, 72-74  
transcapillary escape rate of  
in juvenile diabetics, 884-889
- ALEUTIANS  
diabetes survey among, \*377
- ALLERGY  
to insulin  
and glucagon secretion and plasma insulin, \*363
- and insulin therapy, \*75  
and "single peak" and "single component" insulin, \*326
- ALLOXAN  
and D-glucose anomers  
and glucose-induced insulin secretion and biosynthesis in vitro, 574-578  
and inhibition of glucose-induced insulin secretion  
and site of barbituric acid protection against, \*345  
and pancreatic isletitis in mice, \*344  
and rat pancreatic islet permeability and hexose transport, \*75-76
- ALLOXAN DIABETES  
in dogs  
and acute-and late-phase insulin secretion and glucose tolerance, 161-165  
and alanine infusion, \*236  
and gluconeogenesis from glycerol at rest and during exercise in, \*539  
and heterogeneity of plasma glucagon immunoreactivity in, \*539-540  
electrolyte balance and renin in, \*348  
and macromolecular transport across vascular endothelium, \*386  
in offspring of rats with induced latent diabetes, \*474  
in rabbits  
and induced lactic acidosis, \*534  
rat plasma  
inhibition of lymphocyte blastogenesis by factors in, 614-621  
in rats  
and is transplantation of neonatal pancreas, 180-189  
and is transplantation of organ-cultured neonatal pancreas, \*798  
and liver plasma membrane phospholipids, \*351  
and pancreas transplantation, \*797  
and somatostatin, \*356
- ALPHA-ADRENERGIC RECEPTOR BLOCKADE  
and plasma glucose, free fatty acid, and glucagon responses to epinephrine, 68, 70

DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
February, 81-160  
March, 161-240  
April, 241-320  
Supplement 1, 321-396

May, 397-476  
June, 477-544  
July, 545-644  
August, 645-740

September, 741-804  
Supplement 2, 805-930  
October, 931-1010  
November, 1011-1090  
December, 1091-1170

**ALPHA-ADRENERGIC RECEPTORS**  
and abnormal insulin secretion in  
diabetics, \*1084

**AMERICAN DIABETES ASSOCIATION**  
Annual Awards Banquet, 319  
annual meetings  
Thirty-fifth, 475  
Thirty-sixth, 78, 158-159, 319, 541,  
638, 800, 802  
Thirty-seventh, 1087  
Committees, Editorial Boards  
1976-77, 1165-1169  
Diabetes Day, 641, 644  
DIABETES index, 541  
Investigator Program  
deadline for applications, 638-639,  
737-738, 804  
Lilly Award, 240, 738  
deadline for applications, 640-641,  
804  
Necrology, 78, 160, 240, 320, 541,  
639, 1088  
New Members, 159, 240, 319-320,  
475, 541, 639, 738, 740, 1009,  
1088  
news of Affiliate Associations, 78, 159,  
240, 740, 1009, 1170  
News Notes, 78, 160, 240, 320, 476,  
541, 641, 644, 740,  
1009-1010, 1170  
Officers and Board of Directors,  
1976-1977, 638  
Personals, 160, 1170  
policy statement on blood glucose con-  
trol in diabetes, 237-238  
Postgraduate courses  
Twenty-third, 78  
Twenty-fourth, 1170, 1187-1188  
Research and Development Awards,  
319, 737  
applications deadline, 804, 1009  
Research Grants Program, 78, 1170  
Research Symposia  
Fourteenth, 475-476, 638-639, 738,  
799, 801, 803-804  
Reviewers of manuscripts and books,  
152-153  
summer camp list, 476  
travel grants for ninth IDF Congress,  
541

**AMERICAN INDIANS**  
and diabetes  
diagnosis and management stan-  
dards, 528-531

**AMINO ACIDS**  
and alanine infusion, \*317  
analysis  
in <sup>75</sup>Se-selenomethionine incorpo-  
ration into human apopro-  
teins study, 34, 36-39  
branched chain  
insulin and diabetes effect on, \*332  
utilization during exercise, \*154  
-induced insulin and glucagon release  
in genetically obese rats, \*356  
-induced insulin release  
and theophylline, \*473  
maternal and fetal insulin response to  
\*366  
metabolism  
in isolated perfused rat liver,  
glucagon and, 865-870  
and ketone infusions, \*76  
metabolism in muscle  
and brief starvation, \*317  
skeletal muscle release  
in fasted normal and adrenaec-  
tomized rats, \*333

**AMINOPHYLLINE**  
and arginine-induced insulin secretion  
and hyperthyroidism, 966

**AMPUTATIONS**  
in indigent diabetic population, \*343

**AMYLASE**  
content of infant human pancreas tis-  
sue, 1125-1126

**AMYLOID**  
infiltration of islets of Langerhans  
in nonhuman primates, \*367

**AMYLOIDOSIS**  
of islets of Langerhans, \*367

**AMYOTROPHIC LATERAL  
SCLEROSIS**  
and carbohydrate metabolism abnor-  
malities, 1055-1063

**ANGIOPATHY, DIABETIC**  
and heart abnormalities, 207, 214  
and von Willebrand factor  
and growth hormone, \*347  
wound healing as model for study of,  
811-819

**ANGIOTENSIN II**  
vascular reactivity to  
and diabetes, 268-274

**ANTIBIOTICS**  
and hyperlipoproteinemia type II  
therapy, \*637

**ANTIBODIES**  
anti-insulin IgE  
and insulin therapy, \*75  
anti-insulin receptor  
effect on isolated adipocytes, \*322  
to glucagon, 136-137  
in juvenile diabetics, \*334  
and immunologic indicators in insulin  
and insulin derivatives,  
397-403  
to insulin  
formation rates in juvenile diabet-  
ics, \*362  
in insulin-treated diabetics, \*367  
insulin binding  
and fasting hypoglycemia, \*635  
and insulin resistance  
and acanthosis nigricans, \*636  
and islet allograft destruction in toler-  
ant rats, \*338  
and vitiligo in juvenile diabetics, \*375

**ANTICOAGULANTS**  
and hyperlipoproteinemia type II  
therapy, \*637

**ANTIGENS**  
histocompatibility  
in diabetic identical twins, \*236  
uveoretinal  
and induced leucocyte-migration  
inhibition in diabetic ret-  
inopathy, 1106-1108

**ANTIHISTAMINES**  
cyproheptadine  
and proinsulin synthesis, \*343

**ANTISERUM**  
in insulin immunoassays, 398

**APGAR SCORE**  
correlations with blood glucose gesta-  
tional age, and birth weight  
in premature infants, 431

**APOLIPOPROTEINS**  
in sucrose-fed rats, \*353

**APOPROTEINS**  
<sup>75</sup>Se-selenomethionine incorporation  
into, 32-42, 679-690

DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
February, 81-160  
March, 161-240  
April, 241-320  
Supplement 1, 321-396

May, 397-476  
June, 477-544  
July, 545-644  
August, 645-740

September, 741-804  
Supplement 2, 805-930  
October, 931-1010  
November, 1011-1090  
December, 1091-1170

- and characterization of metabolism of very-low-density and low-density lipoproteins in vivo and in vitro in, 44-50
- ARACHIDONIC ACID**  
and platelet function  
and diabetes, 826-830
- ARGININE**  
blood glucagon response to in pancreatectomized and streptozotocin diabetic monkeys, \*339  
and immunoreactive glucagon levels in obese mice, \*361  
-induced insulin and glucagon release and somatostatin and somatostatin analogs, \*535  
-induced insulin release and pancreatic islet cyclic nucleotides, 256-259  
infusion  
and carbohydrate tolerance, \*361  
and islet-cell tumor, 410  
intravenous, plasma glucagon responses to  
and acute insulin withdrawal and administration in insulin-dependent diabetics, 955-959  
plasma insulin response to and hyperthyroidism, 961-968  
-stimulated glucagon and insulin secretion  
and contraceptive steroids, \*535  
-stimulated glucagon response insulin and, 227-229  
and streptozotocin, 279-280  
-stimulated hyperglucagonemia in diabetic Pima Indians, 404-407
- ARTERIES**  
brachial  
and glucagon infusion and forearm tissue metabolism, 131-132  
growth  
and growth hormone and insulin, 1011-1016  
norepinephrine, epinephrine, and dopamine  
in long-term diabetics, 6-10  
renal  
ligation, and plasma glucagon levels, \*316
- ARTERIOGRAPHY**  
and assessment of peripheral vascular disease in diabetics, 307-314
- ARTHRITIS**  
and intestinal-bypass procedure for morbid obesity, \*318
- ATHEROSCLEROSIS**  
and cholesterol synthesis during hyperglycemia, \*324  
and myocardial infarction  
and diabetic capillaropathy, 928-930  
renal arterial  
and hypertension in diabetics, \*378
- ATP**  
and hepatic responses to glucagon, \*535-536
- ATP CITRATE-LYASE**  
in adipose tissue  
and obesity, \*634
- ATROPINE**  
and pancreatic glucagon levels in rats, \*374  
and scorpion-toxin-induced glucagon release, 647, 649
- AUTOANALYZER**  
and blood glucose monitoring in symptomatic hypoglycemia, 984-987  
in refraction and serum glucose concentration studies, 29-31  
and serum glucose assays, 202
- AUTOANTIBODIES**  
in diabetics, 223-226
- AUTOIMMUNITY**  
and diabetes  
and peripheral T-lymphocytes in juvenile-onset and maternity-onset diabetics, 223-226  
and diabetes pathogenesis and subpopulations of peripheral lymphocytes in juvenile diabetics, 101-103  
and vitiligo in juvenile diabetics, \*375
- AUTOPSY**  
of spontaneously diabetic guinea pigs, 435-439
- B**
- BABOONS**  
glomerulosclerosis in "secondary" diabetes in, \*349
- and somatostatin  
and hemostasis, \*156
- BARBITURIC ACID**  
and alloxan inhibition of glucose-induced insulin secretion, \*345
- BASEMENT MEMBRANE**  
capillary  
in children, carbohydrate metabolism and, 650-659, 661-666  
capillary, thickening  
fixation and morphometric data comparisons, 604-612  
changes in diabetes  
biochemical basis of, 909-912  
glomerular  
and diabetes, 920-924  
quantitation of thickness after renal transplantation, \*357  
kidney  
alterations in kidneys transplanted into diabetics, 709-712  
immunopathology in diabetics, 701-707  
muscle capillary  
and hemoglobin A<sub>1c</sub> levels, 231-232  
synthesis by diabetic rat glomeruli insulin and, \*349  
thickening, 1  
and diabetic microangiopathy, 925-927  
in spontaneously diabetic *Mysomys albicaudatus*, 444-448
- BIGUANIDES**  
and mitochondrial calcium uptake, \*360  
and postprandial hypoglycemia, 729
- BILIRUBIN**  
values in premature infants, 431
- BIOFEEDBACK**  
and diabetes control, \*350
- BLADDER**  
innervation in diabetics  
early detection of, 1100-1105
- BLASTOGENESIS**  
by rat lymphocytes  
inhibition by alloxan diabetic rat plasma, 614-621

DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80	May, 397-476	September, 741-804
February, 81-160	June, 477-544	Supplement 2, 805-930
March, 161-240	July, 545-644	October, 931-1010
April, 241-320	August, 645-740	November, 1011-1090
Supplement 1, 321-396		December, 1091-1170

**BLINDNESS**

and urine testing, \*363

**BLOOD**

coagulation and platelet function  
and somatostatin, \*156  
fibrinolytic activity  
and diabetes, 807-809  
flow  
hepatic, and insulin infusion in  
dogs, 285-286  
retinal, diabetes and, 839-843  
glucagon  
and arginine and somatostatin in  
pancreatectomized and strep-  
tozotocin diabetic monkeys,  
\*339  
hemoglobin  
in diabetic identical twins, \*318  
in diabetic mice, 1-4  
hemoglobin A<sub>1c</sub>  
formation in diabetic pregnancy,  
\*335  
in insulin-dependent and  
independent diabetics,  
890-896  
and pregnancy in normal, gesta-  
tional diabetic and diabetic  
women, 1118-1122  
hemostasis  
and somatostatin, \*156  
insulin and free fatty acids  
in obese rats, \*77  
insulin and glucose  
and diet composition, \*361  
ketone levels and kinetics  
and diabetes and insulin, 778-779  
lactate  
and induced lactic acidosis in  
alloxan-diabetic rabbits, \*534  
and phenformin, \*328  
oxygen transport system  
and muscle metabolism of normals  
and diabetics, 914-919  
peripheral lymphocytes  
in juvenile diabetes, 101-103  
platelet aggregation  
and growth hormone, \*347  
and somatostatin, \*472  
platelets  
prostaglandin synthetase in diabet-  
ics, \*347  
red cell aggregation and deformability  
and diabetes, 897-901  
red cell oxygen affinity  
and diabetic control, 832-834  
red cell reduced glutathione

and streptozotocin, 216-221  
samples  
capillary and venous, serum insulin  
in, \*354  
in insulin secretion and glucose tol-  
erance study in mild alloxan  
diabetic dogs, 162-165  
viscosity  
and diabetic microangiopathy,  
858-863

**BLOOD GLUCOSE. *see also* Blood sugar**

and buformin therapy for reactive  
hypoglycemia, \*734  
C<sup>14</sup> transfer from alanine-I-C<sup>14</sup> to  
in diabetic rats, \*381  
continuous extracorporeal monitoring  
of, 81-89  
and continuous low-dose insulin infu-  
sion, \*537  
control, 237-238  
in dogs, \*316-317  
and hemoglobin glycosylation, \*335  
preserved, in insulin-dependent  
diabetes, \*362  
and diabetes control, 168-172  
in encephalomyocarditis virus-  
infected mice, 190-197  
and exercise, \*1084  
fasting  
and lipid abnormalities, \*368  
in pancreatic islet transplanted  
diabetic rats, 944-947  
and glycerol administration, \*540  
homeostasis  
and glucagon, \*471  
in induced obesity in rats, \*77  
and insulin  
and blood pressure, 92-93  
levels  
and arginine-induced insulin re-  
lease, 961-968  
in community screening for dia-  
betes, 1110-1116  
in tolbutamide-treated diabetics,  
1144-1145  
monitoring  
and hypoglycemia, 984-987  
optical, \*325  
normal  
and diabetes diagnosis, \*362  
and plasma epinephrine  
and insulin-induced hypoglycemia,  
\*1084-1085  
in premature infants, 429-430  
and psychological performance in

juvenile diabetics, \*334  
rapid on-line analyzer, \*358  
regulation  
and hyperglucagonemia in normal,  
obese, and diabetic subjects,  
\*539

**BLOOD PRESSURE. *see also***

Hypertension  
and cardiac denervation in diabetic au-  
tonomic neuropathy, 750  
and diabetes, 268-274  
diurnal variations in  
and autonomic neuropathy, 93  
and familial dysautonomia  
and norepinephrine release, \*1083  
in hypertension, pheochromocytoma  
and depression  
plasma norepinephrine and, \*1082  
and insulin  
in diabetics with autonomic  
neuropathy, 90-94  
of tolbutamide-treated diabetics,  
1135-1137

**BLOOD SUGAR**

and biguanides  
and mitochondrial calcium uptake,  
\*360  
capillary  
and oral glucose tolerance tests in  
normal children, \*378  
control  
and biofeedback, \*350  
fasting  
and hemoglobin A<sub>1c</sub> levels, 230-232  
fibrin deposits  
and diabetes, 807-809  
levels  
and ocular palsies, 462  
in pancreatic islet transplanted rats,  
\*316  
somatostatin and  
in diabetic children, 550-552  
and vasodilator therapy  
and lactic acidosis, \*158  
and vision, 29-31

**BODY**

forearm tissue metabolism  
and glucagon, 128-134  
growth  
and somatomedin in diabetic rats,  
\*335  
lower extremities  
hyperbaric oxygen treatment of ul-  
cers of, \*364

**DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE**

January, 1-80  
February, 81-160  
March, 161-240  
April, 241-320  
Supplement 1, 321-396

May, 397-476  
June, 477-544  
July, 545-644  
August, 645-740

September, 741-804  
Supplement 2, 805-930  
October, 931-1010  
November, 1011-1090  
December, 1091-1170



weight  
and hyperlipidemia of pregnancy,  
\*369  
and hypoglycemia in children, \*734  
and somatomedin activity in dia-  
betic rats, 519  
of tolbutamide-treated patients,  
1139  
weight loss  
and chronic glucagon excess, \*341  
metabolism and, \*361  
and rice diet, \*472-473  
and triglycerides in acute starvation,  
\*388

# BONES

vertebral osteomyelitis in insulin-  
dependent diabetics, \*359

# BOOK REVIEWS

Complications of Diabetes, edited by  
Harry Keen and John Jarrett,  
533  
Diabetes Guidebook, Diet Section, by  
John K. Davidson and Mary  
Goldsmith, 470  
Diabetes Mellitus Case Studies, by  
Buris R. Boshell, 633  
Diabetes and Metabolic Disorders:  
Continuing Education Re-  
view, by J.A. Colwell and G.  
Lizarralde, 233  
Diabetic Retinopathy: Clinical Evalua-  
tion, Prognosis and Treat-  
ment with Photocoagulation,  
by S. Riaskoff, 1007  
Refined Carbohydrate Foods and Dis-  
ease: Some Implications of  
Dietary Fibre, edited by  
D.P. Burkitt and H.C.  
Trowell, 1086

# BRAIN

dysfunction  
and postgastrectomy hypoglycemia,  
\*734  
metabolism  
and insulin, 387  
potassium and sodium transport  
insulin and, 758-762

# BREAST CANCER

insulin receptors and, \*380

# BUFORMIN

therapy  
and reactive hypoglycemia, \*734

# BUTANOL EXTRACTABLE IN- HIBITOR, \*1007

# C

# CALCIUM

deprivation  
glucose-stimulated glucagon release  
during, \*473  
extracellular  
metabolic effects on fat cells, \*372  
and immunoreactive insulin and  
glucagon secretion  
and somatostatin, 1031-1039  
infusion  
and islet-cell tumor, 410  
islet-cell tumor, insulin and proinsu-  
lin release during, \*536  
ionophore  
and somatostatin inhibition of insu-  
lin and glucagon secretion in  
rat islet culture, \*536  
-stimulated insulin release  
and somatostatin, \*472  
uptake  
in glucose-stimulated pancreas is-  
lets, \*346  
mitochondrial, biguanides and,  
\*360  
uptake by isolated islets of Langerhans  
somatostatin and, 1035

# CALCIUM PHOSPHATE

and erythrocytic oxygen release  
in diabetics, 836-837

# CALORIES

and glucose tolerance and insulin se-  
cretion, \*361  
increased  
and diabetes control, \*390  
metabolic effects in man, \*156  
-protein malnutrition in adults  
and insulin secretion and glucose  
tolerance, \*539  
restriction  
and insulin binding in obese diabet-  
ics, \*1163

# CAPILLARIES

basement-membrane thickening  
and diabetic microangiopathy,  
925-927  
fixation and morphometric tech-  
niques, 604-612  
basement-membrane thickness

in diabetic and nondiabetic chil-  
dren, carbohydrate  
metabolism and, 650-659,  
661-666

blood samples  
serum insulin, \*354  
blood sugar  
and oral glucose tolerance tests in  
normal children, \*378  
morphogenesis  
and wound healing in diabetics,  
817-819

# CAPILLAROPATHY, DIABETIC

and myocardial infarction, 928-930

# CARBOHYDRATE METABOLISM

and amyotrophic lateral sclerosis and  
Parkinsonism-dementia,  
1055-1063  
and capillary basement-membrane  
thickness  
in children, 650-659, 661-666  
and ethanol, \*318  
hepatic  
and parasympathetic nervous sys-  
tem, \*332  
and increased hemoglobins, 1  
and insulin and glucagon, \*323  
and mazindol in obesity, \*235-236  
in pancreatic islet-transplanted dia-  
betic rats, \*389  
and periodontal disease, \*390  
and pregnancy  
and relationships between plasma  
insulin and proinsulin in  
normal and diabetic subjects,  
\*317  
and salivary gland insulin, \*328  
and somatostatin, 1097-1098

# CARBOHYDRATES See also Carbohy- drate Metabolism

deprivation  
and reactive hypoglycemia, \*734  
dietary  
and insulin or sulfonylurea dosages,  
\*369  
intolerance  
in gonadal dysgenesis, \*379  
and pancreatic cancer, \*391  
restriction  
and glucose tolerance in normal  
men and reactive hypo-  
glycemic patients, \*153  
and glucose tolerance in normal  
men and hypoglycemic pa-  
tients, \*734

# DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
February, 81-160  
March, 161-240  
April, 241-320  
Supplement 1, 321-396

May, 397-476  
June, 477-544  
July, 545-644  
August, 645-740

September, 741-804  
Supplement 2, 805-930  
October, 931-1010  
November, 1011-1090  
December, 1091-1170

simple and complex  
plasma glucose and insulin re-  
sponses to oral administration  
of, 741-746  
tolerance  
and oral contraception, \*157  
and serotonergic activation, \*361

# CARCINOID SYNDROME

and intravenous glucose and insulin  
and plasma tryptophan and  
tyrosine, \*536

# CARCINOMA

breast  
insulin receptors and, \*380  
islet cell  
and serum insulin suppressibility by  
somatostatin, diazoxide and  
phenytoin, \*354  
pancreatic  
glucose tolerance, plasma insulin,  
and glucagon responses in,  
\*391  
in tolbutamide-treated patients, 1141,  
1143-1144

# CARDIOTHORACIC RATIO

of tolbutamide-treated diabetics, 1137

# CARDIOVASCULAR SYSTEM

and diabetic autonomic neuropathy  
and postural hypotension, 90-94  
and hypoglycemic agents in adult-  
onset diabetics, 1129-1153  
norepinephrine, epinephrine, and  
dopamine  
in long-term diabetics, 6-10, \*1083

# CARNITINE

hepatic  
and ketogenesis in rats, \*330

# CARTILAGE

growth  
and serum somatomedin activity in  
streptozotocin diabetic rats,  
516-526  
metabolism  
serum inhibitor of, \*1007  
porcine, somatomedin assays  
in neonates, \*1007  
somatomedin action on  
and steroids, \*1005  
somatomedin inhibitors and, 995  
and somatomedin-related peptides,  
998-1001

# CASE REPORTS

assessment of peripheral vascular dis-  
ease in diabetics, 308-314  
benign mesothelioma  
and hypoglycemia, 202-205  
buformin therapy for reactive hypo-  
glycemia, \*734  
cerebral edema and diabetic  
ketoacidosis therapy, 111-114  
diabetic retinopathy and  
leucocyte-migration inhibition  
induced by uveoretinal an-  
tigen, 1106-1108  
diabetic retinopathy and multiple  
daily insulin injections,  
463-468  
familial hyperproinsulinemia, \*635  
florid diabetic retinopathy and photo-  
coagulation, 104-110  
hyperbaric oxygen treatment of dia-  
betic ulcerations, \*364  
hyperglucagonemia and glucose  
homeostasis and insulin se-  
cretion, \*341  
hyperlipemia and hypolipemia in  
diabetic ketosis, \*352  
hypoglycemia  
and effect of diphenylhydantoin on  
glucose tolerance, \*735  
insulin-degrading enzyme, \*334  
insulin-dependent diabetics with ver-  
tebral osteomyelitis and disc  
space abscess, \*359  
insulin-induced lipatrophy therapy,  
1052-1054  
insulin reactions and decreased  
glucagon secretion and ele-  
vated plasma insulin \*363  
insulin resistance and acanthosis nigri-  
cans, \*636  
islet-cell tumor producing glucagon,  
insulin, and gastrin  
and mechanisms controlling  
glucagon secretion, 408-419  
Laron's syndrome with increased im-  
munoreactive plasma and  
urinary growth hormone,  
\*1006  
nodular intercapillary glomerulo-  
sclerosis in diabetes second-  
ary to chronic calcific pan-  
creatitis, 713-716  
ocular palsies in diabetic children,  
459-462  
phenformin-associated metabolic  
acidosis 292-296

protein-sparing modified fast in dia-  
betics, 496-501  
reduced plasma norepinephrine re-  
sponse to standing in au-  
tonomic dysfunction, \*1085  
reversed jejunal segment as treatment  
for postoperative reactive  
hypoglycemia \*536, \*733  
total cardiac denervation in diabetic  
autonomic neuropathy,  
748-751  
vasodilator therapy in lactic acidosis,  
\*158  
visceral neuropathy detection in  
diabetics, 1100-1105

# CATARACTS

and diabetes, \*371

# CATECHOLAMINES

and alpha-adrenergic activity  
and abnormal insulin secretion in  
diabetics, \*1084  
in heart tissues of long-term diabetics,  
6-10  
urinary excretion  
and intravenous glucagon, \*318

# CATS

and cardiac muscle responsiveness to  
insulin, \*636

# CENTRAL NERVOUS SYSTEM See

also Brain  
glucoregulator receptor  
and hypophysectomy, \*158

# CEREBRAL EDEMA

and diabetic ketoacidosis therapy,  
111-115

# CEREBRAL GIGANTISM

and somatomedin activity, 996

# CEREBROSPINAL FLUID

insulin injection into  
and pancreatic insulin secretion,  
\*322

# CHARCOAL-COATED DEXTRAN METHOD

and unstable-diabetes therapy, \*329

# CHICK

embryo heart cells  
insulin receptors of, \*365

# DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
February, 81-160  
March, 161-240  
April, 241-320  
Supplement 1, 321-396

May, 397-476  
June, 477-544  
July, 545-644  
August, 645-740

September, 741-804  
Supplement 2, 805-930  
October, 931-1010  
November, 1011-1090  
December, 1091-1170



# SUBJECT INDEX 1976

- CHILDREN.** *see also* Diabetes, Juvenile  
and acute abdomen and diabetes, \*474  
and "chemical" diabetes, \*635  
diabetes prevalence in Michigan schools, 122-127  
diabetic  
and somatostatin, 550-552  
diabetic and nondiabetic  
and carbohydrate metabolism and capillary basement-membrane thickness, 650-659, 661-666  
of diabetic parents  
frequency of diabetes in, \*335  
and growth disorders  
and somatomedin activity, 996-997  
and growth retardation  
and glucocorticoid therapy, \*1004-1005  
healthy  
and insulin and free fatty acid levels during oral glucose tolerance tests, age and, 505-508  
hypopituitary  
and hypoglycemia, \*537, \*734  
and role of growth hormone and cortisone in glucose and gluconeogenic substrate regulation, \*733-734  
and insulin-induced lipoatrophy therapy, 1052-1054  
and ketoacidosis therapy  
and cerebral edema, 111-115  
normal  
and capillary blood sugar and serum insulin values during oral glucose tolerance tests, \*378  
oral glucose loading in  
and insulin response to intravenous glucagon, \*537  
with protein-calorie malnutrition and alanine infusion, \*75  
and vitiligo  
and diabetes development, \*375
- CHINESE HAMSTERS**  
aging changes in intervertebral discs and spondylosis in  
and diabetes, 477-483  
diabetic  
and liver enzyme activity before and after hyperglycemia onset, \*358  
and ultrastructural lesions, \*352  
and ketonuria  
and dietary fat reduction, \*364  
normal and diabetic pancreatic islets  
response to long-term culture, \*371  
streptozotocin effects on plasma, pancreatic, and stomach glucagon level in, \*390
- CHOLECYSTOKININ**  
and glucagon secretion in dogs, \*360  
octapeptide of  
and insulin and glucagon secretion in dog, \*154
- CHOLESTEROL**  
in juvenile diabetics, \*355  
levels  
diabetes control and, \*368  
metabolism  
and diabetes control, \*324
- CHOLESTYRAMINE**  
and hyperlipoproteinemia type II therapy, \*637  
nicotinic acid, and polyunsaturated fatty acids  
in hypercholesterolemia therapy, \*154
- CHOLINERGIC BLOCKADE**  
and insulin secretion, \*361
- CHONDROCYTES**  
rabbit  
response to rat liver somatomedin, \*1007
- CHROMATOGRAPHY**  
gas-liquid  
in D-glucose anomer metabolism study, 452, 453  
gel-filtration column  
of gastrointestinal tissues of dogs, 1019  
hemoglobin  
of pregnant women, 1118-1122  
Sephadex G-75  
and insulin degradation in isolated liver cells, 174-178
- CHROMIUM**  
and insulin aggregation, \*353
- CIGARETTE SMOKING**  
frequency among insulin-treated diabetics, 717-718  
and retinal blood flow measurement in diabetics, 839-843
- CINEFLUORESCIN ANGIOGRAPHY**  
and retinal blood flow measurement in diabetics, 839-843
- CITRATE ANTICOAGULANT**  
in extracorporeal monitoring of animal blood, 86-89
- CMRL 1066**  
as tissue culture medium for long-term perfusion of isolated rat islets in vitro, 484-492
- COLCHICINE**  
intravenous  
and inhibition of glucose-induced insulin secretion, \*325
- COLLAGEN**  
biosynthesis enzymes  
in kidneys of streptozotocin-diabetic rats, 1066-1070  
and platelet function  
and diabetes, 826-830  
synthesis  
and wound healing in diabetics, 815-817
- COLLAGENASE**  
-cultured rat islets  
glucose effect on beta cells of, \*381
- COLLAGENASE DIGESTION TECHNIQUE**  
and neonatal islet transplantation, \*376
- COMPLEMENT**  
levels  
in diabetes, \*374
- COMPUTERS**  
artificial endocrine pancreas  
and comparison of insulin infusion routes, 691-699
- CORONARY ARTERY DISEASE**  
in diabetics and nondiabetics, \*346
- CORTISOL**  
and adipocyte insulin receptors, \*360  
and insulin-induced hypoglycemia, \*1083-1084  
and insulin resistance in diabetic ketoacidosis, \*365  
and somatomedin action in vitro, \*1005
- CORTISONE**  
and glucose and gluconeogenic substrate regulation in fasted

## DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80	May, 397-476	September, 741-804
February, 81-160	June, 477-544	Supplement 2, 805-930
March, 161-240	July, 545-644	October, 931-1010
April, 241-320	August, 645-740	November, 1011-1090
Supplement 1, 321-396		December, 1091-1170

- hypopituitary children,  
\*733-734
- CRITERIA MAPPING**  
and diabetes management, \*235
- CRYOPROTEINS**  
in intestinal-bypass patients with ar-  
thritis, \*318
- CYCLIC ADENOSINE**  
3',5'-MONOPHOSPHATE  
and arginine-induced insulin secretion  
and hyperthyroidism, 967  
of pancreatic islets  
and tolbutamide- and arginine-  
induced insulin release,  
256-259  
phosphodiesterase  
activation and purification in  
adipose tissue, \*386  
and insulin and lipolytic hormones,  
\*77  
and phosphodiesterase inhibitors  
and DNA replication in isolated rat  
islets of Langerhans, \*379  
and phosphorylation of protein  
and insulin release, \*374  
-stimulated protein kinase activity  
in isolated rat islet secretory vesi-  
cles, \*386
- CYPROHEPTADINE**  
proinsulin synthesis and, \*343
- CYSTIC FIBROSIS**  
and hemoglobin A<sub>1c</sub> levels, 895
- CYTOCHALASIN B**  
hexose transport system sensitivity to  
insulin and, \*336  
-stimulated insulin release  
and somatostatin, \*472
- CYTOCHALASINS**  
and insulin and growth hormone bind-  
ing, \*321
- D**
- 2-DEOXY-D-GLUCOSE**  
and inhibition of streptozotocin dia-  
betes in rats, 595-602
- DEPRESSION**  
and blood pressure  
and plasma norepinephrine, \*1082  
and L-tryptophan  
and hypoglycemia, \*369
- DEUTERIUM OXIDE**  
and insulin binding, \*321
- DEXAMETHASONE**  
and glucagon effects on protein and  
amino acid metabolism,  
865-870  
and triglyceride secretion rates, lipo-  
protein lipase, and plasma  
lipoproteins in rats, \*634
- DIABETES MELLITUS**  
and abnormal insulin secretion  
and alpha-adrenergic receptors,  
\*1084  
adult-onset  
and vascular complications, tol-  
butamide and, 1129-1153  
in American Indians  
diagnosis and management stan-  
dards, 528-531  
and arginine-stimulated glucagon re-  
sponse  
and insulin, 227-229  
and autonomic neuropathy  
and cardiac denervation, 748-751  
in baboons  
and glomerulosclerosis, \*349  
and basement membrane changes  
biochemical basis of, 909-912  
and beta-cell function  
and plasma C-peptide response to  
glucagon, \*329  
and biphasic insulin release, \*324  
and bladder and urethral innervation,  
1100-1105  
and blood glucose control, 237-238  
and blood oxygen transport system  
muscle metabolism during rest and  
exercise and, 914-919  
and blood red-cell aggregation and de-  
formability, 897-901  
and capillary basement-membrane  
thickening  
fixation and morphometric data  
comparisons of, 604-612  
and cataracts, \*371  
and cell-mediated immunologic re-  
sponses, \*538  
chemical, \*635  
and insulin responses and resis-  
tance, \*383  
and retinal circulation time, 903-907  
in Chinese hamsters  
and aging changes in intervertebral  
discs and spondylosis,  
477-483  
and dietary fat, \*364  
and liver enzyme activity before and  
after hyperglycemia onset,  
\*358  
and complement activity, \*374  
complications, 1, 785  
contagious, in guinea pigs, 435  
control  
and albumin excretion, 874  
and biofeedback, \*350  
and cholesterol metabolism, \*324  
and hemoglobin glycosylation, \*335  
and insulin-degrading enzyme, \*334  
and triglyceride, cholesterol and in-  
sulin levels, \*368  
and coronary artery disease, \*346  
and coronary heart disease, 561-565  
development  
Israeli survey, \*76  
and stress and urine glucose levels,  
\*356  
diagnosis  
and normal fasting blood glucose,  
\*362  
and dichloroacetate therapy, \*328  
and diet  
and ethanol, \*342  
and "Exchange Lists for Meal Plan-  
ning," 532-533  
duration and age at diagnosis  
and retinopathy, 554-560  
and education, \*350  
and detection, \*350  
encephalomyocarditis virus-induced  
and hereditary and environmental  
factors, 190-197  
and endogenous hyperglycemia  
and glucagon, \*236  
and endotemia  
and glucoregulation, \*383  
and ethanol-induced alterations of glu-  
cose tolerance, postglucose  
hypoglycemia, and insulin  
secretion, \*735  
and exercise  
and fuel utilization, \*154  
metabolism, insulin deficiency and,  
\*354  
and florid diabetic retinopathy  
and photocoagulation and pituitary  
ablation, 104-110  
and gangrene  
and deep wound cultures, \*385

DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
February, 81-160  
March, 161-240  
April, 241-320  
Supplement 1, 321-396

May, 397-476  
June, 477-544  
July, 545-644  
August, 645-740

September, 741-804  
Supplement 2, 805-930  
October, 931-1010  
November, 1011-1090  
December, 1091-1170

- and glomerular basement membrane alterations, 920-924
- and glomerular lesions in rats and reduction of renal mass, \*349
- and glucagon, 136-149
- and glucagon metabolism, \*634
- and glucagon-stimulated glycogenolysis
  - non-insulin mediated suppression of, \*341
- and gluconeogenesis, \*315
- and glucose effects on cultured skin fibroblasts and arterial smooth muscle cells, \*336
- and glucose-induced glucagon suppression, \*352
- and glucose intolerance
  - and hemoglobin A<sub>1c</sub> levels, 230-232
- and glucose receptor dysfunction, \*323
- and glutathione reductase activity, \*383
- and glycogenolysis and gluconeogenesis, \*331
- and growth hormone levels, 167-172
- in guinea pigs, 434-442
- and heart abnormalities, 207
- and hemoglobin A<sub>1c</sub> levels, 890-896
- hemoglobin components and identical twins studies, \*318
- and heredity
  - and histocompatibility antigens in families, \*336
  - in offspring of diabetic couples, \*335
- and high-carbohydrate diets and insulin and sulfonylurea dosages, \*369
- and hyperglucagonemia, \*341
- and blood glucose regulation, \*539
- and hyperglycemia and glucagon, \*534
- and glucagon suppression, insulin and, \*352
- in identical twins
  - and histocompatibility antigens, \*236
- immunopathology of renal extracellular membranes in, 701-707
- and immunoreactive glucagon in eviscerated rats, \*327
- and impaired granulocyte adherence, \*348
- and impotency
  - and luteinizing release hormone tests, 975-977
- and insulin
  - biologic adequacy of, \*382
  - and plasma cAMP, \*373
- and insulin binding to lymphocytes, \*1165
- insulin-dependent
  - and acute withdrawal and administration of insulin, plasma glucagon responses to intravenous arginine and, 955-959
  - and glucagon secretion, \*471
  - preserved beta-cell function and blood glucose control in, \*362
  - and severe insulin reactions, glucagon secretion, and plasma insulin levels and, \*363
  - and vertebral osteomyelitis with disc space abscess, \*359
- and insulin and glucagon, \*323
- and insulin, glucagon and somatostatin, 1091-1098
- and insulin-glucose infusions and plasma glucagon levels, \*157
- and insulin release and glucoreceptors, \*234
- and insulin resistance and insulin receptor, 1154-1160
- and insulin therapy and basement membrane synthesis by glomeruli, \*349
- and cigarette smoking, 717-718
- and circulating insulin antibodies, \*367
- and protamine sodium insulin compared with regular insulin, \*334
- insulin-treated
  - exercise and metabolism and, \*333
  - and glucagon infusions, \*341
- and islet and pancreas transplantation 785-793
- juvenile
  - and acute abdominal pain, \*474
  - and arginine-stimulated glucagon response, 227-229
  - and blood glucose levels and psychological performance, \*334
  - and carbohydrate metabolism and capillary basement membrane thickness 650-659, 661-666
  - and circulating glucagon antibodies, \*334
  - control and management, \*636-637
  - and diabetic microangiopathy and growth hormone, 845-848
  - and early renal damage, \*370
  - and effect of somatostatin on blood sugar, plasma growth hormone, and glucagon levels, 550-552
- and histocompatibility antigen HL-A8 and leukocyte chemotaxis, \*371
- and insulin and glucagon, \*341
- and insulin therapy and antibody formation rates, \*362
- and ketoacidosis therapy, \*376
- and lipids, \*355
- and low-dose insulin therapy, \*153
- and lysosomal glycohydrolase, 420-426
- and microvascular permeability to plasma proteins, 884-889
- and ocular palsies, 459-462
- and pancreatic islet changes, \*365
- and plasma glucagon, 146-147
- prevalence in Michigan school-age children, 122-127
- and protamine sodium insulin therapy \*334
- and renal wastage of insulin, 989-992
- and subpopulations of peripheral lymphocytes, 101-103
- and vitamin deficiency, \*359
- and vitiligo, \*375
- juvenile-onset
  - and peripheral T-lymphocytes, 223-226
- and quantitation of glomerular basement membrane thickness after renal transplantation, \*357
- and serum insulin and growth hormone in monozygotic twin siblings, \*155
- and kidney function, 872-878
- and kidney glomerulosclerosis and kidney transplantation, \*349
- and kidney transplantation, 853-855
- and immunopathology of renal extracellular membranes, 709-712
- and leukocyte chemotaxis, 880-883
- and liver triglycerides, \*378
- long-term
  - and cardiovascular system norepinephrine, epinephrine, and dopamine, 6-10, \*1083
- and maculopathy and photocoagulation, \*471-472
- management
  - and criteria mapping, \*235
  - and outpatient clinic utilization by

DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
 February, 81-160  
 March, 161-240  
 April, 241-320  
 Supplement 1, 321-396

May, 397-476  
 June, 477-544  
 July, 545-644  
 August, 645-740

September, 741-804  
 Supplement 2, 805-930  
 October, 931-1010  
 November, 1011-1090  
 December, 1091-1170

# SUBJECT INDEX 1976

- veterans, \*381
- outpatient model for, \*343
- physician-assistant-protocol system for, 297-305
- and prognosis, \*342
- and team approach to indigent population, \*343
- maternal
  - and pancreas islet fibrosis in infants, \*472
  - and respiratory distress syndrome in infants, \*637
- maturity-onset
  - circulating glutamine disposal in, \*372
  - dietary management, \*323
  - and gastric inhibitory polypeptide, 931-935
  - in hyperlipemic rats, heredity and, \*354
- maturity onset of youth, \*635
- and metabolic response to ketones, 776-783
- in mice
  - and increased hemoglobin A<sub>1c</sub>, 1-4
  - and islet cell population, \*344
- and microangiopathy
  - identical twins and, 24-28
- mild
  - increased caloric intake and control of, \*390
- and mitochondrial fatty acid uptake \*351
- and mortality, 785
- and muscle free amino acid content and release, \*333
- in *Mystromys albicaudatus*, 444-448
- and nephropathy
  - in animals and man, 850-856
  - and renal transplantation, \*367
- nonketotic
  - and location of insulin resistance sites, 673-677
- in obese mice
  - immunologic abnormalities and, \*356
- and obesity
  - and nitrogen metabolism and insulin requirements during protein-sparing modified fast, 494-502
- and oxygen transport impairment, 832-837
- and pancreatic beta-cell stimulation, 11-14
- and pancreatic islet polypeptides, \*330
- pathogenesis
  - and autoimmune mechanisms, 101-103
  - "double-trouble" hypothesis of, 142-149
  - and sugar consumption, \*342
  - and periodontal disease
    - and carbohydrate metabolism, \*390
  - and peripheral vascular disease
    - assessment of, 307-314
  - and phenformin-associated lactic acidosis
    - and serum phenformin levels, \*359
  - and phenformin therapy
    - and lactic acidosis, \*328
    - and metabolic acidosis, 292-296
    - and plasma phenformin levels, \*357
  - in Pima Indians
    - and arginine-stimulated hyperglucagonemia, 404-407
  - and plasma catecholamines
    - and hypoadrenergic and hyperadrenergic postural hypotension, \*347
  - and plasma glycosaminoglycans, \*385
  - and plasma ketone bodies
    - and glucagon, \*157
  - and plasma renin activity and hypertension, 969-973
  - and platelet aggregation
    - and prostaglandin "E-like" production, \*347
  - platelet function and, 826-830
  - and postheparin lipolytic activity, \*234-235
  - and potassium levels
    - and ketoacidosis, \*380
  - pregnancy onset
    - and peripheral T-lymphocytes, 223-226
  - prevalence
    - in Greek rural males and females by age, \*358
    - among Minnesota public school children, \*372
    - in Pima Indians, 404
    - and prolactin release, \*351
    - and protein and branched chain amino acids, \*332
  - in rats
    - and C<sup>14</sup> transfer from alanine-I-C<sup>14</sup> to hepatic and blood glucose in, \*381
    - and pancreatic islet transplantation
      - and carbohydrate, fat and mineral metabolism, \*389
    - and renal arterial stenosis
      - hypertension secondary to, \*378
    - and renin-angiotensin-aldosterone system, 820-825
  - and retinal blood flow, 839-843
  - screening
    - by blood glucose measurement, 1110-1116
    - factors indicating, 530-531
    - and periodontitis, \*390
  - secondary to chronic calcific pancreatitis
    - and nodular intercapillary glomerulosclerosis, 713-716
  - and skin fibroblast abnormalities, \*336
  - and somatostatin therapy
    - and somatotropin and somatomedin, \*339
  - and somatomedin and growth in rats, \*335
  - spontaneous in rats, \*378
  - spontaneous remission in guinea pigs, \*377
  - and steroid-induced ketoacidosis, \*330
  - and sulfonylurea therapy
    - and plasma glucagon, \*387
  - survey
    - in Aleutians of Alaska, \*377
    - in Rochester, Minnesota, 566-572
    - and symptomatic hypoglycemia and blood glucose monitoring, 984-987
  - therapy
    - and somatostatin, \*340
    - and ulcerations of legs
      - and hyperbaric oxygen treatment, \*364
  - ultrastructural lesions in, \*352
  - unstable
    - and continuously pumped intravenous insulin, \*329
  - and urine testing
    - control specimen usage in, \*363
  - Vacor-induced, \*365
  - and vascular reactivity to angiotensin II and norepinephrine, 268-274
  - and vision
    - and serum glucose concentrations, 29-31

## DIAZOXIDE

- and glucagon production, \*387
- and hyperglycemia, \*330
- serum insulin suppressibility by
  - and islet cell adenomas and carcinomas, \*354

## DIBUTYRYL CYCLIC AMP

- induced insulin and growth hormone release

## DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
 February, 81-160  
 March, 161-240  
 April, 241-320  
 Supplement 1, 321-396

May, 397-476  
 June, 477-544  
 July, 545-644  
 August, 645-740

September, 741-804  
 Supplement 2, 805-930  
 October, 931-1010  
 November, 1011-1090  
 December, 1091-1170

- and somatostatin, \*538  
-stimulated insulin release  
from Syrian hamster insulinoma,  
\*474
- DICHLOROACETATE**  
in depancreatized dogs  
glucose metabolism and, \*385  
and diabetes therapy, \*328  
and skeletal muscle metabolism, \*332
- DICHROISM SPECTROSCOPY**  
and chromium effect on insulin ag-  
gregation, \*353
- DIET**  
carbohydrates  
plasma glucose and insulin re-  
sponses to, 741-746  
composition  
and metabolism, \*361  
and diabetes management, \*323  
diabetic  
and ethanol, \*342  
and "Exchange Lists for Meal Plan-  
ning," 532-533  
high-carbohydrate  
and insulin and sulfonylurea dos-  
ages, \*369  
high carbohydrate, high fiber  
lipid-lowering effect of, \*324  
high-protein  
and nonsuppressible increase in  
glucagon secretion by isolated  
rat islets, 51-55  
and pancreatic A cell hyperplasia in  
rats, \*327  
and hypoglycemia  
and glucose tolerance, \*734  
increased calories  
and control of mild diabetes, \*390  
low-carbohydrate  
and glucose tolerance in normals  
and reactive hypoglycemia  
patients, \*153  
low fat  
and ketonuria in Chinese hamsters,  
\*364  
and pancreatic islet polypeptides,  
\*330  
and plasma glucagon levels, \*340  
and plasma renin activity and hyper-  
tension in diabetics, 969-973  
and plasma triglycerides in  
streptozotocin-diabetic rats,  
\*363  
polyunsaturated meats and dairy  
products  
and plasma lipids, \*537  
and postprandial hypoglycemia, 728  
protein-sparing modified fast  
and nitrogen metabolism and insu-  
lin requirements in obese  
diabetics, 494-502  
rice reduction  
and massive obesity, \*472-473  
in streptozotocin-treated rats  
and hyperlipoproteinemia, 509-510  
sucrose-rich  
and apolipoprotein patterns in rats,  
\*353  
sugar consumption  
and diabetes and obesity risk, \*342  
and insulin secretion, \*389  
unmeasured  
and lipids in juvenile diabetics, \*355  
in vascular reactivity to angiotensin II  
and epinephrine study, 269  
and vitamin deficiency  
in juvenile diabetics, \*359
- DIGESTION-FILTRATION METHOD**  
for isolation of pancreatic islets,  
667-672
- DIGITALIS**  
for heart disease  
in tolbutamide-treated diabetics,  
1134-1135
- DILANTIN**  
and postprandial hypoglycemia, 729
- 16, 16 DIMETHYLPROSTAGLANDIN**  
E<sub>2</sub>  
suppression of lipolysis  
and diabetic ketoacidosis, \*331
- DIPHENYLHYDANTOIN**  
and glucose tolerance in hypoglycemia  
patients, \*735  
and insulin and glucagon release sup-  
pression, \*380
- DISODIUM-ETHANE-HYDROXY-1,  
1-DIPHOSPHONATE**  
and erythrocytic oxygen release in  
insulin-treated diabetics,  
836-837
- DISULFIDE BONDS**  
in plasma membrane  
insulin and, \*382
- DNA**  
replication in isolated rat islets of  
Langerhans  
cyclic AMP and phosphodiesterase  
inhibitors and, \*379  
synthesis  
and somatomedin B, \*1005  
and wound healing in diabetics,  
814-817  
synthesis in cultured chick embryo  
fibroblasts  
growth hormone and, \*1005
- DOGS**  
acute kidney exclusion in  
and peripheral plasma glucagon  
levels and pancreatic  
glucagon production, \*316  
alloxan diabetic  
and acute- and late-phase insulin  
secretion and glucose toler-  
ance, 161-165  
and alanine infusions, \*236  
and gluconeogenesis from glycerol  
at rest and during exercise in,  
\*539  
cholecystokinin and gastric inhibitory  
polypeptide in  
and glucagon secretion, \*360  
depancreatized  
dichloroacetate and glucose  
metabolism in, \*385  
insulin infusions in, \*325  
depancreatized and gastrectomized  
glucagon secretion in, \*355  
and diazoxide hyperglycemia, \*330  
gastrointestinal tissues immunoreac-  
tive glucagon  
measurement and partial charac-  
terization of, 1018-1025  
glucagon-secreting tissues of  
"macro-glucagon" in, \*326  
glucose clamp in, \*316-317  
glucose tolerance in  
and portacaval anastomosis, \*316  
glycogenolysis and gluconeogenesis in  
diabetes and, \*331  
and hepatic glucose output in  
and interaction of somatostatin,  
glucagon, and insulin,  
116-120  
insulin and glucagon secretion in  
and octapeptide of cholecystokinin,  
\*154  
and insulin and glucose flux rates,  
\*316  
and insulin infusions

DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80	May, 397-476	September, 741-804
February, 81-160	June, 477-544	Supplement 2, 805-930
March, 161-240	July, 545-644	October, 931-1010
April, 241-320	August, 645-740	November, 1011-1090
Supplement 1, 321-396		December, 1091-1170



and glycogenolysis and gluconeogenesis, 283-290  
 intrapancreatic L-isoproterenol infusion  
 and glucagon and insulin secretion, \*155-156  
 isolated pancreas  
 and epinephrine-induced enhancement of insulin secretion, \*387  
 ketone body turnover and liver ketone production in, \*331  
 kidney  
 glucagon and insulin uptake, \*327  
 normal, depancreatized and alloxan diabetic  
 heterogeneity of plasma glucagon immunoreactivity in, \*539-540  
 and oxygen deficiency  
 and insulin release studies, \*534  
 pancreas  
 polypeptide, cellular localization of, \*364  
 and pancreas transplantation into retroperitoneal jejunal loop, \*795  
 pancreatectomized  
 intrasplenic autotransplantation of pancreatic tissue in, \*795-796  
 pancreatic polypeptide secretion in vitro, \*329  
 stomach immunoreactive glucagon, \*327

**L-DOPA**  
 and glucagon secretion, \*157  
 and prolactin release in diabetics, \*351

**DOPAMINE**  
 cardiovascular system  
 and long-term diabetes, \*1083  
 conversion to norepinephrine in diabetes, 10  
 in heart tissue of long-term diabetics, 6-10  
 radioenzymatic assay for, \*1082

**DUCKS**  
 and diazoxide  
 and glucagon production, \*387

**DWARFISM**  
 Laron  
 receptor-active growth hormone in, \*1006  
 and urinary growth hormone and

increased immunoreactive plasma, \*1006  
 and somatomedin activity, 996-997

## E

**EDTA**  
 and insulin degradation in isolated liver cells, 174, 176-178

**EDUCATION**  
 and diabetes, \*350  
 for diabetic multi-ethnic population, \*350  
 multi-discipline, \*350

**EEL**  
 cold acclimated  
 and microangiopathy and hyperglycemia, \*382

**ELECTRICAL ACTIVITY**  
 in cultured rat islet cells  
 somatostatin inhibition of, \*380  
 of pancreatic islet beta-cells  
 temperature and, \*377  
 in single islet cell membranes  
 biphasic glucose-induced, \*345

**ELECTROCARDIOGRAMS**  
 of Pima Indians, 561-565  
 in tolbutamide-and insulin-treated diabetics, 1131-1134

**ELECTROLYTES**  
 balance  
 in alloxan diabetic rats, \*348

**ELECTROPHORESIS**  
 agarose lipoprotein  
 in juvenile diabetics, \*355  
 polyacrylamide disc gel  
 and glucagon immunoassays of dog gastrointestinal tissues, 1020  
 in <sup>75</sup>Se-selenomethionine incorporation into human apoproteins study, 34-35, 36-39

**EMBRYO**  
 chick  
 insulin receptors of heart cells of, \*365

**EMOTIONAL DEPRIVATION**  
 and short stature  
 and somatomedin and growth hormone levels, 996

**EMOTIONAL PROBLEMS**  
 and postprandial hypoglycemia, 729-730

**ENCEPHALITIS**  
 Venezuelan  
 -induced pancreatic disease in hamsters, 623-630

**ENCEPHALOMYOCARDITIS VIRUS**  
 M variant of  
 diabetes mellitus development and, 190-197

**ENDOCRINE GLANDS**  
 and impotency in diabetic males, 975-977  
 and insulin secretion, 96-100  
 and islet-cell tumor producing glucagon, insulin and gastrin, 409-410, 411

**ENDOTHELIUM**  
 vascular  
 macromolecular transport across in alloxan diabetic rats, \*386

**ENDOTOXEMIA**  
 and glucoregulation in normal and diabetic man, \*383

**S. ENTERITIDIS**  
 and shock in rats  
 and insulin, \*342

**ENZYMATIC ISOTOPE-DERIVATIVE ASSAYS**  
 for norepinephrine and epinephrine, 1071-1080

**ENZYMES**  
 of collagen biosynthesis  
 in streptozotocin-diabetic rat kidney, 1066-1070  
 glutathione reductase  
 and diabetes, \*383  
 glycogen cycle  
 regulation by glucose and galactose in rat liver, \*539  
 hepatic  
 in Chinese hamsters before and after onset of hyperglycemia, \*358  
 insulin-degrading  
 and destruction of subcutaneous insulin, \*334  
 jejunal carbohydrate-metabolizing

## DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
 February, 81-160  
 March, 161-240  
 April, 241-320  
 Supplement 1, 321-396

May, 397-476  
 June, 477-544  
 July, 545-644  
 August, 645-740

September, 741-804  
 Supplement 2, 805-930  
 October, 931-1010  
 November, 1011-1090  
 December, 1091-1170

and insulin, tolbutamide and glucagon, \*75  
and lipogenesis in adipose tissue and obesity, \*634

# EPINEPHRINE

cardiovascular system  
and long-term diabetes, \*1083  
and exercise, \*1084  
and glucagon responses to hypoglycemia, \*315  
in heart tissue of long-term diabetics, 6-10  
-induced hyperglycemia in man  
and pancreatic glucagon secretion, 65-70  
and insulin-induced hypoglycemia and adrenergic mechanisms, \*1083-1084  
and insulin secretion, \*387  
isotope-derivative assays for, 1071-1080  
lipolysis and, \*366  
and oxygen deficiency  
and insulin release, \*534  
and platelet aggregation  
and diabetes, 826-830  
and protein phosphorylation in isolated fat cells, \*337  
radioenzymatic assay for, \*1082  
-stimulated glucagon secretion and streptozotocin-treated pancreas, 279-280  
and streptozotocin effect on red-blood-cell-reduced glutathione, 216-221

# ERYTHROCYTE

avian  
insulin receptors, \*322

# ESTRADIOL

and somatomedin action in vitro, \*1005

# ESTROGENS

and somatomedin activity, 996

# ETHANOL

and carbohydrate metabolism, \*318  
and diabetic diet, \*342  
and glucose-mediated insulin release in pigs, 752-757  
-induced alterations of glucose tolerance, postglucose hypoglycemia, and insulin secretion

in normal, obese and diabetic subjects, \*735

# ETHYLENEDIAMINE TETRAACETIC ACID. *see* EDTA

# "EXCHANGE LISTS FOR MEAL PLANNING—A HELPFUL GUIDE FOR A HEALTHIER YOU," 532-533

# EXERCISE

and cardiac degeneration in diabetic autonomic neuropathy, 750  
and fasting hypoglycemia, \*634-635  
fuel homeostasis in, \*154  
glucagon and plasma catecholamine responses to, \*1084  
and gluconeogenesis from glycerol in normal, diabetic and methylprednisolone-treated dogs, \*539  
and kidney protein excretion, 872-873  
and metabolism  
in insulin-treated diabetics, \*333-354  
and muscle metabolism  
and oxygen transport system in normals and diabetics, 914-919  
and plasma norepinephrine and epinephrine  
and somatostatin, \*235

# EYES

acute refractive changes  
as indication for diabetic screening, 531  
aqueous humor  
and optical monitoring of blood glucose, \*325  
cataracts  
and adult-onset diabetes, \*371  
examinations  
in tolbutamide-treated diabetics, 1137-1138, 1139  
maculopathy  
and photocoagulation, \*471-472  
ocular palsies  
and juvenile diabetes, 459-462

# F

# FAMILIAL DYSAUTONOMIA

and deficient sympathetic nervous response, \*1083

# FAMILY HISTORY

and diabetes  
and histocompatibility antigens, \*336  
in diabetes prevalence study of Michigan school-age children, 125  
in diabetes survey in Rochester, Minnesota, 568, 569  
and histocompatibility antigen HL-A8 and leukocyte chemotaxis  
in first-degree relatives of juvenile diabetics, \*371  
and hyperproinsulinemia, \*635  
as indication for diabetic screening, 531  
and inheritance of large molecular weight immunoreactive glucagon, \*326  
leukocyte chemotaxis, 880-883  
and screening of first-degree relatives of diabetics, \*635

# FASTING

and alanine metabolism, \*358  
and hyperglycemia  
and insulin resistance mechanisms, \*328  
hypoglycemia  
compared with postprandial hypoglycemia, 719-720  
in normal adults, \*634-635  
and immunoreactive glucagon levels in obese mice, \*361  
and inhibition of ketogenesis by ketone bodies, \*534  
insulin binding and glucose transport by fat cells and, \*321  
protein-sparing modified  
and nitrogen metabolism and insulin requirements in obese diabetics, 494-502  
and rat liver plasma membrane phospholipids, \*351  
and rat mitochondrial fatty acid uptake, \*351

# FAT

dietary  
and ketonuria, \*364  
metabolism  
in pancreatic islet transplanted diabetic rats, \*389

# FAT CELLS

in endogenous hypertriglyceridemia, \*236

# DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
February, 81-160  
March, 161-240  
April, 241-320  
Supplement 1, 321-396

May, 397-476  
June, 477-544  
July, 545-644  
August, 645-740

September, 741-804  
Supplement 2, 805-930  
October, 931-1010  
November, 1011-1090  
December, 1091-1170



- extracellular calcium and metabolic effects of, \*372  
hexose transport system sensitivity to cytochalasin B  
  insulin and, \*336  
insulin-binding capacity  
  and cellular response to insulin, \*1164  
insulin binding and glucose transport by  
  fasting and, \*321  
insulin-stimulated protein phosphorylation in, \*357  
rat  
  insulin-induced lipogenesis in, \*1164
- FATTY ACIDS**  
  and exercise, \*1084  
  free  
    and diabetic control, 168-172  
    and insulin resistance in diabetic ketoacidosis, \*365  
    during oral glucose tolerance tests in healthy children, age and 505-508  
    and somatostatin infusion in islet-cell tumor patient, 410-411  
    utilization by sheep hind limb, \*635  
  -glucose cycle in skeletal muscle, \*375  
  metabolism  
    glucagon and, 978-982  
  polyunsaturated  
    in hypercholesterolemia therapy, \*154  
  uptake by mitochondria  
    in fed, fasted and diabetic rats, \*351
- FETUS**  
  insulin response  
    to glucose and amino acids, \*366  
  islets of Langerhans  
    insulin release, glucocorticoids and, \*359  
  mortality  
    and maternal diabetes management, \*373  
  pancreas  
    transplantation in rats, and hepatic-portal route, \*338  
    transplantation into streptozotocin diabetic rats, 56-63, \*338  
  rat  
    glucose-induced insulin secretion in \*362  
  serum insulin and growth hormone response to glucose and leucine, 545-549
- serum somatomedin activity, 996
- FIBRINOGEN**  
  and diabetic retinopathy, 807-809
- FIBRINOLYSIS**  
  and diabetic retinopathy, 807-809
- FIBROBLASTS**  
  abnormalities  
    diabetes and, \*336  
  cultured  
    insulin receptors in, 250-254  
    and glucose and diabetes, \*336  
  response to low-density lipoprotein in homozygous familial hypercholesterolemia, \*154
- FISH**  
  islet cell membranes  
    glucose receptor study, \*323  
  piscine islets  
    xenotransplantation into hyperglycemic rats, \*797
- FLUORESCCEIN ANGIOGRAPHY**  
  and mean retinal circulation time in prediabetic, normal, and chemical diabetic subjects, 903-907
- G**
- GALACTOSE**  
  and rat liver glycogen synthesis and glycogen cycle enzyme activities, \*539
- B-GALACTOSIDASE**  
  assays  
    in juvenile diabetics, 420-426
- GANGRENE**  
  and diabetes  
    and deep wound cultures, \*385
- GASTRECTOMY**  
  and glucagon secretion in dogs, \*355
- GASTRIC INHIBITORY POLYPEPTIDE**  
  and glucagon secretion in dogs, \*360  
  in maturity-onset diabetes, 931-935
- GASTRIN**  
  -secreting islet-cell tumor, 408-419
- GASTRINOMAS**  
  pancreatic polypeptide in, \*474
- GASTROINTESTINAL SYSTEM**  
  alpha cells in dogs, 141  
  bypass for obesity  
    and arthritis, \*318  
  of dogs  
    immunoreactive glucagon of, 1018-1025  
  glucagon, 142-149  
  hormones  
    and endocrine pancreas, \*373  
  jejunal carbohydrate-metabolizing enzymes  
    and insulin, tolbutamide, and glucagon, \*75  
  and liver  
    and oral glucose disposal, \*316  
  retroperitoneal jejunal loop  
    pancreas transplantation into in dogs, \*795  
  reversed intestinal segment  
    for treatment of postoperative reactive hypoglycemia, \*536, \*733  
  surgery  
    and glucose homeostasis, \*234  
    and vagotomy and pyloroplasty, \*736
- GEL FILTRATION**  
  and somatostatin content of rat stomach and pancreas, \*471
- GENES. See also Heredity**  
  and diabetes in offspring of rats with induced latent diabetes, \*474  
  and hemoglobin levels in diabetic mice, 4  
  and histocompatibility antigens in families with diabetes, \*336  
  and hyperlipemia and maturity-onset diabetes in rats, \*354  
  and virus-induced diabetes development in mice, 190-197
- GIP. See Gastric inhibitory polypeptide**
- GLOMERULAR FILTRATION RATE**  
  and diabetes, 872-878
- GLOMERULOPATHY**  
  in animals and man, 856
- GLOMERULOSCLEROSIS**  
  and kidney transplantation, \*349

---

DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80	May, 397-476	September, 741-804
February, 81-160	June, 477-544	Supplement 2, 805-930
March, 161-240	July, 545-644	October, 931-1010
April, 241-320	August, 645-740	November, 1011-1090
Supplement 1, 321-396		December, 1091-1170

nodular intercapillary  
in diabetes secondary to chronic calcific pancreatitis, 713-716  
in "secondary" diabetes in baboons, \*349

**GLUCAGON**  
biosynthesis  
and sequential metabolic cleavage of proglucagon to glucagon, \*156  
and carbohydrate homeostasis and diabetes, \*323  
circulating antibodies to  
in juvenile diabetics, \*334  
-containing islet cells  
in diabetic mice, \*344  
degradation by neutral peptidase, \*387  
and diabetes, 136-149  
and diabetic hyperglycemia, \*534  
and diabetic ketoacidosis, \*1084  
in diabetics and normals, 1091-1098  
and diazoxide hyperglycemia, \*330  
of dog stomach, \*327  
and endogenous hyperglycemia in diabetics, \*236  
and fatty acid metabolism, 978-982  
and gastric surgery, \*234  
of gastrointestinal tract, 142-149  
and glucose homeostasis and insulin secretion, \*341  
glucose-induced suppression of  
in normal, prediabetic, and diabetic Pima Indians, \*352  
growth hormone response to in normals  
and glucose, \*538-539  
hepatic responses to  
and ATP, \*535-536  
hyperglycemia suppression of  
insulin and, \*352  
immunoreactive  
in eviscerated rats with and without stomach and duodenum, \*327  
increased circulating large, in glucagonoma syndrome, \*326  
large molecular weight, inheritance of, \*326  
measurement and partial characterization in gastrointestinal tissues of dogs, 1018-1025  
in obese mice, \*361  
infusions  
in insulin-treated diabetics, \*341  
and metabolism of forearm tissues in man, 128-134

in normal, obese, and diabetic subjects, \*539  
and insulin binding on primate hypothalamus, \*322  
and insulin-induced hypoglycemia, \*1083-1084  
-insulin protease  
proteolytic activity of, \*353  
-insulin ratio  
in gestational diabetes, 16-21  
and insulin resistance in diabetic ketoacidosis, \*365  
insulin response to  
and oral glucose loading in children and adolescents, \*537  
intravenous  
and urinary catecholamine excretion in normal man, \*318  
islet-cell tumor producing, 408-419  
and jejunal carbohydrate-metabolizing enzymes, \*75  
and  $^{14}\text{C}$  leucine incorporation into peripheral nerve myelin proteins, \*348  
levels in diabetic children  
somatostatin and, 550-552  
-like immunoreactivity  
and gastric surgery, \*234  
"macro-immunoreactive"  
in glucagon-secreting tissues of dogs, \*326  
metabolism  
in normals and diabetics, \*634  
and orthophosphate and serine incorporation into phosphatidylserine in cardiac muscle slices, \*473-474  
and pancreatic beta-cell stimulation studies 11-14  
peripheral and portal  
and massive obesity, \*388  
physiologic variations in  
and human forearm tissue, \*341  
plasma C-peptide response to  
and beta-cell function in diabetics \*329  
and plasma glucagon immunoreactivity, \*637  
and plasma ketone body regulation in diabetics, \*157  
production  
and acute kidney exclusion in dogs, \*316  
and protein and amino acid metabolism in isolated perfused rat liver, 865-870  
release

amino acid-induced in genetically obese rats, \*356  
arginine-induced, somatostatin and, \*535  
during calcium deprivation, \*473  
diphenylhydantoin suppression of, \*380  
and insulin secretion, 764-769  
and iodoacetate and iodoacetamide, \*156-157  
and sulfhydryl binding reagents, \*389  
response to hypoglycemia  
sympathectomy and, \*317  
response to insulin-induced hypoglycemia  
and adrenalectomy, \*315  
response to arginine  
and diabetes, 227-229  
and insulin withdrawal and administration in insulin-dependent diabetics, 955-959  
responses  
to exercise, \*1084  
and pancreatic cancer, \*391  
secretion  
 $\alpha$  and  $\beta$  anomers of glucose and, \*155  
and beta and betag adrenoreceptor stimulants, \*155-156  
and cholecystokinin and gastric inhibitory polypeptide in dogs, \*360  
and contraceptive steroids, \*535  
in depancreatized-gastrectomized dogs, \*355  
and diazoxide, \*387  
and L-dopa, \*157  
and epinephrine-induced hyperglycemia in man, 65-70  
and halofenate therapy in genetic hyperlipemia, \*536  
and hyperglycemia in "stable" insulin-dependent diabetics, \*471  
and insulin reaction, \*363  
nonsuppressible increase by isolated islets of high-protein-fed rats, 51-55  
and octapeptide of cholecystokinin, \*154  
from perfused pancreas of streptozotocin-treated rats, 275-282  
scorpion toxin-stimulated in perfused rat pancreas, 645-649  
somatostatin inhibition of,

DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
February, 81-160  
March, 161-240  
April, 241-320  
Supplement 1, 321-396

May, 397-476  
June, 477-544  
July, 545-644  
August, 645-740

September, 741-804  
Supplement 2, 805-930  
October, 931-1010  
November, 1011-1090  
December, 1091-1170

- ionophore and, \*536  
 somatostatin inhibition of, reversal of, 1031-1039  
 suitability of perfused pancreatic islets for study of, \*368  
 suppression and stimulation mechanisms, islet-cell tumor and, 408-419  
 and tumor hypoglycemia, 202-205  
 and somatostatin and insulin and hepatic glucose output in normal dogs, 116-120  
 -stimulated glycogenolysis non-insulin mediated suppression of, \*341  
 -stimulated insulin release and somatostatin, \*339  
 from Syrian hamster insulinoma, \*474  
 uptake  
   by dog kidney, \*327
- GLUCAGONOMA**  
 and circulating large glucagon immunoreactivity, \*326  
 and glucose homeostasis and insulin secretion, \*341  
 malignant  
   metabolism and, \*370  
   pancreatic polypeptides in, \*474
- GLUCOCORTICOIDS**  
 and growth retardation in nephrotic children  
   and somatomedin, \*1004-1005  
 -induced ketoacidosis, \*330  
 and insulin release  
   from human fetal islets of Langerhans, \*359  
 as serum inhibitor of cartilage metabolism, \*1007  
 and triglyceride secretion rates, lipoprotein lipase, and plasma lipoproteins in rats, \*634
- GLUCONEOGENESIS**  
 from alanine  
   and hypoglycemia, \*1083-1084  
   and diabetes in dogs, \*331  
 from glycerol  
   at rest and during exercise in normal, diabetic and methylprednisolone-treated dogs, \*539  
 hepatic  
   insulin and, \*331  
   and insulin infusions in dogs, 283-290  
   nonsuppressibility by glucose in septic patients, \*316  
   renal  
     inhibition by quinolinate and hydrazine in diabetic rats, \*315  
     and substrate regulation in hypopituitary children  
       and growth hormone and cortisone, \*733-734
- GLUCORECEPTORS**  
 and insulin release  
   and diabetes, \*234  
 specificity  
   and insulin biosynthesis, \*75
- GLUCOREGULATION**  
 in normal and diabetic man  
   endotoxemia and, \*383
- GLUCOREGULATOR RECEPTOR**  
 and hypophysectomy, \*158
- GLUCOSE**  
 and alanine infusions in protein-calorie malnutrition, \*75  
 $\alpha$  and  $\beta$  anomers of  
   and insulin and glucagon secretion in perfused rat pancreas, \*155  
   and arginine-induced insulin secretion and hyperthyroidism, 963-964  
 control  
   and diabetic pregnancy, \*384  
 conversion of alanine to  
   fasting and, \*358  
 disappearance rate  
   evaluation by bolus and stimulated-ramp increase of glucose, 580-585  
 disposal  
   and Staub-Traugott effect, \*153  
 disposal sites, 1092  
 -fatty acid cycle in skeletal muscle, \*375  
 flux rates  
   and insulin flux rates, \*316  
   and glycogen synthase in isolated hepatocytes, \*389  
 and growth hormone response to  
   glucagon and propranolol-glucagon in normals, \*538-539  
 and hemoglobin levels  
   and diabetic mice, 3-4  
 homeostasis  
   and chronic glucagon excess, \*341  
   and gastric surgery, \*234  
   -induced biphasic membrane electrical activity in single islet cells, \*345  
   -induced electrical activity beta cells temperature and, \*377  
   -induced glucagon suppression in normal, prediabetic and diabetic Pima Indians, \*352  
   -induced insulin secretion colchicine inhibition of, \*325  
   in isolated pancreas of fed and fasted rats, 949-953  
   magnesium and, \*360  
   in newborn rats, environmental temperature and, 1026-1029  
   in pregnant rats and their fetuses, \*362  
   site of protection of barbituric acid against alloxan inhibition of, \*345  
   -induced insulin secretion and biosynthesis in vitro  
     and alloxan and D-glucose anomers, 574-578  
   and insulin infusions  
     and plasma glucagon levels, \*157  
     and insulin receptors, \*322  
   insulin response to  
     in patients with previous myocardial infarction and patients with peripheral vascular disease, 586-593  
 intravenous  
   and ketone metabolism in normals, 780-781  
   and plasma tryptophan and tyrosine in normals and patients with carcinoid tumors, \*536  
 levels  
   in diabetic mice, 3  
   and diabetic retinopathy, 554-560  
 loading  
   beta-cell response assay after, 241-244  
   and islet-cell tumor, 410  
   peripheral insulin resistance after, 245-249  
   and systemic ingested glucose and suppression of endogenous glucose production, \*332  
 maternal and fetal insulin response to, \*366  
 maternal and fetal serum insulin and growth hormone response to, 545-549  
 in maturity-onset diabetes  
   glycogen as source of, \*372

DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80	May, 397-476	September, 741-804
February, 81-160	June, 477-544	Supplement 2, 805-930
March, 161-240	July, 545-644	October, 931-1010
April, 241-320	August, 645-740	November, 1011-1090
Supplement 1, 321-396		December, 1091-1170

-mediated insulin release  
and ethanol, 752-757  
metabolism  
and dichloroacetate in depan-  
creatized dogs, \*385  
and insulin binding to adipocytes,  
\*368  
nonsuppressability of gluconeogenesis  
by  
in septic patients, \*316  
oral loading  
and insulin response to intravenous  
glucagon in children and ad-  
olescents, \*537  
outflow and inflow  
and epinephrine, norepinephrine,  
glucose, cortisol, and growth  
hormone, \*1083-1084  
oxygen electrode for artificial pan-  
creas, \*385  
and pancreas beta cells, \*381  
and perfusion of rat islets in vitro,  
487-489, 491-492  
plasma alanine conversion to, 287  
and postprandial hypoglycemia, \*733  
and prolactin secretion, \*351  
and rat liver glycogen synthesis and  
glycogen cycle enzyme ac-  
tivities, \*539  
receptor  
of fish islet cell membranes, \*323  
receptor dysfunction  
and diabetes, \*323  
regulation in fasted hypopituitary  
children  
and growth hormone and cortisone,  
\*733-734  
and skin fibroblasts and arterial  
smooth muscle cells of diabet-  
ics, \*336  
splanchnic output  
and benign mesothelioma, 202-205  
-stimulated glucagon release  
during calcium deprivation, \*473  
-stimulated insulin release  
hyperketonemia and, \*381  
from pancreatic islets stored in cold,  
\*315  
and somatostatin, \*472  
stimulation of pancreatic islets  
and calcium uptake, \*346  
phosphate content during, \*346  
and streptozotocin effect on red-  
blood-cell-reduced  
glutathione, 216-221  
tolerance  
and pancreatic cancer, \*391

transport  
by fat cells, fasting and, \*321  
transport and oxidation  
in isolated rat adipocytes, obesity  
and, \*1163  
uptake  
and insulin, 673-677  
in rat adipose tissue, \*366  
utilization  
and exercise, \*154  
in isolated perfused rat liver,  
867-869  
and non-glucose hexoses, \*364  
by sheep hind limb, \*635

#### GLUCOSE-6-PHOSPHATE -6-phosphogluconate ratio insulin and, \*337

GLUCOSE-6-PHOSPHATE DEHY-  
DROGENASE  
<sup>3</sup>H-histidine incorporation into  
and insulin, protamine sulfate, and  
prostaglandins, \*366

GLUCOSE INTOLERANCE  
in animal models, \*236  
and diabetes  
and hemoglobin A<sub>1c</sub> concentration,  
230-232

GLUCOSE METABOLISM  
during fasting  
insulin receptors and, \*321

GLUCOSE-OXIDASE METHOD  
and unstable-diabetes therapy, \*329

GLUCOSE TOLERANCE  
and diet  
and cholinergic effects, \*361  
in dogs  
and portacaval anastomosis, \*316  
and encephalitis-induced pancreatic  
disease in hamsters, 623-630  
ethanol-induced alterations of  
in normal, obese, and diabetic sub-  
jects, \*735  
and hypoglycemia  
and diphenylhydantoin, \*735  
and insulin release  
beta-cell response assay, 241-244  
and peripheral insulin resistance  
after oral glucose loading,  
245-249  
and insulin resistance and acanthosis  
nigricans, \*636

in mild alloxan diabetic dogs, 161-165  
in monozygotic twins, \*155  
in normal men and hypoglycemic  
patients  
and carbohydrate restriction, \*153,  
\*734

oral  
and mazindol in obesity, \*235-236  
and Ovulen therapy, \*157  
and protein-calorie malnutrition in  
adults, \*539  
and relationship of time of day and  
time since last meal to,  
936-942  
restoration in depancreatized dogs  
insulin infusions and, \*325  
screening study, 936-942  
in streptozotocin diabetic rats with  
fetal pancreas transplants,  
57-58

GLUCOSE TOLERANCE TESTS  
in community screening for diabetes,  
1110-1116  
and effects of ethanol on carbohydrate  
metabolism, \*318  
in fetal pancreatic transplanted strep-  
tozotocin diabetic rats, 61-62  
and hemoglobin A<sub>1c</sub> levels, 230-232  
and hypoglycemia, \*734  
hypoglycemic phase of, \*333  
intravenous  
compared with simulated-ramp  
evaluation of glucose removal  
rate, 580-585  
in maturity-onset diabetes  
and serum gastric inhibitory  
polypeptide, 931-935  
normal  
and diabetes diagnosis, \*362  
oral  
and diagnosis of postprandial hypo-  
glycemia, 721-722  
in gestational diabetes, 16-21  
in healthy children, insulin and free  
fatty acid levels during, age  
and, 505-508  
in normal children, \*378  
and postprandial hypoglycemia, 730  
and retinopathy in Pima Indians,  
554-560  
in spontaneously diabetic guinea pigs,  
435, 436, 439

D-GLUCOSE  
anomers  
metabolism in pancreatic islets,  
450-457

#### DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
February, 81-160  
March, 161-240  
April, 241-320  
Supplement 1, 321-396

May, 397-476  
June, 477-544  
July, 545-644  
August, 645-740

September, 741-804  
Supplement 2, 805-930  
October, 931-1010  
November, 1011-1090  
December, 1091-1170

# SUBJECT INDEX 1976

- anomers, alloxan and  
and glucose-induced insulin secretion and biosynthesis in vitro, 574-578  
islet metabolism of, \*345  
transport  
and insulin insensitivity in rat adipocytes, \*1164-1165
- $\alpha$ -GLUCOSIDASE  
assays  
in juvenile diabetics, 420-426
- GLUCOSURIA  
in diabetes survey, \*358
- GLUTAMINE  
disposal  
in maturity-onset diabetes, \*372
- GLUTARALDEHYDE  
fixation, in capillary basement membrane thickening studies, 604-612
- GLUTATHIONE  
red-blood-cell-reduced  
and streptozotocin, 216-221
- GLUTATHIONE REDUCTASE  
and diabetes, \*383
- GLYBURIDE  
and extrapancreatic and pancreatic action in rats, \*367
- GLYCEROL  
gluconeogenesis and  
during rest and exercise in normal, diabetic and methylprednisolone-treated dogs, \*539  
-stimulated insulin secretion in man, \*540
- GLYCOGEN  
and fuel utilization in exercise, \*154  
as source of circulating glucose in maturity-onset diabetes, \*372  
synthase  
regulation in isolated hepatocyte, \*389  
synthase and synthase D-phosphatase and vagal stimulation, \*332  
synthesis  
and insulin, 758  
and insulin-potentiating peptides, 413-418  
synthesis in rat liver  
regulation by glucose and galactose, \*539
- GLYCOGENOLYSIS  
and diabetes in dogs, \*331  
glucagon-stimulated  
non-insulin mediated suppression of, \*341  
and insulin infusions in dogs, 283-290
- GLYCOLYSIS  
and iodoacetate and iodoacetamide, \*156-157
- GLYCOSURIA  
in streptozotocin-treated rats, 510
- GONADS  
dysgenesis  
and carbohydrate intolerance, \*379
- GOUT  
and colchicine  
and inhibition of glucose-induced insulin secretion, \*325
- GRANULOCYTES  
impaired adherence in diabetics, \*348
- GREECE  
diabetes survey by sex and age of rural population in, \*358
- GROWTH. *See also* Body, growth; Dwarfism  
retardation  
glucocorticoid and, \*1004-1005  
and somatomedin, 994-1001  
and somatomedin activity in streptozotocin-diabetic rats, 516-526
- GROWTH HORMONE  
and alanine infusions in protein-calorie malnutrition, \*75  
and arterial medial cell growth in vitro, 1011-1016  
deficiency  
and hypoglycemia in children, \*734  
-dependent serum stimulation of DNA synthesis in chick embryo fibroblasts, \*1005  
and diabetes control, 167-172  
and diabetic microangiopathy, 845-848  
and glucose and gluconeogenic substrate regulation in fasted hypopituitary children, \*733-734
- immunoreactive  
and Laron dwarfism, \*1006  
and insulin-induced hypoglycemia, \*1083-1084  
and insulin resistance  
in diabetic ketoacidosis, \*365  
receptor-active  
in Laron dwarfism, \*1006  
receptors  
cell surface distribution of, \*321  
regulation of von Willebrand factor activity, \*347  
release  
dibutyl cyclic AMP-induced, somatostatin and, \*538  
response to glucagon and propranolol-glucagon in normals  
and glucose, \*538-539  
response to glucose and leucine maternal and fetal, 545-549  
responses  
in neonatal hyperglycemia, 428-431  
and somatomedin  
and growth disorders, 996
- GUAM  
amyotrophic lateral sclerosis and Parkinsonism-dementia on carbohydrate metabolism study and, 1055-1063
- GUINEA PIGS  
and diabetes mellitus, 434-442  
diabetic  
spontaneous remission in, \*377
- ## H
- HALOFENATE  
and genetic hyperlipemia therapy and insulin and glucagon secretion, \*536  
and sulfonylurea-induced hypoglycemia, \*236
- HAMSTERS. *See also* Chinese hamsters; Syrian hamsters  
and encephalitis virus-induced pancreatic disease in, 623-630
- HAPTOGLOBIN  
synthesis  
in isolated perfused rat liver, glucagon and, 867

## DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80	May, 397-476	September, 741-804
February, 81-160	June, 477-544	Supplement 2, 805-930
March, 161-240	July, 545-644	October, 931-1010
April, 241-320	August, 645-740	November, 1011-1090
Supplement 1, 321-396		December, 1091-1170



# HEART

- abnormalities
  - and diabetes, 207
- contraction and responsiveness to norepinephrine
  - and insulin, \*636
- examinations
  - in tolbutamide-treated diabetics, 1131-1132
- isolated chick embryo
  - insulin receptors of, \*365
- muscle slices
  - and orthophosphate and serine incorporation into phosphatidylserine, glucagon and, \*473-474
- myocardial infarction
  - diabetic capillaropathy and, 928-930
  - and hypoglycemic drug therapy, \*369
  - and insulin response to oral glucose in former patients with, 586-593
  - in Pima Indians, 561-565
  - previous, and insulin response to oral glucose, 586-593
  - in tolbutamide- and insulin-treated diabetics, 1132-1134
- norepinephrine, epinephrine, and dopamine
  - in long-term diabetics, 6-10
- norepinephrine stores
  - in diabetics, \*1083
- rate
  - loss of autonomic regulation of, in diabetic autonomic neuropathy, 748-751
  - of tolbutamide-treated diabetics, 1137
- tachycardia
  - and postural hypotension in diabetic autonomic neuropathy, 93-94
  - and tolbutamide, \*535

# HEART DISEASE. *See also* Cardiovascular disease

- coronary
  - and cigarette smoking, 718
  - in diabetics and nondiabetics, \*346
  - as indication for diabetic screening, 531
  - in Pima Indians, 561-565
- and tolbutamide therapy in diabetes, 1131-1137

# HEMOGLOBIN

## components

- in diabetic identical twins, \*318
- glycosylation in vivo
  - as diabetic control monitor, \*335

# HEMOGLOBIN A<sub>1c</sub>

- and diabetes, 928
- in diabetic mice, 1-4
- formation in diabetic pregnancy, \*335
- and glucose intolerance in diabetes, 230-232
- in insulin-dependent and independent diabetics, 890-896
- and pregnancy
  - in normal, gestational diabetic, and diabetic women, 118-1122

# HEMORRHAGE

- pulmonary
  - and somatostatin in baboons, \*156

# HEMOSTASIS

- and somatostatin, \*156

# HEPARIN

- and lipolysis
  - and diabetes, \*234-235
- and <sup>75</sup>Se-SM-lipoprotein metabolism in vivo, 45-50

# HEPATOCYTES

- glycogen synthase regulation in, \*389
- rat
  - and insulin control of hepatic gluconeogenesis, \*331

# HEREDITY

- and diabetic offspring of diabetic couples, \*335
- and discordance of diabetic microangiopathy in identical twins, 24-28
- and encephalomyocarditis virus-induced diabetes development, 190-197
- and histocompatibility antigen HL-A8
  - and leukocyte chemotaxis in juvenile diabetics and their first-degree relatives, \*371
- and histocompatibility antigens
  - in diabetic identical twins, \*236
  - in families with maturity-onset diabetes of the young and juvenile, insulin-dependent diabetes, \*336
- and homozygous familial hypercholesterolemia, \*154

- and hyperlipemia and maturity-onset diabetes in rats, \*354
- and hyperproinsulinemia, \*635
- and large molecular weight immunoreactive glucagon, \*326
- and leukocyte chemotaxis in diabetics and their nondiabetic first-degree relatives, 880-883
- and "maturity-onset" diabetes of youth, \*635
- and overt diabetes in offspring of rats with induced latent diabetes, \*474
- and serum insulin and growth hormone in monozygotic twin siblings of juvenile-onset diabetics, \*155

# HEXOKINASE

- adipose tissue activity
  - and obesity, \*634

# HEXOSE

- non-glucose
  - and insulin release and glucose utilization, \*364
- transport
  - sensitivity to cytochalasin B, insulin and, \*336
- transport in rat pancreatic islets and alloxan, \*75-76

# <sup>3</sup>H-HISTIDINE

- incorporation into protein and glucose-6-phosphate dehydrogenase
  - insulin, protamine sulfate, and prostaglandins and, \*366
- and blood glucose regulation
  - in normal, obese and diabetic subjects, \*539
- and diabetic ketoacidosis therapy, \*371
- in dogs, 1018-1025
- and glucose homeostasis and insulin secretion, \*341
- in pancreatic islet-transplanted diabetic rats, 944-947
- response in diabetics and normals to, 1092-1095

# HISTOCOMPATIBILITY ANTIGENS

- in families with maturity-onset diabetes of the young and juvenile insulin-dependent diabetes, \*336

## DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
 February, 81-160  
 March, 161-240  
 April, 241-320  
 Supplement 1, 321-396

May, 397-476  
 June, 477-544  
 July, 545-644  
 August, 645-740

September, 741-804  
 Supplement 2, 805-930  
 October, 931-1010  
 November, 1011-1090  
 December, 1091-1170

- HL-A8**  
in juvenile diabetics, and their first-degree relatives, \*371
- HORMONES**  
and diabetic ketoacidosis, \*1084  
gastrointestinal  
and endocrine pancreas, \*373  
and hyperlipidemia of pregnancy, \*369  
and insulin resistance in diabetic ketoacidosis, \*365  
lipolytic  
and cyclic AMP phosphodiesterase activity in normal and diabetic rat adipose tissue, \*77  
luteinizing hormone-release hormone in impotent diabetic males, 975-977  
polypeptide  
transport in mouse islets of Langerhans, \*344  
and regulation of human adipocyte insulin receptors, \*360  
somatostatin  
and inhibition of insulin release, \*472  
and platelet aggregation, \*472  
in rat stomach and pancreas, \*471  
steroid  
and somatomedin activity in vitro, \*1005
- HYDRAZINE**  
and inhibition of gluconeogenesis in diabetic rats, \*315
- HYDROCORTISONE**  
and fibroblast collagen and protein synthesis  
and diabetes, \*336
- HYDROQUINIDINE**  
and pancreatic glucagon levels in rats, \*374
- B-HYDROXYBUTYRATE**  
and blood ketone levels  
and diabetes and insulin, 776-783
- BETA-HYDROXYBUTYRIC ACID**  
-induced lactic acidosis in alloxan diabetic rabbits, \*534
- 3-HYDROXY-3-METHYLGLUTARYL COENZYME A**  
reductase activity  
in homozygous familial hypercholesterolemia patients, \*154
- HYPERCHOLESTEROLEMIA**  
homozygous familial, \*154
- HYPERGLUCAGONEMIA**  
arginine-stimulated  
in diabetic Pima Indians, 404-407
- HYPERGLYCEMIA**  
alimentary  
and gastric surgery, 234  
and cholesterol metabolism, \*324  
and constant-infusion insulin therapy and insulin adsorbance to polyvinyl-chloride surfaces, 72-74  
and diazoxide, \*330  
endogenous in diabetics  
and glucagon, \*236  
epinephrine-induced  
and pancreatic glucagon secretion, 65-70  
fasting  
and insulin resistance mechanisms in \*328  
and glucagon suppression  
insulin and, \*352  
and "glycogen nephrosis," 850-856  
inappropriate  
animal models of, \*236  
liver enzyme activity before and after onset of  
in diabetic Chinese hamsters, \*358  
and microangiopathy  
in cold-acclimated eel, \*382  
and myopia, 29-31  
neonatal  
and insulin and growth hormone responses, 428-431  
neurotensin-induced  
and pancreatic islet and adrenal medulla mediation of, \*337  
nonketotic  
and renin-angiotensin-aldosterone system in diabetics, 824  
in obese mice  
and insulin binding to liver plasma membranes, \*1162-1163  
and insulin receptors, \*1162  
insulin secretion and, \*372  
and liver insulin removal, \*636  
in rats  
and xenotransplantation of piscine islets into, \*797  
in "stable" insulin-dependent diabetics  
and glucagon secretion, \*471
- HYPERINSULINISM**  
and myocardial infarction and peripheral vascular disease, 586-593  
in pancreatic islet-transplanted diabetic rats, 944-947  
in Pima Indians  
age of onset of, \*384
- HYPERKETONEMIA**  
and glucose-stimulated insulin release, \*381  
and starvation  
and inhibition of ketogenesis by ketone bodies, \*534
- HYPERLIPEMIA**  
and diabetes in rats  
heredity and, \*354  
and diabetic ketosis, \*352  
genetic  
and halofenate therapy, insulin and glucagon secretion and, \*536
- HYPERLIPIDEMIA**  
as indication for diabetes screening, 531  
of pregnancy, \*369
- HYPERLIPOPROTEINEMIA**  
in juvenile diabetics, \*355  
in streptozotocin-treated rats, 509-514  
type II  
and cholestyramine and neomycin therapies compared, \*637
- HYPEROPIA**  
and blood sugar levels, 29-31
- HYPERPARATHYROIDISM**  
diagnosis  
and intravenous tolbutamide tolerance test, \*355
- HYPERPROINSULINEMIA**  
and heredity, \*635
- HYPERTENSION**  
and catecholamine assays, 1082  
essential  
plasma norepinephrine and, \*1082  
as indication for diabetes screening, 531  
and nephropathy  
and renin-angiotensin-aldosterone system, 820-825

DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80	May, 397-476	September, 741-804
February, 81-160	June, 477-544	Supplement 2, 805-930
March, 161-240	July, 545-644	October, 931-1010
April, 241-320	August, 645-740	November, 1011-1090
Supplement 1, 321-396		December, 1091-1170



- and plasma renin activity in diabetics, 969-973  
and renal arterial stenosis in diabetics, \*378  
in tolbutamide-treated diabetics, 1136-1137
- HYPERTHYROIDISM**  
and plasma insulin response to arginine, 961-968
- HYPERTRIGLYCERIDEMIA**  
endogenous  
and adipocyte metabolism, \*236  
and myocardial infarction and peripheral vascular disease, 586-593  
and sodium dichloroacetate, \*363
- HYPOALDOSTERONISM**  
and renin-angiotensin-aldosterone system in diabetics, 824-825
- HYPOCALCEMIA**  
and acute pancreatitis  
and inadequate parathyroid response, \*538
- HYPOGLYCEMIA**  
alimentary. *See* Hypoglycemia, postprandial  
and benign mesothelioma, 202-205  
blood glucose monitoring during, 984-987  
differentiation from hypotension, 94  
and diphenylhydantoin effect on glucose tolerance, \*735  
and exercise in diabetics, \*333  
fasting  
in normal adults, \*634-635  
glucagon response to  
and adrenalectomy, \*315  
and sympathectomy, \*317  
in glucose tolerance tests, \*333  
in hypopituitary children, \*537, \*734  
insulin-induced  
and adrenergic mechanisms, \*1083-1084  
and plasma catecholamines, \*1084-1085  
prolactin response to, \*351  
and plasma norepinephrine and epinephrine  
and somatostatin, \*235  
postprandial, 719-730  
ethanol and, \*735  
without gastrointestinal surgery, \*733
- post-vagotomy and pyloroplasty, \*736  
in premature infants, 430  
reactive, \*155  
and buformin therapy, \*734  
and carbohydrate restriction and glucose tolerance, \*153 \*734  
diagnosis and therapy, \*735-736  
and insulin secretion abnormalities, \*735  
and intravenous tolbutamide tolerance tests, \*355  
and organic brain dysfunction, \*734  
and psychiatric illness, \*734-735  
and reversed intestinal segment, \*536  
reactive postoperative  
and reversed intestinal segment, \*733  
sulfonylurea-induced  
and halofenate, \*236  
and L-tryptophan, \*369
- HYPOGLYCEMIC AGENTS**  
and vascular complications  
and adult-onset diabetes, 1129-1153  
and myocardial infarction therapy  
and plasma glucose levels, \*369
- HYPOLIPEMIA**  
and hyperlipemia  
during diabetic ketosis, \*352  
and protamine-zinc-somatostatin and lente insulin, \*377
- HYPOMAGNESEMIA**  
and magnesium depletion  
in diabetes, \*363
- HYPOPHYSECTOMY**  
and insulin-sensitive central nervous system glucoregulator receptor, \*158
- HYPOPITUITARISM**  
in children  
and hypoglycemia, \*537, \*734  
and role of growth hormone and cortisone in glucose and gluconeogenic substrate regulation, \*733-734  
and Staub-Traugott effect, \*153
- HYPOTENSION**  
hypoadrenergic and hyperadrenergic  
postural  
and plasma catecholamines in diabetics, \*347  
orthostatic
- and renin-angiotensin-aldosterone system in diabetics, 823  
postural  
insulin-induced in diabetic autonomic neuropathy, 90-94  
and plasma norepinephrine, \*1085
- HYPOTHALAMUS**  
and insulin secretion, 96-100  
lateral  
-induced obesity and stimulation of, 77  
and neurotensin  
and hyperglycemia, \*337  
primate  
insulin action on, \*322  
stimulation  
and liver gluconeogenesis and glycolysis in rats, \*76
- I**
- IMMUNE HEMOLYSIS INHIBITION ASSAY**  
and immunologic cross-reactivity of insulin derivatives, 398, 399-400
- IMMUNOFLUORESCENCE**  
of tubular basement membrane in diabetics, 701-707
- IMMUNOLOGY**  
abnormalities of  
in obese diabetic mice, \*356  
and diabetes, \*538  
and histocompatibility antigens  
in diabetic identical twins, \*236  
and immunopathology of renal extracellular membranes in diabetics, 701-707  
and inhibition of lymphocyte blastogenesis by factors in alloxan diabetic rat plasma, 614-621  
and insulin and insulin derivatives, 397-403
- IMMUNOPATHOLOGY**  
of renal extracellular membranes in kidneys transplanted into diabetics, 709-712
- IMPOTENCY**  
and diabetes  
and luteinizing hormone-release hormone tests, 975-977

DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80	May, 397-476	September, 741-804
February, 81-160	June, 477-544	Supplement 2, 805-930
March, 161-240	July, 545-644	October, 931-1010
April, 241-320	August, 645-740	November, 1011-1090
Supplement 1, 321-396		December, 1091-1170

INFANTS

- of diabetic mothers
  - and glucose control during pregnancy, \*384
  - pancreas islet fibrosis in, \*472
  - and respiratory-distress syndrome, \*637
- identical twins
  - birth weights and development of diabetes in, 25
- neonatal
  - plasma somatomedin activity variations in, \*1007
- neonatal hyperglycemia
  - and insulin and growth hormone responses, 428-431
- and obstetric abnormalities
  - as indications for diabetic screening, 530
- pancreas
  - as source of islet tissue for transplantation, 1123-1128

INFECTION. *See also* Viruses

- and basement-membrane thickening, 926-927
- and deep wound cultures in diabetic gangrene, \*385
- endotoxemia
  - and glucoregulation in normals and diabetics, \*383
- and impaired granulocyte adherence in diabetics, \*348
- and nonsuppressibility of gluconeogenesis by glucose, \*316
- recurrent
  - as indication for diabetic screening, 531
- ulcerations
  - and hyperbaric oxygen treatments, \*364
- Venezuelan encephalitis virus
  - and pancreatic disease in hamsters, 623-630

INSULIN

- action
  - in normal subjects, \*325
  - on primate hypothalamus, \*322
- acute withdrawal and administration in insulin-dependent diabetics
  - and plasma glucagon responses to intravenous arginine, 955-959
- and adipocyte insulin receptors, \*360
- and adipocyte plasma membrane sulfhydryl groups, \*382

- aggregation
  - and chromium, \*353
- and alanine infusions in protein-calorie malnutrition, \*75
- allergy
  - and glucagon secretion and plasma insulin, \*363
  - and insulin therapy, \*75
- amylase content
  - of neonatal and adult rat pancreases, \*796
- antibodies
  - in insulin-treated diabetics, \*367
- and arterial medial cell growth
  - and growth hormone, 1011-1016
- assays
  - of isolated rat islets, 486
- binding
  - to fat cells, cellular response to insulin and, \*1164
  - by fat cells, fasting and, \*321
  - and glucose metabolism during fasting \*321
  - in isolated rat adipocytes, obesity and, \*1163
  - to liver plasma membranes in obese hyperglycemic mice, \*1162-1163
  - to lymphocytes, diabetes and, \*1165
  - and obesity, \*158
  - and obesity and calorie restriction, \*1163
  - to thymocytes from suckling and hypophysectomized rats, \*154
- binding to adipocytes
  - age and obesity and, \*76
  - and glucose metabolism, \*368
- binding to adipocytes and circulating monocytes
  - and obesity, \*1163
- biosynthesis
  - in B-cells of obese hyperglycemic mice and anti-insulin serum coupled to sepharose 4B, \*154
  - and monoaminergic mechanisms and "glucoreceptor" specificity, \*75
  - in streptozotocin- and radiation-induced B-cell tumors from rat pancreas, \*343
- and brain metabolism, \*387
- and brain potassium and sodium transport, 758-762
- and carbohydrate homeostasis and diabetes, \*323
- and cardiac muscle contraction and re-

- sponsiveness to norepinephrine, \*636
- constant-infusion therapy
  - and adsorbance to polyvinylchloride surfaces, 72-74
- content of infant human pancreas, 1124-1125
- continuous low-dose infusion
  - and ketosis and acidosis, \*537
- and cyclic AMP phosphodiesterase activity
  - in normal and diabetic rat adipose tissue, \*77
- and cyproheptadine inhibition of proinsulin synthesis, \*343
- deficiency
  - and metabolic effects of exercise in diabetics, \*354
- degradation
  - in isolated liver cells, 173-178
  - and peptidase, \*387
  - and serum insulin-like activity, \*315
- degradation in serum by insulin-specific protease, \*318
- degrading enzyme, \*334
- dependence
  - and plasma C-peptide response to glucagon, \*329
- dependent concentrations of insulin receptors, \*1163-1164
- dependent diabetes
  - and hemoglobin A<sub>1c</sub> levels, 890-896
  - and pancreatectomy, \*534
  - preserved beta-cell function and blood glucose control in, \*362
  - and vertebral osteomyelitis with disc space abscess, \*359
- deprivation
  - and diabetic ketoacidosis, hormones and, \*1084
- derivatives
  - cross-reaction between, 397-403
- and diabetes
  - and glucagon infusions, \*341
- and diabetes control
  - and growth hormone levels, 167-172
- and diabetic acidosis
  - and hyperglucagonemia, \*371
- in diabetics and normals, 1091-1098
- and dog kidney glucagon uptake, \*327
- dosage
  - and diabetic ketoacidosis therapy, 771-775
  - and high carbohydrate diets, \*369
  - low, in juvenile diabetics, \*153
- effect on plasma cAMP in diabetics, \*373
- and exercise, \*1084

DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
 February, 81-160  
 March, 161-240  
 April, 241-320  
 Supplement 1, 321-396

May, 397-476  
 June, 477-544  
 July, 545-644  
 August, 645-740

September, 741-804  
 Supplement 2, 805-930  
 October, 931-1010  
 November, 1011-1090  
 December, 1091-1170

- exogenous, in isolated rat pancreatic islets  
and 6-phosphogluconate/glucose-6-phosphate ratio, \*337
- flux rates  
and glucose flux rates, \*316
- glucagon contamination of  
and glucagon antibodies in juvenile diabetics, \*334
- and glucagon effects on protein and amino acid metabolism, 865-870
- glucagon protease, \*353
- glucagon ratio  
in gestational diabetes, 16-21  
and glucagon response to arginine and diabetes, 227-229  
and glucagon suppressibility by hyperglycemia  
diabetes and, \*352
- and glucose infusions  
and plasma glucagon levels, \*157  
and glucose uptake and protein synthesis  
in rat adipose tissue, \*366  
and glucose utilization and exercise, \*154
- and hexose transport system sensitivity to cytochalasin B in isolated fat cells, \*336
- human diabetic and nondiabetic biologic adequacy of, \*382
- hypersecretion  
and respiratory-distress syndrome in infants of diabetic mothers, \*637
- immunoreactive  
in pancreatic islet-transplanted diabetic rats, 944-947  
and tumor hypoglycemia, 203, 205  
and immunoreactive glucagon levels in obese mice, \*361
- induced hypoglycemia  
and adrenergic mechanisms, \*1083-1084  
and glucagon response and adrenalectomy, \*315  
and plasma catecholamines, \*1084-1085  
and sympathectomy, \*317
- induced lipotrophy  
therapy for, 1052-1054
- induced lipogenesis  
and insulin receptors in isolated rats fat cells, \*1164
- infusion  
comparison of peripheral and portal routes, 691-699  
and restoration of glucose tolerance in depancreatized dogs, \*325
- infusions in dogs  
and glycogenolysis and gluconeogenesis, 283-290
- insensitivity  
in large rat adipocytes, \*1164-1165
- intravenous  
and plasma tryptophan and tyrosine in normals and patients with carcinoid tumors, \*536
- intravenous, continuously pumped  
and unstable diabetes, \*329  
and jejunal carbohydrate-metabolizing enzymes, \*75  
and ketoacidosis  
and somatostatin, \*538
- kinetics  
pregnancy and, \*234
- lente  
and protamine-zinc-somatostatin and hypolipemic action, \*377  
and lethal endotoxin shock pathogenesis, \*342  
and  $I^{14}C$  leucine incorporation into peripheral nerve myelin proteins, \*348
- levels  
diabetes control and, \*368  
during oral glucose tolerance tests in healthy children, age and, 505-508
- like activity  
in human serum, \*315  
liver plasma membrane receptors for, \*1006  
and lipotrophy therapy, 1052-1054  
and liver gluconeogenesis, \*331  
liver plasma membrane receptors for, \*1006
- low-dose infusion  
in ketoacidosis, \*376  
and macrophage function, \*348
- maternal and fetal serum  
response to glucose and leucine infusions, 545-549  
and metabolic response to ketones, 776-783
- metabolism  
and mazindol in obesity, \*235-236  
multiple daily injections of diabetic retinopathy and, 463-468  
pancreatic content  
in normal and alloxan-diabetic rats, 185  
and pancreatic islet-polypeptides, \*330
- parotid gland, \*328
- peripheral and portal  
in massive obesity, \*388
- peripheral resistance after glucose loading, 245-249
- polyvinylpyrrolidone-coupled, \*370
- portal vs. peripheral vein administration  
in fetal pancreas-transplanted rats, \*338  
and postural hypotension in diabetic autonomic neuropathy, 90-94
- potentiating peptides  
and glycogen synthesis, 413-418
- protamine sodium  
action, \*334  
and protein and branched chain amino acids, \*332  
and protein phosphorylation in isolated fat cells, \*337
- radioreceptor assay  
and plasma and pancreatic insulins and proinsulins, \*315
- release  
amino acid induced in genetically obese rats, \*356  
amino-acid induced, theophylline inhibition of, \*473  
arginine-induced, somatostatin and, \*535  
biphasic, in aging, obesity, and diabetes, \*324  
and calcium infusion in patient with islet-cell tumor, \*536  
from cold-stored pancreas islets, \*798-799  
dibutyl cyclic AMP-induced, somatostatin and, \*538  
diphenylhydantoin suppression of, \*380  
and encephalitis virus-induced pancreatic disease in hamsters, 623-630  
and gastric inhibitory polypeptide in maturity-onset diabetics, 931-935  
glucagon-stimulated, somatostatin and, \*339  
and glucoreceptors and diabetes, \*234  
glucose-induced, glucose potentiation of in isolated pancreas of fed and fasted rats, 949-953  
glucose-mediated, ethanol and, 752-757  
glucose-stimulated, hyperketonemia and, \*381

## DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
February, 81-160  
March, 161-240  
April, 241-320  
Supplement 1, 321-396

May, 397-476  
June, 477-544  
July, 545-644  
August, 645-740

September, 741-804  
Supplement 2, 805-930  
October, 931-1010  
November, 1011-1090  
December, 1091-1170

- and glucose tolerance, 241-244, 245-249  
and D-glucose anomers, 455-456  
hypoxic inhibition of, and beta adrenergic receptor dysfunction, \*534  
from human fetal islets of Langerhans, glucocorticoids and, \*359  
inhibition by scorpion toxin in rat pancreatic islets, 198-201  
and movement of B-granules in pancreatic B-cells, \*346  
and non-glucose hexoses, \*364  
from pancreatic islets stored in cold, \*315  
and phosphorylation and dephosphorylation, \*374  
and pressure on islet cells, \*351  
scorpion toxin inhibition of, \*1082-1083  
and somatostatin, \*472  
and tannic acid, \*376  
tolbutamide- and arginine-induced, pancreatic islet cyclic adenosine 3',5'-monophosphate and, 256-259  
from transplantable Syrian hamster insuloma, regulation of, \*474  
release and metabolism starvation and, \*391  
removal  
in liver of obese hyperglycemic mice, \*636  
renal handling of, \*382  
renal wastage in juvenile diabetics, 989-992  
requirements  
in obese diabetics on protein-sparing modified fast, 494-502  
resistance  
and acanthosis nigricans, \*636, \*1165  
and anti-insulin receptor antibodies, \*322  
and carbohydrate intolerance in gonadal dysgenesis, \*379  
in diabetic ketoacidosis, hormones and free fatty acids and, \*365  
and fasting hyperglycemia, \*328  
and insulin receptors in obese hyperglycemic mice, \*1162  
in myotonic dystrophy, glucose and free fatty acid response to insulin infusion in assessment of, \*379  
in obesity and diabetes, insulin receptor and, 1154-1160  
resistance sites  
in nonketotic diabetics, 673-677  
response  
of gestational diabetics, age and, \*324  
to glucose and amino acids, maternal and fetal, \*366  
glucose-induced, and temperature, 1026-1029  
response to glucose  
and neonatal hyperglycemia, 428-431  
response to intravenous glucagon  
in children and adolescents and oral glucose loading, \*537  
response to oral glucose  
and increased calorie intake, \*156  
in patients with previous myocardial infarction and patients with peripheral vascular disease, 586-593  
response to oral glucose and intravenous arginine  
and hypoglycemia, \*734  
responses and resistance  
in normal subjects and patients with chemical diabetes, \*383  
secretion  
and acute streptozotocin treatment in rats, 277-279  
and alpha-adrenergic receptors, \*1084  
and beta and beta<sub>2</sub>, \*155-156  
during beta cell depolarization with potassium, \*345  
and chronic glucagon excess, \*341  
conditioned in rats, \*390  
and contraceptive steroids, \*535  
diet and cholinergic effects and, \*361  
endogenous regulators of, \*384  
epinephrine and, \*387  
ethanol and, \*735  
and glucagon release, 764-769  
glucose-induced, colchicine inhibition of, \*325  
glucose-induced, magnesium and, \*360  
glucose-induced, in pregnant rats and their fetuses, \*362  
glucose-induced, site of protection of barbituric acid against alloxan inhibition of, \*345  
and halofenate in genetic hyperlipemia, \*536  
and intravenous stimulations, \*370  
by islet-cell tumor, 408-419  
in mild alloxan diabetic dogs, 161-165  
monoamine inhibition of, species variation in, \*375  
neuroendocrine control of, 96-100  
in obese hyperglycemic mice, \*372  
and octapeptide of cholecystokinin, \*154  
and oral glycerol administration, \*540  
in perfused rat pancreas,  $\alpha$  and  $\beta$  anomers of glucose and, \*155  
and postprandial hypoglycemia, \*733  
and prediabetes, preobesity, and dietary sugar, \*389  
and protein-calorie malnutrition in adults, \*539  
and reactive hypoglycemia, \*735  
somatostatin and, \*340  
somatostatin inhibition of, and ionophore, \*536  
somatostatin inhibition of, reversal of, 1031-1039  
in streptozotocin diabetic rats with fetal transplants, 57-58  
suitability of perfused pancreatic islets for study of, \*368  
secretion and biosynthesis  
glucose-induced, alloxan and D-glucose anomers and, 574-578  
secretion rates  
calculation in pancreatic beta-cell stimulation studies, 12-14  
sensitivity, \*154  
lipotrophic diabetes and, \*355  
"single peak" and "single component" and insulin lipotrophy, \*326  
and somatostatin, \*340  
and somatostatin and glucagon and hepatic glucose output in normal dog, 116-120  
-stimulated protein phosphorylation, \*357  
structure and function  
and zinc, \*383  
therapy  
and antibody formation rates in juvenile diabetics, \*362  
and basement membrane synthesis by glomeruli, \*349  
in diabetic children in Michigan survey, 125, 126  
for ketoacidosis, low dose vs. in-

DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
February, 81-160  
March, 161-240  
April, 241-320  
Supplement 1, 321-396

May, 397-476  
June, 477-544  
July, 545-644  
August, 645-740

September, 741-804  
Supplement 2, 805-930  
October, 931-1010  
November, 1011-1090  
December, 1091-1170

travenous, \*366  
and ketoacidosis in children, \*376  
and somatomedin activity in streptozotocin-diabetic rats, 522, 523-524  
and systemic insulin allergy, \*75  
and vascular complications, compared with tolbutamide therapy, 1129-1153  
-treated diabetes  
and cigarette smoking, 717-718  
exercise and metabolism and, \*333  
and wound healing, 811-814

# INSULIN RECEPTORS

and acanthosis nigricans, \*1165  
adipocyte  
hormonal regulation of, \*360  
antibodies to  
and isolated adipocytes, \*322  
binding  
and insulin-induced lipogenesis in isolated rat fat cells, \*1164  
cell surface distribution of, \*321  
in cultured human fibroblasts, 250-254  
deficiency  
in genetic and acquired obesity, \*158  
distribution, grouping and nonmigratory nature of, \*321  
glucose and, \*322  
and glucose metabolism during fasting, \*321  
in human breast cancer, \*380  
on human macrophages, \*348  
in human placental cell membranes, \*1005  
on human placental syncytial trophoblast, \*379  
insulin binding to  
obesity and calorie restriction and, \*1163  
and insulin binding to adipocytes and circulating monocytes, obesity and, \*1163  
insulin-dependent regulation of concentrations of, \*1163-1164  
insulin-induced dissociation into subunits, \*322  
and insulin resistance in obesity and diabetes, 1154-1160  
of isolated chick embryo heart cells, \*365  
in isolated rat adipocytes  
obesity and, \*1163  
in lipoatrophic diabetes, \*355  
in liver plasma membranes

in obese hyperglycemic mice, \*1162-1163  
in lymphocytes  
diabetes and, \*1165  
of mouse adipocytes  
and insulin insensitivity, \*368  
in obese hyperglycemic mice, \*1162  
in rat adipocytes  
and insulin insensitivity, \*1164-1165  
of skeletal muscle, \*317

# <sup>125</sup>I-INSULIN

binding to cultured human fibroblasts, 250-254  
and insulin receptors on human placental trophoblast, \*379  
preparation for radioimmunoassay and receptor assay, 260-266

# <sup>131</sup>I-INSULIN

in insulin flux rate study, \*316

# INSULINOMAS

diagnosis  
and intravenous tolbutamide tolerance test, \*355  
pancreatic polypeptide in, \*474  
rat  
transplantable, \*344  
regulation of in vitro insulin release from, \*474

# INTERVERTEBRAL DISCS

aging changes in diabetic and non-diabetic Chinese hamsters, 477-483

# IODOACETATE

-induced alterations of pancreatic  $\alpha$  and  $\beta$ -cell responses, \*156-157

# ISLETS OF LANGERHANS

amyloid infiltration  
in diabetic nonhuman primates, \*367  
calcium uptake  
and somatostatin, 1035  
fetal  
insulin release and glucocorticoids, \*359  
intrahepatic transplantation in rats and liver function, \*796  
intraportal transplantation in streptozotocin diabetic rats, 1041-1051

# isolated rat

DNA replication and cyclic AMP and phosphodiesterase inhibitors, \*379

# mouse

and polypeptide hormone transport in, \*344  
and neuroendocrine control of insulin secretion, 96-100  
survival in tissue culture, \*796  
transplantability in rats  
donor age and, \*338  
transplantation  
in diabetic rhesus monkeys, \*796  
transplantation in rats with severe ketotic diabetes  
metabolic response and, \*797-798

# ISOPROTERENOL

and insulin release  
and oxygen deficiency, \*534

# L-ISOPROTERENOL

infusion  
and glucagon and insulin secretion, \*155-156

# ISOTRANSPLANTATION

of neonatal pancreas  
and reversal of alloxan diabetes in rat, 180-189

# ISRAEL

diabetes development survey in, \*76

# J

# JEJUNUM

reversed segment  
as therapy for postoperative reactive hypoglycemia, \*733

# K

# KETOACIDOSIS. See also

Ketoacidosis, diabetic  
and renin-angiotensin-adosterone system, 824  
steroid-induced, \*330

# KETOACIDOSIS, DIABETIC

and alpha and beta cells, 147  
in children  
insulin therapy for, \*376  
and glucagon, \*1084

# DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
February, 81-160  
March, 161-240  
April, 241-320  
Supplement 1, 321-396

May, 397-476  
June, 477-544  
July, 545-644  
August, 645-740

September, 741-804  
Supplement 2, 805-930  
October, 931-1010  
November, 1011-1090  
December, 1091-1170



# SUBJECT INDEX 1976

- in indigent diabetic population, \*343  
and insulin resistance  
hormones and free fatty acids and,  
\*365  
and insulin therapy  
low dose vs. intravenous, \*366  
pharmacokinetic evaluation of dos-  
ing regimens for, 771-775  
in juvenile diabetics with acute ab-  
dominal pain, \*474  
and lipolysis suppression with 16, 16  
dimethylprostaglandin E<sub>2</sub>  
and persistence of ketosis, \*331  
management  
and low-dose insulin infusion, \*376  
potassium levels in  
and newly diagnosed vs. known  
diabetics, \*380  
and red cell oxygen affinity, 833-834  
and somatostatin, \*538  
therapy  
and cerebral edema, 111-115  
and hyperglucagonemia, 371
- KETOGENESIS**  
inhibition by ketone bodies in fasting  
humans, \*534  
and ketone body production assays,  
\*331  
and liver carnitine content in rats \*330
- KETONE BODIES**  
breath acetone  
in obese and diabetic mice, \*374  
glucagon regulation of, \*157  
and inhibition of ketogenesis in fasting  
humans, \*534  
turnover  
in dogs, \*331
- KETONES**  
infusions  
and amino acid and nitrogen  
metabolism, \*76  
metabolism  
and diabetes and insulin, 776-783  
in obese and diabetic mice, \*374
- KETONURIA**  
in Chinese hamsters  
and dietary fat reduction, \*364  
and fasting, 495
- KETOSIS, DIABETIC**  
and continuous low-dose insulin infu-  
sion, \*537  
and 16, 16 dimethylprostaglandin E<sub>2</sub>  
suppression of lipolysis, \*331
- and hyperlipemia and hypolipemia,  
\*352  
in streptozotocin diabetic rats  
and islet of Langerhans transplanta-  
tion, \*797-798
- KIDNEYS**  
arterial stenosis in diabetics  
hypertension secondary to, \*378  
bilateral exclusion in dogs  
and peripheral plasma glucagon  
levels and pancreatic  
glucagon production, \*316  
damage  
in early juvenile diabetes, \*370  
dog  
glucagon and insulin handling by,  
\*327  
extracellular membranes  
immunopathology in diabetics,  
701-707  
function  
and diabetes, 872-878  
and phenformin therapy, \*357  
of tolbutamide-treated diabetics,  
1138-1139  
glomerular basement membrane al-  
terations  
and diabetes, 920-924  
glomerular basement membrane  
thickness  
quantitation after renal transplanta-  
tion, \*357  
glomerular lesions  
in diabetic rats treated with pan-  
creatic islet transplantation,  
\*798  
glomerular lesions in rats  
and reduction of renal mass, \*349  
glomeruli  
basement membrane synthesis, in-  
sulin and, \*349  
glomeruli basement membrane  
changes  
biochemical basis for, 909-912  
glomerulosclerosis  
in "secondary" diabetes in baboons,  
\*349  
gluconeogenesis  
inhibition by quinolinate and hy-  
drazine in diabetic rats, \*315  
and insulin, proinsulin and C-peptide  
metabolism, \*382  
and insulin wastage in diabetic chil-  
dren, 989-992  
nephropathy, 785-786  
in animals and man, 850-856
- and renin-angiotensin-aldosterone  
system, 820-825  
nephrosis  
and glucocorticoid therapy and  
somatomedin, \*1004-1005  
nodular intercapillary glomerulo-  
sclerosis  
in diabetes secondary to chronic cal-  
cific pancreatitis, 713-716  
protein excretion  
provocation tests for, 872-874  
rat  
intracellular enzymes of collagen  
biosynthesis in streptozotocin  
diabetes and, 1066-1070  
transplanted in diabetics  
and immunopathology of renal ex-  
tracellular membranes,  
709-712  
transplantation  
and diabetes, 853-855  
and diabetic glomerulosclerosis,  
\*349  
and diabetic nephropathy, \*367  
and pancreatic grafts, 787-788
- KUSSMAUL'S RESPIRATIONS**  
and diabetic ketoacidosis, 111, 113
- L**
- LARON DWARFISM**  
receptor-active growth hormone in,  
\*1006  
and somatomedin activity and growth  
hormone levels, 996-997  
and urinary growth hormone and in-  
creased immunoreactive  
plasma, \*1006
- LESIONS**  
glomerular  
and reduction of renal mass in  
diabetic rats, \*349  
in streptozotocin-diabetic rats  
treated with pancreatic islet  
transplantation, \*798  
kidney glomerulosclerosis  
and kidney transplantation, \*349  
leg ulcerations  
and hyperbaric oxygen treatments,  
\*364  
microvascular  
in juvenile diabetics, 884-889  
ultrastructural  
in animal diabetic models, \*352

## DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
February, 81-160  
March, 161-240  
April, 241-320  
Supplement 1, 321-396

May, 397-476  
June, 477-544  
July, 545-644  
August, 645-740

September, 741-804  
Supplement 2, 805-930  
October, 931-1010  
November, 1011-1090  
December, 1091-1170

- LEUCINE**  
maternal and fetal serum insulin and growth hormone response to, 545-549
- <sup>14</sup>C LEUCINE**  
incorporation into proteins of peripheral nerve myelin and insulin and glucagon, \*348
- LEUKOCYTES**  
and basement-membrane thickening and infection, 926-927  
chemotaxis  
in diabetics and their nondiabetic first-degree relatives, 880-883  
in juvenile diabetics and their first-degree relatives, \*371  
migration  
uveoretinal antigen-induced inhibition of, 1106-1108
- LIPIDS**  
and acute starvation, \*388  
and diabetes control, \*368  
and high carbohydrate high fiber diet, \*324  
in juvenile diabetics diet and, \*355
- LIPOATROPHIC DIABETES**  
and insulin sensitivity, \*355
- LIPOATROPHY**  
insulin-induced therapy, 1052-1054  
and "single peak" and "single component" insulin, \*326
- LIPOGENESIS**  
in adipose tissue obesity and, \*634  
insulin-induced in isolated rat fat cells, insulin receptors and, \*1164
- LIPOLYSIS**  
16, 16 dimethylprostaglandin E<sub>2</sub> suppression or and persistence of ketosis, \*331  
and epinephrine, \*366  
and hyperobesity, \*357  
postheparin and diabetes, \*234-235
- LIPOPROTEIN**  
apolipoprotein distribution among in sucrose-fed rats, \*353
- low-density  
and fibroblast response in homozygous familial hypercholesterolemia patients, \*154  
metabolism studies, 679-690  
very-low-density and low-density metabolism in <sup>75</sup>Se-selenomethionine incorporation into human apoproteins study, 44-50  
specificity of incorporation of <sup>75</sup>Se-selenomethionine and, 32-42
- LIPOPROTEIN LIPASE**  
and glucocorticoids, \*634
- LIVER**  
adenylate cyclase activity and somatostatin, \*387  
carnitine  
and ketogenesis in rats, \*330  
enzyme activity  
and hyperglycemia in diabetic Chinese hamsters, \*358  
function  
and intrahepatic transplantation of islets of Langerhans in rats, \*796  
gluconeogenesis, \*76  
and diabetes, \*315  
insulin and, \*331  
and L-tryptophan in rats, \*369  
gluconeogenesis and glycolysis and hypothalamic stimulation, \*76  
glucose  
C<sup>14</sup> transfer from alanine-I-C<sup>14</sup> to, in diabetic rats, \*381  
glucose output in normal dogs and somatostatin, glucagon and insulin 116-120  
glucose production  
insulin inhibition of, 673-677  
glycogen synthase and synthase-D phosphatase and vagal stimulation, \*332  
glycogen synthesis and glycogen cycle enzyme activities  
regulation by glucose and galactose, \*539  
glycogenolysis and gluconeogenesis and insulin infusions in dogs, 283-290  
insulin and  
in fetal pancreas-transplanted diabetic rats, \*338  
insulin extraction ratio and ethanol, 756-757
- interaction with gut and oral glucose disposal, \*316  
isolated cells  
insulin degradation pathway in, 173-178  
isolated hepatocytes and glycogen synthase, \*389  
isolated perfused rat and glucagon effects on protein and amino acid metabolism, 865-870  
ketone production in dogs, \*331  
mitochondria  
fatty acid uptake in diabetic, fed and fasted rats, \*351  
mitochondrial calcium uptake and biguanides, \*360  
perfused, of obese hyperglycemic mice  
and insulin removal, \*636  
and plasma insulin level regulation evidence against feedback mechanism in, \*368  
plasma membrane receptors for non-suppressible insulin-like activity, soluble in acid ethanol, \*1006  
plasma membranes  
insulin binding to, in obese hyperglycemic mice, \*1162-1163  
rat  
plasma membrane phospholipids, fasting and alloxan diabetes and, \*351  
somatomedin, rabbit articular and epiphyseal chondrocyte response to, \*1007  
responses to glucagon and ATP content, \*535-536  
and somatomedin production, 995  
triglyceride biosynthesis and diabetes, \*378
- LUTEINIZING HORMONE-RELEASE HORMONE**  
in impotent diabetic males, 975-977
- LYMPHOCYTES**  
function  
in obese diabetic mice, \*356  
inhibition of blastogenesis by alloxan diabetic rat plasma, 614-621  
insulin binding to diabetes and, \*1165  
obesity and, \*1163  
insulin receptor concentrations

DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
February, 81-160  
March, 161-240  
April, 241-320  
Supplement 1, 321-396

May, 397-476  
June, 477-544  
July, 545-644  
August, 645-740

September, 741-804  
Supplement 2, 805-930  
October, 931-1010  
November, 1011-1090  
December, 1091-1170



insulin dependence of, \*1163-1164  
receptor assay for insulin, \*315

**B-LYMPHOCYTES**  
in juvenile diabetics, 101-103

**T-LYMPHOCYTES**  
in juvenile diabetics, 101-103  
peripheral  
in juvenile-onset and maturity-onset diabetics, 223-226

**LYSINE**  
and kidney protein excretion tests, 873-874

**LYSOSOMAL GLYCOHYDROLASE**  
and juvenile diabetes mellitus, 420-426

## M

**$\alpha^2$ -MACROGLOBULIN**  
and fibrinolysis  
and diabetic retinopathy, 807-809

**MACROPHAGES**  
function  
insulin and, \*348

**MACULOPATHY**  
and photocoagulation, \*471-472

**MAGNESIUM**  
depletion and hypomagnesemia  
and diabetes, \*363  
and glucose-induced insulin secretion, \*360

**MALNUTRITION**  
protein-calorie  
and alanine infusions effect on growth hormone, insulin and glucose, \*75  
protein-calorie in adults  
and glucose tolerance and insulin secretion, \*539

**MAZINDOL**  
and carbohydrate and insulin metabolism  
in obesity, \*235-236

**MENTAL ILLNESS**  
and blood glucose, \*362  
and reactive hypoglycemia, \*734-735

**MESANGIUM**  
thickening  
and diabetes, 850-856

**MESOTHELIOMA**  
benign  
and hypoglycemia, 202-205

**METABOLISM**  
adipocyte  
and endogenous hypertriglyceridemia, \*236  
adipose tissue  
and hyperobesity, \*357  
alanine  
and diabetes, \*333  
fasting and, \*358  
amino acid and nitrogen  
and ketone infusions, \*76  
of apoprotein moiety of plasma lipoproteins, 32-42  
brain  
insulin and, \*387, 758-762  
calcium  
in glucose-stimulated pancreatic islets, \*346  
carbohydrate  
and amyotrophic lateral sclerosis and Parkinson's disease, 1055-1063  
and capillary basement-membrane thickness in children, 650-659, 661-666  
and insulin and glucagon, \*323  
and periodontal disease, \*390  
and salivary gland insulin, \*328  
and somatostatin, 1097-1098  
carbohydrate, fat and mineral  
and pancreatic islet transplanted diabetic rats, \*389  
carbohydrate and insulin  
and obesity and mazindol, \*235-236  
cartilage  
serum inhibitor of, \*1007  
cholesterol  
and diabetes control, \*324  
and diet, \*361  
and exercise  
in insulin-treated diabetics, \*333, \*354  
of fat cells  
and extracellular calcium, \*372  
fatty acid  
and glucagon, 978-982  
of forearm tissues in man  
and glucagon infusion, 128-134  
in gestational diabetes, 16-21

glucagon  
in normals and diabetics, \*634  
and glucagon biosynthesis, \*156  
glucose  
and dichloroacetate in depancreatized dogs, \*385  
evaluation of fractional removal rate, 580-585  
and glucose-fatty acid cycle in skeletal muscle, \*375  
and insulin binding to adipocytes, \*368  
and insulin receptors in rat adipocytes during fasting, \*321  
and increased caloric intake in man, \*156  
insulin  
in isolated liver cells, 173-178  
in normal subjects, \*325  
and pregnancy, \*234  
islet  
of D-glucose, \*345  
ketones  
and diabetes and insulin. 776-783  
in obese and diabetic mice, \*374  
lipid  
and steroid contraceptives, \*535  
and malignant glucagonoma, \*370  
muscle  
and blood oxygen transport system in normals and diabetics, 914-919  
muscle amino acid  
and brief starvation, \*317  
nitrogen  
in obese diabetics on protein-sparing modified fast, 494-502  
and pancreatic islet transplantation in rats, \*316  
phosphorus  
and diabetes, 835-836  
protein and amino acid  
in isolated perfused rat liver, glucagon and, 865-870  
of sheep hind limb, \*635  
skeletal muscle  
and dichloroacetate, \*332  
and smoking, \*1083  
of very-low-density and low-density lipoproteins  
in  $^{75}\text{Se}$ -selenomethionine incorporation into human apoproteins study, 44-50  
**3-O-METHYL-D-GLUCOSE**  
and inhibition of streptozotocin diabetes in rats, 595-602

## DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
February, 81-160  
March, 161-240  
April, 241-320  
Supplement 1, 321-396

May, 397-476  
June, 477-544  
July, 545-644  
August, 645-740

September, 741-804  
Supplement 2, 805-930  
October, 931-1010  
November, 1011-1090  
December, 1091-1170

**METHYLENE BLUE**

and alanine release from muscles of diabetic and normal rats, \*333

**METHYLPREDNISOLONE**

-treated dogs  
gluconeogenesis from glycerol at rest and during exercise in, \*539

**METOCLOPRAMIDE**

and endocrine secretion from isolated perfused rat pancreas, \*375

**MICE**

brain  
insulin and, \*387  
brain metabolism  
insulin and, 758-762  
diabetic  
and immunologic responses, \*538  
and increased hemoglobin A<sub>1c</sub>, 1-4  
and insulin binding to adipocytes, glucose metabolism and, \*368  
and islet cell population, \*344  
and ultrastructural lesions, \*352  
and diabetic nephropathy, 850-856  
and genetic and acquired obesity  
and insulin receptor deficiency, \*158  
and inappropriate hyperglycemia, \*236  
islets of Langerhans  
polypeptide hormones transport in, \*344  
obese  
immunoreactive glucagon levels in, \*361  
obese diabetic  
breath acetone and ketone metabolism in, \*374  
and immunologic abnormalities, \*356  
obese hyperglycemic  
insulin binding to liver plasma membranes in, \*1162-1163  
insulin biosynthesis study in, \*154  
and insulin receptors, \*1162  
insulin removal in perfused liver of, \*636  
insulin secretion from isolated islets from, \*372  
pancreatic islets  
D-glucose anomer metabolism in, 450-457  
and virus-induced diabetes, 190-197

**MICHIGAN**

diabetes prevalence study of school-age children in, 122-127

**MICROANGIOPATHY**

and hyperglycemia  
in cold-acclimated eel, \*382

**MICROANGIOPATHY, DIABETIC**

and basement membrane thickening, 925-927  
discordance of, in identical twins, 24-28  
growth hormone and, 845-848  
and plasma protein changes  
and blood viscosity, 858-863  
and red-cell aggregation and deformability in diabetics, 897-901

**MICROSCOPY**

and basement membrane changes in diabetes, 909-912  
electron  
of alpha cells, 139-146  
of fetal pancreas transplants in streptozotocin diabetic rats, 59  
and localization of somatostatin in pancreatic islets of rat, \*155  
of muscle capillary from diabetic and nondiabetic *Mystromys albicaudatus*, 446, 447  
of pancreatic islets of intraportal-islet transplanted rats, 1045-1050  
of glomerular basement membrane of diabetics, 923  
of intervertebral discs of diabetic and nondiabetic Chinese hamsters, 478-481  
and islet fibrosis in infants of diabetic mothers, \*472  
of isotransplanted neonatal pancreas in alloxan diabetic rats, 185, 186  
light  
of fetal pancreas transplants in streptozotocin diabetic rats, 58  
of isolated rat islets in vitro, 486  
and pancreatic islets of rats with streptozotocin diabetes, 600, 601  
light and electron  
and wound healing as model for diabetic angiopathy, 811-819  
of pancreas of newly diagnosed juvenile diabetic, \*365  
pancreatic  
and encephalitis virus-induced pancreatic disease in hamsters, 626-628

**MINERALS**

calcium  
metabolic effects on fat cells, \*372  
and reversal of somatostatin inhibition of insulin and glucagon secretion, \*536  
uptake in glucose-stimulated pancreas islets, \*346  
chromium  
and insulin aggregation, \*353  
magnesium  
and diabetes, \*363  
and glucose-induced insulin secretion, \*360  
metabolism  
and pancreatic islet-transplanted diabetic rats, \*389  
phosphate  
pancreatic islet content during secretory stimulation, \*346  
phosphorus  
and diabetes, 835-836  
zinc  
and insulin structure and function, \*383

**MINNESOTA**

diabetes survey  
among public school children, \*372

**MITOCHONDRION**

calcium uptake  
biguanides and, \*360

**MONKEYS**

hypothalamus  
insulin action on, \*322  
islets of Langerhans  
amyloid infiltration, \*367  
cultivation, \*339  
isolation of, \*386  
pancreatectomized and streptozotocin diabetic  
and blood glucagon response to arginine and somatostatin, \*339  
Rhesus  
plasma insulin, glucagon and glucose synchronous stable oscillations in, \*340

**MONOAMINES**

and insulin biosynthesis, \*75  
pancreatic islet uptake and action, species variation in, \*375

**MONOCYTES**

circulating, insulin binding to obesity and, \*1163

**DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE**

January, 1-80  
February, 81-160  
March, 161-240  
April, 241-320  
Supplement 1, 321-396

May, 397-476  
June, 477-544  
July, 545-644  
August, 645-740

September, 741-804  
Supplement 2, 805-930  
October, 931-1010  
November, 1011-1090  
December, 1091-1170

**MORPHOMETRIC TECHNIQUES**

and measurement of capillary basement membrane thickening, 604-612

**MORTALITY**

causes

in diabetes survey in Rochester, Minnesota, 566-572

and cerebral edema in diabetic ketoacidosis therapy, 111-115

and diabetes, 785

fetal

and maternal diabetes management, \*373

of infants of diabetic mothers

and glucose control during pregnancy, \*384

and neonatal hyperglycemia, 431-432

and pancreas transplantation, 788

into retroperitoneal jejunal loop in dogs, \*795

and pancreatic islet transplantation

in rats with severe ketotic diabetes, \*797-798

and phenformin-associated metabolic acidosis, 292-296

and renal transplantation in diabetic nephropathy, \*367

**MUSCLE**

amino acid metabolism

and brief starvation in nonobese man, \*317

capillary basement membrane

in discordant identical twins, 26-28

capillary basement membrane thickening

in spontaneously diabetic *Myotomys albicaudatus*, 444-448

cardiac

and insulin, \*636

and orthophosphate and serine incorporation into phosphatidylserine, glucagon and, \*473-474

and tolbutamide, \*535

cells

and glucose and diabetes, \*336

free amino acid content and release diabetes and, \*333

metabolism

and blood oxygen transport system in normals and diabetics, 914-919

ocular

and diabetes, 459-462

rabbit aortic

growth in media containing diabetic and hyperlipemic serum, 207-214

skeletal

of fasted normal and adrenalectomized rats, amino acid release and protein turnover in, \*333

fuel utilization during exercise in, \*154

glucose-fatty acid cycle in, \*375

insulin receptors in, \*317

metabolism, dichloroacetate and, \*332

**MYOCARDIAL INFARCTION**

diabetic capillaropathy and, 928-930

and hypoglycemic drug therapy

and plasma glucose levels, \*369

in Pima Indians, 561-565

previous

and insulin response to oral glucose, 586-593

in tolbutamide- and insulin-treated diabetics, 1132-1134

**MYOPIA**

and serum glucose concentration, 29-31

**MYOTONIC DYSTROPHY**

and insulin resistance

plasma glucose and free fatty acid response to low-dose insulin

infusion for assessment of, \*379

and tolbutamide tolerance tests, \*355

**MYSTROMYS ALBICAUDATUS**

spontaneous diabetes in

and muscle capillary basement membrane thickening, 444-448

**N**

**NEOMYCIN**

and hyperlipoproteinemia type II therapy, \*637

**NEPHROPATHY, DIABETIC**

in animals and man, 850-856

and basement-membrane thickening, 925

and glomerular basement membrane changes, 920-924

renal transplantation in, \*367

**NERVOUS SYSTEM**

autonomic dysfunction

and reduced plasma norepinephrine response to standing in, \*1085

and insulin release

and endocrine glands, 96-100

and insulin secretion and glucose tolerance

and diet, \*361

parasympathetic

and liver carbohydrate metabolism, \*332

peripheral

<sup>14</sup>C leucine incorporation into proteins of, insulin and glucagon and, \*348

sympathetic

and essential hypertension, \*1082

and familial dysautonomia, \*1083

and glucagon response to hypoglycemia, \*317

and norepinephrine and insulin release, 198-201

regulation of endocrine pancreas and pancreatic norepinephrine turnover and, \*391

**NEUROPATHY, DIABETIC**

autonomic

and impotency in diabetic males, 977

and insulin-induced postural

hypotension, 90-94

and total cardiac denervation, 748-751

and bladder and urethral innervation

detection of, 1100-1105

and heart norepinephrine, epinephrine, and dopamine in long-term diabetics, 6-10

**NEUROPATHY, PERIPHERAL**

as indication for diabetes screening, 531

**NEUROTENSIN**

-induced hyperglycemia

and pancreatic islet and adrenal medulla mediation of, \*337

**NICOTINAMIDE**

and streptozotocin effect on red-blood-cell-reduced glutathione, 216-221

**DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE**

January, 1-80

February, 81-160

March, 161-240

April, 241-320

Supplement 1, 321-396

May, 397-476

June, 477-544

July, 545-644

August, 645-740

September, 741-804

Supplement 2, 805-930

October, 931-1010

November, 1011-1090

December, 1091-1170

**NICOTINIC ACID**

- in hypercholesterolemia therapy, \*154
- and pancreatic glucagon levels in rats, \*374

**NITROGEN**

- metabolism
  - and ketone infusions, \*76
  - in obese diabetics on protein-sparing modified fast, 494-502

**NITROPRUSSIDE**

- and idiopathic lactic acidosis therapy, \*158

**NOREPINEPHRINE**

- cardiac muscle responsiveness to, insulin and, \*636
- cardiovascular system
  - and long-term diabetes, \*1083
  - and exercise, \*1084
- in heart tissue of long-term diabetics, 6-10
- and insulin-induced hypoglycemia
  - and adrenergic mechanisms, \*1083-1084
- and insulin release inhibition, 198-201
- isotope-derivative assays for, 1071-1080
- pancreatic turnover in rats
  - and assessment of sympathetic regulation of endocrine pancreas, \*391
- radioenzymatic assay for, \*1082
- release
  - and hypertension and hypotension in familial dysautonomia, \*1083
  - and smoking during adrenergic blockade, \*1083
- and scorpion toxin inhibition of insulin release in rat pancreatic islets, \*1082-1083
- secretion
  - scorpion-toxin-stimulated in perfused rat pancreas, 645-649
- vascular reactivity to
  - and diabetes, 268-274

**NUTRITION**

- associated conditioned insulin secretion in rats, \*389
- and postprandial hypoglycemia, 719-730
- and somatomedin
  - and cartilage growth activity in streptozotocin-diabetic rats, 516-526

**O**

**OBESITY**

- and adipose tissue metabolism, \*357
- and amino acid-induced insulin and glucagon release in rats, \*356
- and biphasic insulin release, \*324
- and diabetes
  - and nitrogen metabolism and insulin requirements during protein-sparing modified fast, 494-502
- in diabetic mice
  - and immunologic abnormalities, \*356
- and ethanol-induced alterations of glucose tolerance, postglucose hypoglycemia, and insulin secretion, \*735
- and fasting
  - and inhibition of ketogenesis by ketone bodies, \*534
- genetic and acquired
  - and insulin receptor deficiency, \*158
- and hyperglucagonemia and blood glucose regulation, \*539
- and hyperglycemia in mice
  - and insulin binding to liver plasma membranes, \*1162-1163
  - and insulin receptors, \*1162
  - insulin secretion and, \*372
  - and liver insulin removal, \*636
- and immunoreactive glucagon levels, \*361
- as indication for diabetes screening, 531
- induced
  - and eating behavior, blood glucose, and insulin in rats, \*77
  - and insulin binding to adipocytes and circulating monocytes, \*1163
  - and insulin binding, glucose transport, and glucose oxidation
    - in isolated rat adipocytes, \*1163
  - and insulin binding to isolated adipocytes, \*76
  - and insulin binding to receptors, \*1163
  - and insulin receptors in skeletal muscle, \*317
  - and insulin resistance
    - insulin receptor and, 1154-1160
  - and intestinal-bypass procedure
    - and arthritis, \*318
  - and lipogenesis in adipose tissue
    - and enzymes, \*634

massive

- and peripheral and portal insulin and glucagon levels, \*388
- and rice/reduction diet program, \*472-473
- and maturity-onset diabetes
  - and serum gastric inhibitory polypeptide, 931-935
- and mazindol
  - and carbohydrate and insulin metabolism, \*235-236
- and myocardial infarction and peripheral vascular disease, 586-593

**OBITUARIES**

- Williams, Frederick W., 632-633

**OCULAR PALSIES**

- in juvenile diabetics, 459-462

**ORAL CONTRACEPTIVES**

- and carbohydrate tolerance, \*157
- steroids
  - and arginine-stimulated glucagon and insulin secretion, \*535

**ORAL HYPOGLYCEMIC AGENTS**

- and capillary basement-membrane thickness in children, 663-665
- and control of mild diabetes
  - and increased caloric intake, \*390
- and myocardial infarction
  - and plasma glucose levels, \*369

**ORTHOPHOSPHATE**

- incorporation into phosphatidylserine and glucagon, \*473-474

**OSMIUM TETROXIDE**

- fixation, in capillary basement membrane thickening studies, 604-612

**OSTEOMYELITIS**

- vertebral
  - in insulin-dependent diabetics, \*359

**OVULEN**

- and carbohydrate tolerance, \*157

**OXYGEN**

- deficiency
  - and insulin release, and beta adrenergic receptor dysfunction, \*534

DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
 February, 81-160  
 March, 161-240  
 April, 241-320  
 Supplement 1, 321-396

May, 397-476  
 June, 477-544  
 July, 545-644  
 August, 645-740

September, 741-804  
 Supplement 2, 805-930  
 October, 931-1010  
 November, 1011-1090  
 December, 1091-1170

hyperbaric  
and diabetic ulcerations, \*364  
transport  
and diabetes, 832-837  
transport system  
in normals and diabetics, muscle  
metabolism and, 914-919

# OXYHEMOGLOBIN DISSOCIATION CURVES and diabetes, 832-837

## P

## PANCREAS

alpha and beta cell responses  
and iodoacetate and iodoacetamide,  
\*156-157  
alpha cell function  
and insulin reaction, \*363  
alpha cell hyperplasia  
in rats fed high protein diet, \*327  
alpha cell response  
and circulating glucagon antibodies  
in juvenile diabetics, \*334  
alpha cells  
abnormalities in diabetics, \*157  
and diabetes, 136-149  
artificial  
prototype glucose oxygen electrode  
for, \*385  
artificial endocrine  
and comparison of peripheral and  
portal routes of insulin infu-  
sion, 691-699  
beta-cell function  
and plasma C-peptide response to  
glucagon, \*329  
preserved, in insulin-dependent  
diabetes, \*362  
beta-cell response assay  
and glucose loading, 241-244  
beta-cell stimulation  
in diabetics, normals, and pan-  
creatitis patients, 11-14  
beta-cell toxicity  
and streptozotocin anomers, \*384  
beta cells  
depolarization with potassium, insu-  
lin secretion during, \*345  
glucose effect on, \*381  
movement of B-granules in, insulin  
release and, \*346  
response to glucose in newborn rats,  
temperature and, 1026-1029  
in spontaneously diabetic guinea  
pigs, 442

temperature and electrical activity  
of, \*377  
beta cells of obese hyperglycemic mice  
insulin biosynthesis study in, \*154  
cancer  
and glucose tolerance, plasma insu-  
lin and glucagon responses,  
\*391  
chronic fibrocalcific pancreatitis  
diabetes secondary to, nodular  
glomerulosclerosis and,  
713-716  
and contraceptive steroids, \*535  
disease in hamsters  
Venezuelan encephalitis virus-  
induced, 623-630  
dog  
and insulin secretion and epineph-  
rine, \*387  
endocrine  
intestinal substances influencing,  
\*373  
fetal  
transplantation into diabetic rats,  
\*338  
transplantation, hepatic-portal route  
and, \*338  
transplantation, in streptozotocin-  
induced diabetic rats, 56-63,  
\*798  
glucagon levels  
and reserpine, propranolol, hydro-  
quinidine, procaine, ver-  
apamil, atropine, and  
nicotinic acid in rat, \*374  
in streptozotocin-treated Chinese  
hamsters, \*390  
glucagon production  
and acute kidney exclusion in dogs,  
\*316  
glucagon secretion  
and epinephrine-induced hyper-  
glycemia, 65-70  
immunoreactive glucagon  
in normal dogs, 1020  
infant  
as source of islet tissue for trans-  
plantation, 1123-1128  
insulin secretion  
and insulin receptors in third cere-  
bral ventricle, \*322  
insulins and proinsulins  
compared with plasma insulins and  
proinsulins, \*315  
islet allografts  
and antibodies in tolerant rats, \*338  
islet-cell adenoma  
and fasting hypoglycemia, \*635

islet cell adenomas and carcinomas  
and serum insulin suppressibility by  
somatostatin, diazoxide and  
phenytoin, \*354  
islet cell function  
and obesity, \*356  
islet cell membranes  
and tannic acid, \*376  
islet-cell tumor  
and glucagon secretion suppression  
and stimulation mechanisms,  
408-419  
and insulin and proinsulin release  
during calcium infusion, \*536  
pancreatic polypeptide in, \*474  
islet cells  
in diabetic mice, \*344  
and pressure-induced insulin re-  
lease, \*351  
islet fibrosis  
in infants of diabetic mothers, \*472  
islet function  
somatostatin and, \*340  
islet polypeptides  
in healthy subjects and diabetics,  
\*330  
islet transplantation  
and carbohydrate, fat and mineral  
metabolism in diabetic rats,  
\*389  
and glomerular lesions in strep-  
tozotocin diabetic rats, \*798  
with neonatal rat pancreases, \*796  
islet transplantation in diabetic rats  
and development of hyperin-  
sulinemia and hyper-  
glucagonemia, 944-947  
metabolic response to, \*316  
islets  
biphasic glucose-induced mem-  
brane electrical activity in,  
\*345  
cold stored, and insulin release,  
\*315, \*798-799  
cyclic adenosine  
3',5'-monophosphate,  
tolbutamide- and arginine-  
induced insulin release and,  
256-259  
digestion-filtration method for isola-  
tion of, 667-672  
and glucagon and insulin secretion  
studies, \*368  
D-glucose anomer metabolism,  
450-457  
glucose stimulation of, calcium up-  
take and, \*346

## DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
February, 81-160  
March, 161-240  
April, 241-320  
Supplement 1, 321-396

May, 397-476  
June, 477-544  
July, 545-644  
August, 645-740

September, 741-804  
Supplement 2, 805-930  
October, 931-1010  
November, 1011-1090  
December, 1091-1170



- of high-protein-fed rats, and non-suppressible glucagon secretion, 51-55
- inhibition of insulin release by scorpion toxin, \*1082-1083
- isolation from adult primate, \*386
- metabolism of D-glucose, \*345
- monoamine uptake and action, species variation in, \*375
- neuroendocrine control of, 96-100
- and neurotensin-induced hyperglycemia, \*337
- of normal and diabetic Chinese hamsters, response to long-term culture, \*371
- from obese hyperglycemic mice, insulin secretion from, \*372
- phosphate content during glucose stimulation, \*346
- phosphatidylinositol hydrolysis in, \*337
- 6-phosphogluconate/glucose-6-phosphate ratio in, insulin and, \*337
- phosphoprotein phosphatase, \*374
- rat and monkey, cultivation in vitro, \*339
- structural and functional changes in juvenile diabetics, \*365
- isletitis
- streptozotocin-induced in mice, \*344
- isolated, of fed and fasted rats
- glucose potentiation of glucose-induced insulin release in, 949-953
- isolated, perfused rat
- and metoclopramide effect on endocrine secretion from, \*375
- isolated rat islets
- and insulin secretion and biosynthesis, and alloxan and D-glucose anomers, 574-578
- long-term perfusion in vitro, 484-492
- starvation and insulin release and metabolism and, \*391
- L-isoproterenol infusion in dogs and glucagon and insulin secretion, \*155-156
- neonatal rat islets transplantation, \*376
- norepinephrine turnover in rats and assessment of sympathetic regulation of endocrine pancreas, \*391
- organ-cultured neonatal
- isotransplantation in alloxan diabetic rats, 180-189, \*798
- perfused rat
- and glucose-stimulated glucagon release during calcium deprivation, \*473
- insulin and glucagon secretion,  $\alpha$  and  $\beta$  anomers of glucose and, \*155
- scorpion-toxin-stimulated glucagon secretion in, 645-649
- and theophylline inhibition of amino-acid-induced insulin release, \*473
- of perfused streptozotocin-treated rats and glucagon secretion, 275-282
- piscine islets
- transplantation into hyperglycemic rats, \*797
- polypeptide
- cellular localization of, \*364
- polypeptide secretion in dogs, \*329
- rat
- B-cell tumors, insulin biosynthesis in, \*343
- and glyburide, \*367
- somatostatin content, \*471
- and streptozotocin diabetes, 600-602
- rat endocrine
- and somatostatin inhibition of insulin release, \*472
- rat islets
- and alloxan, \*75-76
- cyclic AMP-stimulated protein kinase in, \*386
- electrical activity, somatostatin inhibition of, \*380
- and ionophore reversal of somatostatin inhibition of insulin and glucagon secretion, \*536
- and scorpion toxin inhibition of insulin release in, 198-201
- tissue
- intrasplenic transplantation in totally pancreatectomized dogs, \*795-796
- transplantation, 785-793
- in alloxan diabetic rats, \*797
- into retroperitoneal jejunal loop, \*795
- ultrastructural localization of somatostatin in islets of, \*155
- PANCREATECTOMY
- and diabetes in baboons and glomerulosclerosis, \*349
- in dogs
- and dichloroacetate and glucose metabolism, \*385
- and heterogeneity of plasma glucagon immunoreactivity, \*539-540
- and insulin infusions, \*325
- and intrasplenic autotransplantation of pancreatic tissue, \*795-796
- and glucagon secretion in dogs, \*355
- and hyperglycemia without glucagon, \*534
- in monkeys
- and blood glucagon response to arginine and somatostatin, \*339
- partial, in rat and diabetes, 187
- PANCREATIC POLYPEPTIDE
- in islet cell tumors, \*474
- PANCREATITIS
- acute
- and inadequate parathyroid response \*538
- chronic
- and beta-cell stimulation studies, 11-14
- chronic calcific
- diabetes secondary to, and nodular intercapillary glomerulosclerosis, 713-716
- PARAMUTATION
- and overt diabetes in offspring of rats with induced latent diabetes, \*474
- PARATHYROID
- response
- and acute pancreatitis, \*538
- PARKINSON'S SYNDROME
- and carbohydrate metabolism, 1055-1063
- PAROTID GLAND
- insulin, \*328
- PEPTIDASE
- neutral
- and degradation of B chain of insulin, glucagon and ACTH, \*387
- C-PEPTIDE
- human circulating
- heterogeneity of, \*329
- renal handling of, \*382

DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
February, 81-160  
March, 161-240  
April, 241-320  
Supplement 1, 321-396

May, 397-476  
June, 477-544  
July, 545-644  
August, 645-740

September, 741-804  
Supplement 2, 805-930  
October, 931-1010  
November, 1011-1090  
December, 1091-1170

- PEPTIDES**  
insulin potentiating  
and glycogen synthesis, 413-418
- PERFUSION SCANNING**  
and assessment of peripheral vascular  
disease in diabetics, 307-314
- PERIODONTAL DISEASE**  
and diabetes, \*390
- PHENFORMIN**  
and lactic acidosis  
and serum phenformin levels, \*359  
and plasma glucagon levels, \*328  
and postprandial hypoglycemia, 729  
therapy  
and metabolic acidosis, 292-296  
and plasma phenformin levels, \*357
- PHENOXYBENZAMINE**  
and insulin release, \*1082-1083  
and scorpion-toxin-induced glucagon  
release, 647
- PHEHTOLAMINE**  
and glucose-induced insulin release  
and oxygen deficiency, \*534  
and scorpion-toxin-induced glucagon  
release, 647
- PHENYLEPHRINE**  
and heart rate  
in diabetic autonomic neuropathy,  
749
- PHEOCHROMOCYTOMA**  
and blood pressure  
and plasma norepinephrine con-  
centrations, \*1082
- PHOSPHATE**  
pancreatic islet  
during glucose stimulation, \*346  
and red blood cell oxygen transport in  
diabetics, 834-836
- PHOSPHATIDYLINOSITOL**  
hydrolysis  
in stimulated pancreatic islets, \*337
- PHOSPHATIDYLSERINE**  
orthophosphate and serine incorpora-  
tion into  
and glucagon, \*473-474
- PHOSPHODIESTERASE**  
adipose tissue cyclic AMP  
activation and purification of, \*386  
inhibitors  
and DNA replication in isolated rat  
islets of Langerhans, \*379
- 6-PHOSPHOFRUCTOKINASE**  
adipose tissue activity  
and obesity, \*634
- 6-PHOSPHOGLUCONATE**  
glucose-6-phosphate ratio  
insulin and, \*337
- PHOSPHOLIPIDS**  
of rat liver plasma membrane  
fasting and diabetes and, \*351
- PHOSPHORYLATION**  
and insulin release, \*374
- PHOTOCOAGULATION**  
and diabetic retinopathy, 104-110,  
\*347  
and maculopathy in diabetics,  
\*471-472
- PIGS**  
and cardiac muscle responsiveness to  
insulin, \*636  
and glucose-mediated insulin release  
and ethanol, 752-757
- PIMA INDIANS**  
and coronary heart disease, 561-565  
and diabetes  
and arginine-stimulated hyper-  
glucagonemia, 404-407  
hyperinsulinism in  
age of onset of, \*384  
normal, prediabetic and diabetic  
glucose-induced glucagon suppres-  
sion in, \*352  
retinopathy study in, 554-560
- PITUITARY GLAND**  
ablation  
and florid diabetic retinopathy,  
104-110  
anterior  
and Staub-Traugott effect, 153  
disorders  
and somatomedin activity, 996
- PLACENTA**  
cell membrane insulin and  
somatomedin-C receptors,  
\*1005
- human syncytial trophoblast  
insulin receptors on, \*379
- PLAINS INDIANS**  
and insulin secretion  
and prediabetes, preobesity and  
dietary sugar, \*389
- PLASMA**  
alanine  
conversion to glucose, and insulin  
infusion in dogs, 286-287  
alloxan diabetic rat  
inhibition of lymphocyte blas-  
togenesis by, 614-621  
apoprotein  
metabolism studies, 679-690  
catecholamine assays, 1071-1080  
catecholamines  
and diabetes, \*347  
and exercise, \*1084  
and insulin-induced hypoglycemia  
and epinephrine infusions,  
\*1084-1085  
and postural hypotension in diabetic  
neuropathy, 94  
cholesterol  
and diet of polyunsaturated meats  
and dairy products, \*537  
in homozygous familial hypercholes-  
terolemia, \*154  
cAMP  
and insulin, \*373  
dopamine, norepinephrine, and  
epinephrine  
radioenzymatic assay for, \*1082  
free fatty acids  
and glycerol administration, \*540  
glucagon  
and chronic sulfonylurea therapy in  
adult-onset diabetes, \*387  
diet and, \*340  
in gestational diabetes, 16-21  
and insulin-glucose infusions in fast-  
ing diabetics and nondiabet-  
ics, \*157  
phenformin and, \*328  
and prostaglandins, \*317-318  
in streptozotocin-treated Chinese  
hamsters, \*390  
glucagon disappearance time  
in normals and diabetics, \*634  
glucagon immunoreactivity  
in glucagonoma syndrome, \*326,  
\*637  
in normal, depancreatized, and

DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80	May, 397-476	September, 741-804
February, 81-160	June, 477-544	Supplement 2, 805-930
March, 161-240	July, 545-644	October, 931-1010
April, 241-320	August, 645-740	November, 1011-1090
Supplement 1, 321-396		December, 1091-1170

- alloxan-diabetic dogs, \*539-540
- glucagon and insulin
  - in high-protein-fed rats, 51-55
- glucagon, insulin, growth hormone, fatty acids, ketone bodies and glucose
  - and glucagon infusion, 978-982
- glucagon levels
  - and acute kidney exclusion in dogs, \*316
- glucagon responses to intravenous arginine and acute insulin withdrawal and administration in insulin-dependent diabetics, 955-959
- glucose
  - and alanine infusions in protein calorie malnutrition, \*75
  - and diabetic control and management, \*636-637
  - and dichloroacetate, \*328
  - during fasting in normal adults, \*634-635
  - in fetal pancreas transplanted streptozotocin diabetic rats, 60-61
  - and insulin resistance in fasting hyperglycemia, \*328
  - in mild alloxan diabetic dogs, 163-165
  - normalization by continuously pumped intravenous insulin, \*329
  - and relationship of time of day and time since last meal to, 936-942
  - in streptozotocin-treated rats, 511-512
- glucose and amino acid
  - and ketone infusion in diabetics, 779-780
- glucose and free fatty acid
  - response to low-dose insulin infusion, insulin resistance in myotonic dystrophy and, \*379
- glucose and glucagon
  - in alloxan diabetic rats, somatostatin and, \*356
- glucose, glucagon and insulin
  - and L-dopa, \*157
- glucose and insulin responses
  - to oral carbohydrates, 741-746
- glucose levels
  - and myocardial infarction and hypoglycemic drug therapy, \*369
- glycosaminoglycans
  - and diabetes, \*365
- growth hormone
  - somatostatin and, in diabetic children, 550-552
- immunoreactive glucagon
  - and diabetic ketoacidosis therapy, \*371
  - inheritance of, \*326
- immunoreactive growth hormone
  - and Laron dwarfism, \*1006
- inorganic phosphate
  - and red blood cell oxygen transport in diabetics, 834-836
- insulin
  - and insulin allergy, \*363
  - liver regulation of, \*368
  - and pancreatic cancer, \*391
  - in streptozotocin-treated rats, 511-512
- insulin and glucagon
  - in newborn rats, temperature and, 1027-1028
- insulin, glucagon and glucose
  - oscillations in rhesus monkey, \*340
- insulin, glucose and triglyceride
  - and increased caloric intake, \*156
- insulin and growth hormone
  - in premature infants, 430
- insulin and proinsulin
  - in late pregnancy in normal and diabetic subjects, \*317
- insulin response to arginine
  - and hyperthyroidism, 961-968
- insulins and proinsulins
  - compared with pancreatic insulins and proinsulins, \*315
- ketone bodies
  - and glucagon in diabetics, \*157
- lipids
  - and diet of polyunsaturated meats and dairy products, \*537
- lipoproteins
  - and glucocorticoids, \*634
  - in streptozotocin-treated rats, 512-513
- membrane phospholipids of rat liver
  - fasting and diabetes and, \*351
- membrane sulphydryl groups
  - modification by insulin, \*382
- noradrenaline
  - and blood pressure in essential hypertension, pheochromocytoma and depression, \*1082
- norepinephrine
  - response to standing in autonomic dysfunction, \*1085
- norepinephrine and dopamine-beta-hydroxylase activity
  - and familial dysautonomia, \*1083
- norepinephrine and epinephrine
  - isotope-derivative measurements of, 1071-1080
  - and smoking, \*1083
  - and somatostatin, \*235
- C-peptide
  - response to glucagon, and beta cell function in diabetics, \*329
- peripheral venous in dogs
  - and effects of octapeptide of cholecystokinin on insulin and glucagon levels, \*154
- phenformin levels
  - after standard phenformin dose in diabetics, \*357
- polypeptides
  - characterization as somatomedin B, \*1006
- protein
  - and diabetic microangiopathy, 858-863
  - microvascular permeability to, in juvenile diabetics, 884-889
- renal flow
  - and diabetes, 872-878
- renin activity
  - and hypertension in diabetics, 969-973
- renin activity and aldosterone
  - and diabetes with nephropathy and hypertension, 820-825
- somatotropin
  - and diabetic microangiopathy, 912
- somatomedin activity
  - in neonates, \*1007
- triglycerides
  - and sodium dichloroacetate in streptozotocin-diabetic rats, \*363
  - in streptozotocin-treated rats, 512
  - tryptophan and tyrosine in normals and patients with carcinoid tumors, glucose and insulin and, \*536
- viscosity
  - and diabetes, 897-901
- PLASMA FACTOR ACTIVITY
  - and diabetes, 827-828
- PLASMINOGEN ACTIVATOR RELEASE MECHANISM
  - and diabetic retinopathy, 807-809

DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80	May, 397-476	September, 741-804
February, 81-160	June, 477-544	Supplement 2, 805-930
March, 161-240	July, 545-644	October, 931-1010
April, 241-320	August, 645-740	November, 1011-1090
Supplement 1, 321-396		December, 1091-1170

**PLATELETS**

- aggregation
  - and diabetes, \*347, 826-830
  - and growth hormone, \*347
  - and somatostatin, \*472

**POISONS**

- Vacor
  - and induced diabetes, \*365

**POLYPEPTIDES. See also**

- Somatomedin
- canine pancreatic
  - secretion in vitro, \*329
- gastric inhibitory
  - and glucagon secretion in dogs, \*360
- human pancreatic islet
  - in healthy subjects and diabetics, \*330
- pancreatic
  - cellular localization of, \*364
  - transport in mouse islets of Langerhans, \*344

**PORTACAVAL ANASTOMOSES**

- and glucose tolerance in dogs, \*316

**PORTAL VEIN**

- insulin and glucagon
  - and massive obesity, \*388

**POTASSIUM**

- and beta-cell depolarization
  - insulin secretion during, \*345
- and immunoreactive insulin and glucagon secretion, 1033
- levels
  - in diabetic ketoacidosis, \*380
- transport in mouse brain
  - insulin and, 758-762

**PREDIABETES**

- and glucose-induced glucagon suppression, \*352
- and histocompatibility antigen HL-A8
  - in first-degree relatives of juvenile diabetics, \*371
- and insulin secretion, \*389
- in monozygotic twin siblings of juvenile-onset diabetics, \*155
- in Pima Indians
  - and age of onset of hyperinsulinism, \*384
- and retinal circulation time, 903-907

**PREGNANCY**

- and carbohydrate metabolism, \*317

- and glucose and leucine infusion
  - maternal and fetal serum insulin and growth hormone response to, 545-549
- and hemoglobin A<sub>1c</sub> levels, 894, 896, 1118-1122
- and insulin kinetics, \*234
- and maternal and fetal insulin response to glucose and amino acids, \*366
- in rats
  - and glucose-induced insulin secretion, \*362
- and triglyceride regulation, \*369

**PREGNANCY, DIABETIC**

- and carbohydrate metabolism, \*317
- and glucose control
  - and mortality and morbidity of infants, \*384
- and hemoglobin A<sub>1c</sub> formation, \*335, 1118-1122
- and hyperlipidemia, \*369
- and insulin response
  - age and, \*324
  - management, \*373
  - and peripheral T-lymphocytes, 223-226
- plasma glucagon and insulin:glucagon ratio in, 16-21
- and respiratory distress syndrome in newborn, \*637

**PREOBESITY**

- and insulin secretion, \*389

**PROCAINE**

- and pancreatic glucagon levels in rats, \*374

**PROGLUCAGON**

- sequential metabolic cleavage to glucagon, \*156

**PROINSULIN**

- assays, \*318
- and familial hyperproinsulinemia, \*635
- plasma and pancreatic, \*315
- release
  - and calcium infusion in patient with islet-cell tumor, \*536
- renal handling of, \*382
- synthesis
  - ciproheptadine and, \*343

**PROLACTIN**

- secretion
  - glucoregulation of, \*351

**PROPANOLOL**

- and glucagon
  - growth hormone response in normals to glucose and, \*538-539
- and pancreatic glucagon levels in rats, \*374
- and postprandial hypoglycemia, 729
- and protein phosphorylation in isolated fat cells, \*337
- and scorpion-toxin-induced glucagon release, 647

**PROSTAGLANDIN E**

- and insulin secretion, \*384
- like material
  - increased production in diabetics, \*347

**PROSTAGLANDINS**

- and glucose uptake and protein synthesis in rat adipose tissue, \*366
- and plasma glucagon levels in rats, \*317-318
- production by platelets
  - diabetes and, 828

**PROTAMINE**

- zinc-somatostatin and lente insulin hypolipemic action and, \*377

**PROTAMINE SULFATE**

- and glucose uptake and protein synthesis in rat adipose tissue, \*366

**PROTEASE**

- insulin-glucagon
  - proteolytic activity of, \*353
- insulin-specific
  - degradation of insulin in serum by, \*318

**PROTEIN(S)**

- calorie malnutrition
  - and alanine infusions effect on growth hormone, insulin and glucose, \*75
- and insulin secretion and glucose tolerance, \*539
- dietary
  - and nonsuppressible increase in glucagon secretion by rat iso-

DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
 February, 81-160  
 March, 161-240  
 April, 241-320  
 Supplement 1, 321-396

May, 397-476  
 June, 477-544  
 July, 545-644  
 August, 645-740

September, 741-804  
 Supplement 2, 805-930  
 October, 931-1010  
 November, 1011-1090  
 December, 1091-1170

lated islets, 51-55  
and pancreatic A-cell hyperplasia in rats, \*327  
and plasma glucagon concentrations, \*340  
ingestion  
in diabetics and normals, 1093-1094  
insulin and diabetes effect on, \*332  
kidney excretion of  
provocation tests for, 872-874  
kinase  
cyclic AMP-stimulated in isolated rat islet secretory vesicles, \*386  
metabolism  
in isolated perfused rat liver, glucagon and, 865-870  
in perfused skeletal muscle of fasted normal and adrenalectomized rats, \*333  
of peripheral nerve myelin  
<sup>14</sup>C leucine incorporation into, insulin and glucagon and, \*348  
phosphorylation  
and insulin, epinephrine and propranolol, \*337  
insulin-stimulated, \*357  
phosphorylation and dephosphorylation  
and insulin release, \*374  
-sparing modified fast  
and nitrogen metabolism and insulin requirements in obese diabetics, 494-502  
synthesis  
in rat adipose tissue, \*366  
and wound healing in diabetics, 814-817  
**PROTEINURIA**  
as indication for diabetes screening, 531  
intermittent, 874  
**PSYCHOMETRIC TESTS**  
in juvenile diabetics  
blood glucose levels and, \*334  
**PULMONARY EDEMA**  
and lactic acidosis therapy, \*158  
**N-3-PYRIDYLMETHYL-N'-P-NITROPHENYL UREA**  
and induced diabetes, \*365

## Q

**QUINOLINATE**  
and inhibition of gluconeogenesis in diabetic rats, \*315

## R

**RABBITS**  
alloxan diabetes in  
and induced lactic acidosis, \*534  
aortic smooth-muscle cells  
growth in media containing diabetic and hyperlipemic serum, 207-214  
arterial medial cell growth  
and growth hormone, 1011-1016  
continuous extracorporeal blood glucose monitoring in, 81-89  
isolated articular and epiphyseal chondrocyte response to rat liver somatomedin, \*1007  
parotid gland insulin, \*328  
and platelet aggregation  
and somatostatin, \*472  
**RACE**  
and acanthosis nigricans and insulin resistance, \*636  
and diabetes prevalence in Michigan school-age children, 124, 126  
and glucose tolerance relationship to time of day and time since last meal, 937, 938  
**RADIATION**  
-induced rat pancreatic tumors  
insulin biosynthesis in, \*343  
**RADIOENZYMATIC ASSAY**  
for dopamine, norepinephrine, and epinephrine, \*1082  
for serum catecholamines  
and hypertension, \*1082  
**RADIOIMMUNOASSAYS**  
of glucagon, 136, 1020  
of glucagon and insulin, 276  
of insulin and insulin derivatives 397-403  
of radioiodoinsulin, 260-266  
of somatomedin A and somatomedin C, 1000-1001, \*1005-1006  
**RADIORECEPTOR ASSAYS**  
hepatic, for growth hormone

in Laron dwarfism, \*1006  
of insulin  
and plasma and pancreatic insulins and proinsulins, \*315  
preparation of radioiodoinsulin for, 260-266

## RAT

adipocytes  
and anti-insulin receptor antibodies, \*322  
and insulin binding, glucose transport and glucose oxidation, obesity and, \*1163  
insulin insensitivity in, \*1164-1165  
insulin receptors and glucose metabolism during fasting and, \*321  
adipose tissue  
glucose uptake and protein synthesis, \*366  
adrenalectomized and normal  
skeletal muscle amino acid release and protein turnover in, \*333  
alloxan diabetic  
and electrolyte balance and renin, \*348  
and islet transplantation of neonatal pancreas, 180-189, \*798  
macromolecular transport across vascular endothelium in, \*386  
and pancreas transplantation, \*797  
somatostatin and, \*356  
alloxan diabetic plasma from inhibition of lymphocyte blastogenesis by factors in, 614-621  
and arginine-induced insulin and glucagon release  
and somatostatin, \*535  
diabetic  
and C<sup>14</sup> transfer from alanine-1-C<sup>14</sup> to hepatic and blood glucose, \*381  
and dichloroacetate, \*328  
and fetal pancreas transplantation, \*338  
and liver triglyceride biosynthesis, \*378  
and muscle metabolism of amino acids, \*333  
and pancreatic islet transplantation and carbohydrate, fat and mineral metabolism, \*389  
and quinolate and hydrazine inhibition of renal gluconeogenesis, \*315

## DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
February, 81-160  
March, 161-240  
April, 241-320  
Supplement 1, 321-396

May, 397-476  
June, 477-544  
July, 545-644  
August, 645-740

September, 741-804  
Supplement 2, 805-930  
October, 931-1010  
November, 1011-1090  
December, 1091-1170



# SUBJECT INDEX 1976

and somatomedin and growth, \*335  
and ultrastructural lesions, \*352  
diabetic, fed and fasted  
and mitochondrial fatty acid uptake,  
\*351  
and diabetic nephropathy, 850-856  
endocrine pancreas  
and gastrointestinal hormones, \*373  
endocrine pancreas monolayer cul-  
tures  
and somatostatin inhibition of insu-  
lin release, \*472  
epididymal fat pad  
lipolytic response to epinephrine,  
\*366  
eviscerated  
immunoreactive glucagon in, \*327  
fat cells  
and insulin binding and glucose  
transport, fasting and, \*321  
insulin-induced lipogenesis in,  
\*1164  
metabolism, and extracellular cal-  
cium, \*372  
fetal pancreas transplantation in  
and hepatic-portal route, \*338  
genetically obese  
amino acid-induced insulin and  
glucagon release in, \*356  
glomerular lesions in  
and reduction of renal mass, \*349  
and glucocorticoids effect on tri-  
glyceride transport and secre-  
tion rates, lipoprotein lipase,  
and plasma lipoproteins, \*634  
heart  
norepinephrine, 9  
hepatocytes  
and insulin control of hepatic  
gluconeogenesis, \*331  
and high protein diet  
nonsuppressible increase in  
glucagon secretion by isolated  
islets of, 51-55  
and pancreatic  $\alpha$  cell hyperplasia,  
\*327  
hyperglycemic  
xenotransplantation of piscine islets  
into, \*797  
induced obesity in  
and eating behavior, blood glucose,  
and insulin, 77  
and insulin-potentiating peptides  
and glycogen synthesis, 413-418  
insulinoma  
transplantable, \*344  
and intrahepatic transplantation of is-

lets of Langerhans  
and liver function, \*796  
islet allograft destruction in  
antibodies and, \*338  
islet cells  
electrical activity, somatostatin in-  
hibition of, \*380  
islet cultures  
and somatostatin inhibition of insu-  
lin and glucagon secretion,  
ionophore and, \*536  
islets of Langerhans transplantation in  
donor age and, \*338  
isolated islets  
cyclic AMP-stimulated protein  
kinase activity in, \*386  
and glucagon-stimulated insulin re-  
lease, somatostatin and, \*339  
and insulin secretion and biosyn-  
thesis studies, 574-578  
and starvation and insulin release  
and metabolism, \*391  
isolated pancreas  
glucose potentiation of glucose-  
induced insulin release in,  
949-953  
isolated perfused liver  
and glucagon effects on protein and  
amino acid metabolism,  
865-870  
isolated perfused pancreas  
metoclopramide effect on endocrine  
secretion from, \*375  
and ketogenesis  
and liver carnitine content, \*330  
kidney glomeruli basement membrane  
synthesis  
insulin and, \*349  
and lethal endotoxin shock  
and insulin, \*342  
liver adenylate cyclase  
and somatostatin, \*387  
liver gluconeogenesis and glycolysis  
and hypothalamic stimula-  
tion, \*76  
liver glycogen synthesis and glycogen  
cycle enzyme activities regu-  
lation by glucose and galac-  
tose, \*539  
liver plasma membrane phospholipids  
and fasting and alloxan diabetes,  
\*351  
maturity-onset diabetes and hyper-  
lipemia in  
heredity and, \*354  
meal-associated conditioned insulin  
secretion in, \*390

neonatal  
effect of temperature on glucose-  
induced insulin response in,  
1026-1029  
neonatal islet transplantation, \*376  
neonatal pancreases  
transplantation, \*796  
obese  
decreased insulin binding sites in  
skeletal muscle of, \*317  
pancreas  
 $\beta$ -cell tumors, insulin biosynthesis  
in, \*343  
and glyburide, \*367  
pancreas islets  
ultrastructural localization of  
somatostatin in, \*155  
pancreatic glucagon levels  
pharmacological compounds affect-  
ing, \*374  
and pancreatic islet transplantation  
and hyperinsulinemia and hyper-  
glucagonemia following,  
944-947  
quantitative aspects of metabolic re-  
sponse to, \*316  
pancreatic islets  
and alloxan, \*75-76  
cultivation, \*339  
digestion-filtration method for isola-  
tion of, 667-672  
DNA replication, cyclic AMP and  
phosphodiesterase inhibitors  
and, \*379  
glucose effect on beta cells of, \*381  
glucose stimulation and calcium up-  
take in, \*346  
long-term perfusion in vitro,  
484-492  
6-phosphogluconate/glucose-6-  
phosphate ratio in, insulin  
and, \*337  
scorpion toxin inhibition of insulin  
release in, 198-201  
scorpion toxin inhibition of insulin  
release by, \*1082-1083  
pancreatic norepinephrine turnover in  
and assessment of sympathetic regu-  
lation of endocrine pancreas,  
\*391  
parotid gland insulin, \*328  
perfused pancreas  
and glucose-stimulated glucagon re-  
lease during calcium depriva-  
tion, \*473  
scorpion-toxin-stimulated glucagon  
secretion in, 645-649

## DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
February, 81-160  
March, 161-240  
April, 241-320  
Supplement 1, 321-396

May, 397-476  
June, 477-544  
July, 545-644  
August, 645-740

September, 741-804  
Supplement 2, 805-930  
October, 931-1010  
November, 1011-1090  
December, 1091-1170

and theophylline inhibition of  
amino-acid-induced insulin  
release, \*473  
and phenformin  
and plasma glucagon levels, \*328  
plasma glucagon levels  
and prostaglandins, \*317-318  
pregnant  
glucose-induced insulin secretion  
in, \*362  
and proinsulin synthesis  
cyproheptadine inhibition of, \*343  
spontaneous diabetic syndrome in,  
\*378  
SRIF suppression of serum growth  
hormone and insulin in, \*353  
starved  
and dichloroacetate effects on  
skeletal muscle metabolism,  
\*332  
stomach and pancreas  
somatostatin content, \*471  
and streptozotocin  
and red-blood-cell-reduced  
glutathione, 216-221  
and streptozotocin anomers  
and pancreatic beta cell toxicity,  
\*384  
streptozotocin diabetic  
and fetal pancreas transplantation,  
56-63, \*798  
and inhibitory agents, 595-602  
and intracellular enzymes of col-  
lagen biosynthesis in kidneys  
of, 1066-1070  
and intraportal-islet transplantation,  
1041-1051  
and magnesium depletion and  
hypomagnesemia, \*363  
and pancreatic islet transplantation  
and glomerular lesions, \*798  
and serum somatomedin activity  
and cartilage growth activity,  
516-526  
and sodium dichloroacetate effect  
on plasma triglycerides, \*363  
streptozotocin diabetic with severe  
ketosis  
and islet of Langerhans transplan-  
tation, \*797-798  
and suppression of lipolysis, \*331  
streptozotocin-treated  
and glucagon secretion from per-  
fused pancreas of, 275-282  
and hyperlipoproteinemia, 509-514  
suckling and hypophysectomized  
insulin binding to thymocytes from,  
\*154

sucrose-fed  
and apolipoproteins, \*353  
and L-tryptophan, \*369  
weanling  
offspring of rats with induced latent  
diabetes, diabetes in, \*474

RDS SCORE  
in premature infants, 431

REDOX POTENTIAL  
and muscle free-amino-acid content  
and release, \*333

RENIN  
in alloxan diabetic rats, \*348

RENIN-ANGIOTENSIN-ALDOS-  
TERONE SYSTEM  
and diabetes, 820-825

RESERPINE  
and pancreatic glucagon levels in rats,  
\*374

RESPIRATORY-DISTRESS SYN-  
DROME  
in infants of diabetic mothers, \*637

RETINA  
blood flow  
diabetes and, 839-843  
circulation time  
in normal, prediabetic, and  
chemical-diabetic subjects,  
903-908

RETINOPATHY, DIABETIC  
and basement-membrane thickening,  
925-926  
and blood flow in diabetes, 839-843  
development of, 785-786  
etiology and control, \*537-538  
and fibrinolysis, 807-809  
florid  
and photocoagulation and pituitary  
ablation, 104-110  
and multiple daily insulin injections,  
463-468  
and photocoagulation, \*347  
in Pima Indians  
and glucose level, diabetes dura-  
tion, and age, 554-560  
and renin-angiotensin-aldosterone sys-  
tem, 823-824  
study  
photocoagulation therapy prelimi-  
nary report, \*347

and uveoretinal antigen-induced  
leucocyte-migration inhibi-  
tion, 1106-1108  
and vascular reactivity to angiotensin  
II and norepinephrine,  
268-274

RETINOSCOPY  
in serum glucose concentration and re-  
fraction study, 29-31

RHESUS MONKEYS  
diabetic  
and islets of Langerhans transplan-  
tation, \*796

ROCHESTER, MINNESOTA  
diabetes survey in, 566-572

## S

SCORPION VENOM  
and inhibition of insulin release in rat  
pancreatic islets, 198-201,  
\*1082-1083  
-stimulated glucagon secretion in per-  
fused rat pancreas, 645-649

SECRETIN  
and glucose homeostasis  
and gastric surgery, \*234

<sup>75</sup>SE-SELENOMETHIONINE  
incorporation into human apoproteins,  
679-690  
characterization of metabolism of  
very-low-density and low-  
density lipoproteins in vivo  
and in vitro in, 44-50  
and characterization of specificity in  
very-low-density and low-  
density lipoproteins, 32-42

SEPHAROSE 4B  
and anti-insulin serum  
and insulin biosynthesis in beta cells  
of obese, hyperglycemic  
mice, \*154

SERINE  
incorporation into phosphatidylserine  
and glucagon, \*473-474

SEROTONIN  
and carbohydrate tolerance, \*361  
and insulin secretion, \*384

## DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
February, 81-160  
March, 161-240  
April, 241-320  
Supplement 1, 321-396

May, 397-476  
June, 477-544  
July, 545-644  
August, 645-740

September, 741-804  
Supplement 2, 805-930  
October, 931-1010  
November, 1011-1090  
December, 1091-1170

# SUBJECT INDEX 1976

## SERUM

- anti-insulin
  - and sepharose 4B for insulin biosynthesis study, \*154
- cartilage metabolism inhibitor, \*1007
- catecholamine assays
  - hypertension and, \*1082
- cholesterol
  - and diabetes development, \*76
  - of tolbutamide-treated diabetics, 1139-1140
- creatinine levels
  - of tolbutamide-treated diabetics, 1138-1139
- diabetic and hyperlipemic
  - growth of rabbit aortic smooth muscle cells in media containing, 207-214
- gastric inhibitory polypeptide
  - in maturity-onset diabetes, 931-935
- glucose
  - and changes in refraction, 29-31
  - and streptozotocin, 277-279
- glucose and insulin
  - and ethanol, 753-755
- growth hormone
  - and rabbit aortic medial cell culture growth, 1011-1016
- growth hormone and insulin
  - SRIF suppression of, \*353
- immunoreactive insulin
  - in pancreatic islet-transplanted diabetic rats, 944-947
- insulin
  - in capillary and venous blood samples, \*354
  - in normal subjects, \*325
  - renal wastage in juvenile diabetics, 989-992
  - suppressibility by somatostatin, diazoxide, and phenytoin in patients with islet cell adenomas and carcinomas, \*354
  - and tumor hypoglycemia, 203-205
- insulin degradation in
  - and insulin-specific protease, \*318
- insulin and growth hormone
  - human maternal and fetal, response to glucose and leucine, 545-549
- in monozygotic twin siblings of juvenile-onset diabetics, \*155
- insulin-like activity
  - nonsuppressible, \*315
- insulin response
  - in fetal pancreatic transplanted

- streptozotocin diabetic rats, 61-62
- in pancreatic beta-cell stimulation studies in diabetics, normals, and pancreatitis patients, 11-14
- insulin values
  - and oral glucose tolerance tests in normal children, \*378
- lipids
  - and contraceptive steroids, \*535
  - in spontaneously diabetic guinea pigs, 435, 440
- lysosomal glycohydrolase
  - and juvenile diabetes mellitus, 420-426
- maternal and fetal
  - insulin response to glucose and amino acids, \*366
- C-peptide assays, \*329
- peptides
  - nonsuppressible insulin-like activity, soluble in acid ethanol, \*1006
- phenformin
  - and phenformin-associated lactic acidosis, \*359
- serotonin
  - and carbohydrate tolerance, \*361
- somatomedin activity, 995-996
  - and cartilage growth activity in streptozotocin diabetic rats, 516-526
  - and glucocorticoids, \*1004-1005
- stimulated DNA synthesis in cultured chick embryo fibroblasts
  - growth hormone and, \*1005
- testosterone
  - in impotent diabetic rats, 975-977
- triglycerides
  - and acute starvation, \*388
- triglycerides and cholesterol
  - and high carbohydrate, high fiber diet, \*324

## SEX

- and acanthosis nigricans and insulin resistance, \*636
- and coronary heart disease in Pima Indians, 562, 563
- and diabetes prevalence in Greek rural population by age, \*358
- and diabetes prevalence in Michigan school-age children, 124-125
- and fasting hypoglycemia, \*634-635
- and glucose tolerance relationship to time of day and time since last

- meal, 937, 938
- and retinopathy in Pima Indians, 554-560

## SHEEP

- hind limb
  - substrate utilization by, \*635

## SHOCK

- lethal endotoxin
  - role of insulin in, \*342
- and phenformin-associated metabolic acidosis, 292-296

## SKIN

- dermatitis
  - and hyperglucagonemia, \*341
- fibroblast abnormalities
  - and diabetes, \*336
- fibroblast cultures
  - insulin receptors in, 250-254
- fibroblasts
  - and glucose and diabetes, \*336

## SMOKING

- and adrenergic blockade
  - and epinephrine and norepinephrine release, \*1083

## SODIUM

- transport in mouse brain
  - insulin and, 758-762

## SODIUM BICARBONATE

- induced lactic acidosis in alloxan diabetic rabbits, \*534
- and phenformin-associated metabolic acidosis, 292-296

## SODIUM DICHLOROACETATE

- and plasma triglycerides
  - in streptozotocin diabetic rats, \*363

## SOMATOMEDIN

- activity, 995
  - and growth disorders, 996-998
  - in neonates, \*1007
  - and steroid hormones, \*1005
- bioassays, 995
- bovine
  - purification methods, \*1007
- and cartilage growth activity in streptozotocin-diabetic rats, 516-526
- discovery of, 994
- and glucocorticoid therapy, \*1004-1005

## DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
 February, 81-160  
 March, 161-240  
 April, 241-320  
 Supplement 1, 321-396

May, 397-476  
 June, 477-544  
 July, 545-644  
 August, 645-740

September, 741-804  
 Supplement 2, 805-930  
 October, 931-1010  
 November, 1011-1090  
 December, 1091-1170

- and growth in diabetic rats, \*335  
and growth disorders, 996-997  
rat liver  
  isolated rabbit articular and epiphyseal chondrocyte response to, \*1007  
receptors, 999-1001  
-related peptides  
  isolation from biologic fluids, 998-1001  
-somatostatin-somatotropin axis, \*339
- SOMATOMEDIN A.** *See* Laron dwarfism
- SOMATOMEDIN B**  
isolation from human plasma, \*1006  
radioimmunoassays, 1000-1001, \*1005-1006
- SOMATOMEDIN C**  
receptors  
  in human placental cell membranes, \*1005
- SOMATOSTATIN**  
in alloxan diabetic rats, \*356  
blood glucagon response to  
  in pancreatectomized and streptozotocin-diabetic monkeys, \*339  
and blood sugar, plasma growth hormone and glucagon levels in diabetic children, 550-552  
and coagulation and platelet function in man, \*156  
-containing islet cells  
  in diabetic mice, \*344  
and diabetes therapy, \*340  
and diabetic ketoacidosis, \*538  
in diabetics and normals, 1091-1098  
and diazoxide hyperglycemia and glucagon, \*330  
and dibutyl cyclic AMP-induced insulin and growth hormone release, \*538  
and glucagon and insulin  
  and hepatic glucose output in normal dogs, 116-121  
and glucagon-stimulated insulin release, \*339  
and hemostasis in baboons, \*156  
infusion  
  and islet cell tumor, 410-411  
and inhibition of arginine-induced insulin and glucagon release in rats, \*535  
inhibition of electrical activity in cultured rat islet cells, \*380  
inhibition of insulin and glucagon secretion  
  and ionophore, \*536  
  reversal of, 1031-1039  
and insulin secretion, 96-100, \*340  
and liver adenylate cyclase activity in rats, \*388  
and plasma glucose, free fatty acid, and glucagon responses to epinephrine, 67-68, 69  
and plasma norepinephrine and epinephrine  
  and exercise and hypoglycemia, \*235  
and platelet aggregation, \*472  
protamine-zinc and lente insulin hypolipemic action and, \*377  
in rat stomach and pancreas, \*471  
and scorpion-toxin-induced glucagon release, 647, 649  
serum insulin suppressibility by  
  and islet cell adenomas and carcinomas, \*354  
ultrastructural localization in pancreatic islets of rat, \*155
- SOMATOTROPIN**  
-somatostatin-somatomedin axis, \*339
- SPINAL FLUID**  
pressure  
  during diabetic ketoacidosis therapy, 111
- SPLANCHNIC NERVE**  
alanine uptake  
  and insulin infusion in dogs, 286  
glucose and glucose-<sup>14</sup>C production  
  and insulin infusion in dogs, 286  
glucose output  
  and benign mesothelioma, 202-205  
glucose uptake assays, \*332
- SPLEEN**  
pancreatic tissue transplantation into  
  in pancreatectomized dogs, \*795-796
- SPONDYLOSIS**  
in diabetic and nondiabetic Chinese hamsters, 477-483
- STARVATION**  
acute  
  and increased triglycerides with weight loss, \*388  
in diabetics and nondiabetics  
  and effect of insulin-glucose infusions on plasma glucagon levels, \*157  
and forearm tissue metabolism  
  and glucagon, 128-134  
and glucose potentiation of glucose-induced insulin release in isolated rat pancreas, 949-953  
insulin receptors and glucose metabolism during, \*321  
and insulin release and metabolism in isolated rat pancreatic islets, \*391  
and muscle amino acid metabolism, \*317  
in rats  
  and dichloroacetate effects on skeletal muscle metabolism, \*332  
and splanchnic glucose production, 205  
and substrate utilization by sheep hind limb, \*635
- STAUB-TRAUGOTT EFFECT**  
and hypopituitarism, \*153
- STEROIDS**  
contraceptive  
  and arginine-stimulated glucagon and insulin secretion, \*535  
and human breast cancer, \*380  
-induced ketoacidosis, \*330  
and somatomedin action in vitro, \*1005
- STOMACH**  
glucagon  
  in streptozotocin-treated Chinese hamsters, \*390  
immunoreactive glucagon of dogs, \*327  
rat  
  somatostatin content, \*471
- STREPTOZOTOCIN**  
anomers  
  and pancreatic beta cell toxicity, \*384  
-induced diabetic ketoacidosis in rats  
  and suppression of lipolysis, \*331  
-induced pancreatic B-cell tumors in rats  
  insulin biosynthesis in, \*343  
-induced pancreatic isletitis and diabetes, \*344

DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80	May, 397-476	September, 741-804
February, 81-160	June, 477-544	Supplement 2, 805-930
March, 161-240	July, 545-644	October, 931-1010
April, 241-320	August, 645-740	November, 1011-1090
Supplement 1, 321-396		December, 1091-1170

- and plasma, pancreatic, and stomach  
glucagon levels in Chinese  
hamsters, \*390
- and red-blood-cell-reduced  
glutathione and glucose,  
nicotinamide, and epineph-  
rine, 216-221
- treated rats  
glucagon secretion from perfused  
pancreas of, 275-282
- STREPTOZOTOCIN DIABETES**  
collagen biosynthesis enzymes in rat  
kidney in, 1066-1070
- in mice  
and breath acetone and ketone  
metabolism, \*374
- in monkeys  
and blood glucagon response to ar-  
ginine and somatostatin, \*339
- in rats  
fetal pancreas transplantation for re-  
versal of, 56-63, \*338  
and hyperlipoproteinemia, 509-514  
and hypomagnesemia and mag-  
nesium depletion, \*363  
and intraportal-islet transplantation  
studies, 1041-1051  
and pancreatic islet cell composi-  
tion, \*344  
and pancreatic islet transplantation,  
\*316  
and pancreatic islet transplantation,  
glomerular lesions and, \*798  
protective agents against, 595-602  
and serum somatomedin activity  
and cartilage growth activity,  
516-526  
and sodium dichloroacetate effect  
on plasma triglycerides, \*363  
and transplantation of fetal pan-  
creas, \*798
- in rhesus monkeys  
and islet of Langerhans transplanta-  
tion, \*796  
and severe ketosis in rats  
and islet of Langerhans transplanta-  
tion, \*797-798
- STRESS**  
and steroid-induced ketoacidosis, \*330  
and urine glucose levels, \*356
- SUCROSE**  
and apolipoprotein patterns in rats,  
\*353
- SUGAR**  
consumption  
and diabetes risk, \*342  
and insulin secretion, \*389
- SULFHYDRYL**  
-binding reagents  
and glucagon release from isolated  
secretion granules, \*389
- SULFONYLUREAS**  
dosages  
and high-carbohydrate diet, \*369  
and hemoglobin A<sub>1c</sub> levels, 895  
and hypoglycemia  
and halofenate, \*236  
and pancreatic islet polypeptides,  
\*330  
and postprandial hypoglycemia,  
728-729  
therapy  
and plasma glucagon, \*387
- SURGERY. See also Isotransplantation;**  
Transplantation  
adrenalectomy  
and glucagon response to insulin-  
induced hypoglycemia, \*315  
gastrectomy  
and hypoglycemia, and organic  
brain dysfunction, \*734  
gastric  
and glucose homeostasis, \*234  
hypophysectomy  
and insulin-sensitive central ner-  
vous system glucoregulator  
receptor, \*158  
pancreatectomy  
and hyperglycemia, \*534  
pancreatectomy in dogs  
and insulin infusions, \*325  
pancreatectomy and gastrectomy in  
dogs  
glucagon secretion and, \*355  
and postprandial hypoglycemia, 730  
reversed intestinal segment  
and postoperative reactive hyper-  
glycemia, \*536, \*733  
sympathectomy  
and glucagon response to hypo-  
glycemia, \*317  
vagotomy and pyloroplasty  
and hypoglycemia, \*736
- SYMPATHECTOMY**  
and glucagon response to hypo-  
glycemia, \*317
- SYRIAN HAMSTER**  
transplantable insulinoma in  
and regulation of in vitro insulin re-  
lease from, \*474
- T**
- TANNIC ACID**  
and pancreatic islet cell membranes,  
\*376
- TEMPERATURE**  
and beta cell electrical activity, \*377  
and glucose-induced insulin response  
in newborn rats, 1026-1029
- TESTOSTERONE**  
and somatomedin action in vitro,  
\*1005
- THEOPHYLLINE**  
and amino-acid -induced insulin re-  
lease, \*473  
-stimulated insulin release  
and somatostatin, \*472
- THROMBOCYTOPENIA**  
and somatostatin in baboons, \*156
- THYMOCYTES**  
insulin binding to, \*154
- THYROID**  
function  
in identical twins, 26
- TISSUE**  
culture of islets of Langerhans  
survival of, \*796  
dog stomach  
and immunoreactive glucagon, \*327  
dopamine, norepinephrine, and  
epinephrine  
radioenzymatic assay for, \*1082  
forearm  
metabolism, glucagon and, 128-134  
and variations in glucagon concen-  
trations, \*341  
gastrointestinal of dogs  
immunoreactive glucagon meas-  
urement and characterization  
in, 1018-1025  
glucagon-secreting in dogs  
"macro-immunoreactive" glucagon  
in, \*326

DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80	May, 397-476	September, 741-804
February, 81-160	June, 477-544	Supplement 2, 805-930
March, 161-240	July, 545-644	October, 931-1010
April, 241-320	August, 645-740	November, 1011-1090
Supplement 1, 321-396		December, 1091-1170



- heart  
  norepinephrine, epinephrine, and dopamine in long-term diabetics, 6-10
- islet  
  transplantation, 788-793
- isolated adipocytes  
  insulin binding studies and, \*76
- pancreatic  
  intrasplenic transplantation in totally pancreatectomized dogs, \*795-796
- rabbit aortic smooth-muscle cells  
  growth in media containing diabetic and hyperlipemic serum, 207-214
- rat adipose  
  and insulin and lipolytic hormone effects on cyclic AMP phosphodiesterase activities, \*77
- rat epididymal fat pad  
  lipolytic response to epinephrine, \*366
- rat hemidiaphragms  
  and insulin-potentiating peptides and glycogen synthesis, 413-418
- rat pancreatic islet  
  scorpion toxin inhibition of insulin release in, 198-201
- of Syrian hamster insulinoma  
  and insulin release regulation studies, \*474
- TOLBUTAMIDE**  
  cardiac reactions to, \*535  
  and diabetes  
    and vascular complications, 1129-1153  
  and hypoglycemia  
    and halofenate, \*236  
  -induced insulin release  
    and pancreatic islet cyclic nucleotides, 256-259  
  and jejunal carbohydrate-metabolizing enzymes, \*75  
  and pancreatic beta-cell stimulation studies, 11-14  
  -stimulated insulin release  
    and somatostatin, \*472
- TOLBUTAMIDE TOLERANCE TEST**  
  intravenous  
    in evaluation of disease states, \*355
- TRANSCAPILLARY ESCAPE RATE**  
  in juvenile diabetics, 884-889
- TRANSPLANTATION**  
  fetal pancreas in rats  
    and hepatic-portal route, \*338  
  of fetal pancreases  
    and reversal of diabetes in rats, \*338  
    and streptozotocin diabetes in rats, 56-63, \*798  
  intrahepatic of islets of Langerhans in rats  
    and liver function, \*796  
  intraportal-islet in streptozotocin-diabetic rats, 1041-1051
- islet  
  in diabetic rats, 855-856
- islet and pancreas, 785-793
- of islets of Langerhans  
  in diabetic rhesus monkeys, \*796  
  in ketotic diabetic rats, \*797-798  
  in rats, donor age and, \*338
- kidney  
  and diabetes in man, 853-855  
  and diabetic glomerulosclerosis, \*349
- of organ-cultured neonatal pancreas in rat  
  and alloxan diabetes, \*798
- pancreas  
  in alloxan diabetic rats, \*797
- pancreas islet  
  and carbohydrate, fat and mineral metabolism in long-term diabetic rats, \*389  
  and development of hyperinsulinemia and hyperglucagonemia in rats, 944-947  
  and glomerular lesions in streptozotocin diabetic rats, \*798  
  infant human pancreas as source for, 1123-1128  
  with neonatal rat pancreases, \*796  
  and survival of islets in tissue culture, \*796
- pancreatic islet in rats  
  quantitative aspects of metabolic response to, \*316
- of pancreatic tissue  
  intrasplenic in totally pancreatectomized dogs, \*795-796
- of piscine islets into hyperglycemic rats, \*797
- of primate pancreas  
  and isolation of islets, \*386
- of rat insulinoma, \*344
- rat neonatal islets  
  following minimal collagenase digestion, \*376
- renal  
  in diabetic nephropathy, \*367  
  in diabetics, and immunopathology of renal extracellular membranes in transplanted kidneys, 709-712  
  quantitation of glomerular basement membrane thickness after, \*357
- TRIGLYCERIDES**  
  and acute starvation, \*388  
  formation  
    and obesity, \*634  
  in juvenile diabetics, \*355  
  levels  
    diabetic control and, \*368  
  liver biosynthesis  
    and diabetes, \*378  
  regulation in pregnancy, \*369  
  transport and secretion rates  
    glucocorticoids and, \*634
- TRYPSIN**  
  and insulin binding to fat cells, \*1164
- L-TRYPTOPHAN**  
  hypoglycemic effects of, \*369
- TUBERCULOSIS**  
  as indication for diabetes screening, 531
- TUMORS**  
  B-cell  
    streptozotocin and radiation-induced in rat pancreas, insulin biosynthesis in, \*343  
  carcinoid  
    and intravenous glucose and insulin, plasma tryptophan and tyrosine and, \*536  
  glucagonomas  
    and glucose homeostasis and insulin secretion, \*341  
    and increased circulating large glucagon immunoreactivity, \*326  
    and plasma glucagon immunoreactivity, \*637  
  hypoglycemia  
    and deficient splanchnic glucose output and deficient glucagon secretion, 202-205  
  insulinoma  
    regulation of insulin release from, \*474  
    transplantable rat, \*344

DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80	May, 397-476	September, 741-804
February, 81-160	June, 477-544	Supplement 2, 805-930
March, 161-240	July, 545-644	October, 931-1010
April, 241-320	August, 645-740	November, 1011-1090
Supplement 1, 321-396		December, 1091-1170

islet-cell  
and glucagon-secretion suppression  
and stimulation mechanisms,  
408-419  
and insulin and proinsulin release  
during calcium infusion, \*536  
pancreatic polypeptide in, \*474  
islet-cell adenoma  
diagnosis, \*635  
islet cell adenomas and carcinomas  
and serum insulin suppressibility by  
somatostatin, diazoxide, and  
phenytoin, \*354

## TWINS

identical diabetic  
discordance of diabetic microan-  
giopathy in, 24-28  
hemoglobin components in, \*318  
histocompatibility antigens in, \*236  
monozygotic  
and serum insulin and growth hor-  
mone in siblings of juvenile  
diabetics, \*155

## U

### ULCERS

of legs  
hyperbaric oxygen treatment of,  
\*364

### UNIVERSITY GROUP DIABETES PROGRAM

hypoglycemic agents and vascular  
complications in adult-onset  
diabetics, 1129-1153

### UREA

synthesis  
in isolated perfused rat liver,  
glucagon and, 869

### URETHRA

innervation in diabetics  
early detection of, 1100-1105

### URINE

acidic glycosidase excretion  
in juvenile diabetics, \*370  
catecholamine excretion  
and intravenous glucagon, \*318  
glucose  
in fetal pancreatic transplanted  
streptozotocin diabetic rats,  
61

in spontaneously diabetic guinea  
pigs, 435  
and stress, \*356  
immunoreactive growth hormone  
and Laron dwarfism, \*1006  
immunoreactive insulin  
in nondiabetic and insulin-  
dependent diabetic children,  
989-992  
lysosomal glycohydrolase  
and juvenile diabetes, 420-426  
reducing sugar concentrations  
and diabetic control and manage-  
ment, \*636-637  
testing  
control specimen usage in, \*363  
volume  
in fetal pancreatic transplanted  
streptozotocin diabetic rats,  
61

### URTICARIA

and insulin allergy  
and insulin therapy, \*75

## V

### VAGUS NERVE

and insulin secretion and glucose tol-  
erance  
and diet, \*361  
stimulation  
and hepatic glycogen synthase and  
synthase-D phosphatase,  
\*332

### VALSALVA'S MANEUVER

and heart rate  
in diabetic autonomic neuropathy,  
749-750

### VASCULAR DISEASE

peripheral  
assessment in diabetics, 307-314  
and insulin response to oral glucose,  
586-593

### VASCULAR SYSTEM

endothelium  
macromolecular transport across, in  
alloxan diabetic rats, \*386  
and microvascular permeability to  
plasma proteins  
in juvenile diabetics, 884-889  
reactivity to angiotensin II and  
norepinephrine

and diabetes, 268-274

### VASODILATOR THERAPY

and lactic acidosis, \*158

### VASOPRESSIN

and heart rate  
in diabetic autonomic neuropathy,  
750

### VEINS

blood samples  
serum insulin, \*354

### VERAPAMIL

and pancreatic glucagon levels in rats,  
\*374

### VERTEBRAE

and aging changes in diabetic and  
nondiabetic Chinese ham-  
sters, 477-483

### VIPOMAS

pancreatic polypeptides in, \*474

### VIRUSES

M variant of encephalomyocarditis  
and diabetes development, 190-197  
Venezuelan encephalitis  
and pancreatic disease in hamsters,  
623-630

### VISION

and diabetic retinopathy  
and photocoagulation, \*347  
in florid diabetic retinopathy study,  
106-110  
and maculopathy  
and photocoagulation, \*471-472  
and serum glucose concentration,  
29-31

### VITAMINS

deficiency  
in juvenile diabetics, \*359  
riboflavin  
and glutathione reductase in diabet-  
ics, \*383

### VITILIGO

and juvenile diabetes, \*375

### VON WILLEBRAND FACTOR

activity  
growth hormone regulation of,  
\*347

## DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
February, 81-160  
March, 161-240  
April, 241-320  
Supplement 1, 321-396

May, 397-476  
June, 477-544  
July, 545-644  
August, 645-740

September, 741-804  
Supplement 2, 805-930  
October, 931-1010  
November, 1011-1090  
December, 1091-1170

W

WEIGHT. *See also* Body; Obesity  
and diabetes development, \*76  
gain  
in pancreatic islet-transplanted rats,  
\*316

WILLIAMS, FREDERICK W., 632-633

WOUND HEALING

as model for diabetic angiopathy,  
811-819

X

XYLITOL

and arginine-induced insulin secretion  
and hyperthyroidism,  
965-966, 967-968

Y

YTTRIUM-90

and pituitary ablation  
and florid diabetic retinopathy,  
104-110

Z

ZINC

and insulin structure and function,  
\*383

---

DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80	May, 397-476	September, 741-804
February, 81-160	June, 477-544	Supplement 2, 805-930
March, 161-240	July, 545-644	October, 931-1010
April, 241-320	August, 645-740	November, 1011-1090
Supplement 1, 321-396		December, 1091-1170

# AUTHOR INDEX 1976

In this index are the names of authors of articles that have appeared in **DIABETES** and those whose articles have been abstracted in the **Journal** during 1976. Entries marked with an asterisk (\*) indicate material that appeared in the Abstracts only. The Subject Index appears on page 1.

## A

Abraira, Carlos, \*153  
 Abrams, Marc A., \*322  
 Adachi, R., \*373, \*375  
 Adams, Lonnie D., \*371  
 Adrian, T.E., \*474  
 Ahmed, M., \*340  
 Aiello, Lloyd M., 268-274  
 Ajlouni, Kamel, \*351  
 Akanuma, Y., \*368  
 Akerblom, Hans K., 1066-1070  
 Akgun, Suat, \*325  
 Akhtar, M.S., \*337  
 Albers, J., \*634  
 Alberti, K.G.M.M., \*471, \*538, \*1084-1085  
 Albisser, A.M., \*325, \*333, 691-700  
 Albright, John T., \*352  
 Albrink, Margaret J., \*324  
 Alexander, Ralph, \*370  
 Aleyassine, H., \*351  
 Alford, Frank P., \*634  
 Almer, Lars-Olof, 807-810  
 Almira, E.C., \*351  
 Alogna, M., \*343  
 Alpers, David H., \*733  
 Alsever, Robert N., \*535  
 Altszuler, Norman, 116-121, \*330  
 Amamoo, David G., \*796  
 Amatruda, J., \*351  
 Ammon, H.P.T., \*337  
 Anapolle, Steven E., \*352  
 Anavekar, S.N., \*1082  
 Andersen, D.K., \*324  
 Andersen, H., \*1006  
 Andersen, Jens T., 1100-1105  
 Andersen, O., 752-757  
 Anderson, G., \*361  
 Anderson, J.H., Jr., \*339  
 Anderson, James W., \*153, \*369, \*734  
 Anderson, N.T., \*340  
 Anderson, S., \*75-76  
 Andersson, Arne, \*796  
 Andres, R., \*324

Ansell, J., \*380  
 Anthony, J., \*316-317  
 Aoki, Thomas T., \*317, \*326, \*332  
 Araujo, Diana C., 1-5  
 Archer, Juanita A., \*636, \*1163, \*1165  
 Arieff, Allen I., \*534  
 Arimura, Akira, \*155, \*471  
 Arky, R., \*388, \*391  
 Arnett, David M., \*535  
 Aronoff, Stephen L., \*352, 404-407  
 Arquilla, Edward R., \*383, 397-403, 811-819  
 Arseni, A., \*381  
 Ash, Patricia, \*1007  
 Assan, Roger, 1026-1030  
 Assimakopoulos-Jeannet, Françoise, \*636  
 Atkins, Robert F., 275-282  
 Aubry, Jean-Pierre, 463-469  
 Austin, James, \*322  
 Austin, Paul, \*322  
 Auzuki, Tadao, \*315  
 Avery, M., \*637  
 Aviner, Zvi, 1106-1109  
 Avogaro, Pietro, \*352  
 Avruch, J., \*357  
 Ayalon, Daniel, \*736  
 Aydin, Ismet, 227-229, \*352  
 Aynsley-Green, \*153  
 Ayotte-Ferron, L., \*357  
 Axelrod, L., \*331

## B

Bacon, Virginia C., \*317  
 Bader, Pearl, 307-314  
 Baetens, D., \*344  
 Bagdade, J.D., \*348, \*634  
 Baird, K., \*322  
 Baker, B.A., \*377  
 Baker, Geraldine, \*350  
 Balasse, E.O., \*534  
 Ballantine, Elmer J., 554-560  
 Ballard, F.J., \*635  
 Ballinger, Walter F., \*796

Bally, C., \*335  
 Bar, Robert S., \*348, \*636, \*1165  
 Barbosa, Jose, \*336, 709-712  
 Barham, Frances W., \*1164  
 Barker, C.F., \*338  
 Barnes, A.J., \*471, \*534  
 Bar-On, Hanoch, \*353, 509-515  
 Baska, R. Eugene, 459-462  
 Baskin, Frankie K., \*353  
 Batchelor, J.R., \*236  
 Bauer, G. Eric, \*156  
 Baum, David, \*534  
 Baum, J.D., \*153  
 Baum, Stephen, \*474  
 Baur, Sonia, \*317  
 Beachey, E.H., \*472  
 Beathard, G., \*349  
 Beattie, C.W., \*353  
 Beck, Paul, \*535  
 Becker, D.J., \*75  
 Belfiore, Francesco, \*634  
 Bellman, Otto, 234  
 Belusko, Ronald J., \*353  
 Ben-Jonathan, Nira, \*1082  
 Bendayan, M., \*382  
 Benedict, G. William, 984-988  
 Bennett, Leslie L., \*360  
 Bennett, Peter H., \*324, \*384, 404-407, 554-560, 561-565  
 Bennion, Lynn J., \*324  
 Benson, James W., \*317, \*326  
 Berchtold, P., \*354  
 Berdanier, C.D., \*354  
 Bergenstal, Richard, \*317  
 Berger, M., \*354  
 Bergman, Richard N., \*322  
 Berkowitz, D., \*375  
 Berkson, David M., 936-943  
 Berne, Christian, \*154  
 Bernstein, R., \*328  
 Bernstein, R.S., \*366  
 Bernstein, Robert, \*733  
 Bertolini, Donald, \*360  
 Bessman, A., \*385  
 Bessman, S.P., 81-89, \*385  
 Bhatena, S.J., \*327, 1031-1040

## DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
 February, 81-160  
 March, 161-240  
 April, 241-320  
 Supplement 1, 321-396

May, 397-476  
 June, 477-544  
 July, 545-644  
 August, 645-740

September, 741-804  
 Supplement 2, 805-930  
 October, 931-1010  
 November, 1011-1090  
 December, 1091-1170

Bierman, Edwin L., \*234-235, \*336  
 Bilginturan, A.N., \*354, \*362  
 Binder, Christian, \*329, \*362  
 Bishop, J.S., \*355  
 Bistran, Bruce R., 494-504  
 Bjornorp, Per, \*236  
 Blach, R.K., \*471-472  
 Blackard, W.G., \*339  
 Blackburn, George L., \*341, 494-504  
 Blake, K.C.H., 11-15  
 Blanks, M.C., \*364  
 Bleicher, S.J., \*335  
 Blix, P., \*329  
 Block, Marshall B., \*735  
 Bloom, Arnold, \*471  
 Bloom, S.R., \*471, \*474, \*534, \*634  
 Bobo, R., \*355  
 Boden, G., \*341  
 Boehm, T.M., \*355  
 Bohannon, Nancy V., \*340, \*387, 955-960  
 Bolande, Robert, \*365  
 Bomback, Fredric M., 420-427  
 Bomboy, J.D., \*341  
 Bonar, Jeanne R., \*355, \*365  
 Borden, J., \*343  
 Borensztajn, Jayme, \*391  
 Borg, Hakan, \*796  
 Borzi, Vito, \*634  
 Botha, J.L., 11-15  
 Botz, Charles K., \*325, 691-700  
 Bowen, H.F., \*372  
 Boyer, Joseph, \*157  
 Boykin, Lorraine, \*356  
 Bradley, William E., 1100-1105  
 Branca, S., 167-172  
 Brandsborg, O., \*1084-1085  
 Bray, George A., \*360, \*734-735  
 Breslow, Jan L., \*154  
 Breuer, R.I., \*234  
 Brinn, Jack E., \*344  
 Brodows, Robert G., \*315  
 Brooks, R., \*340  
 Brown, A.C., \*340  
 Brown, David M., \*349, \*356, \*798, 850-857  
 Brown, Josiah, 56-64, \*338, \*798  
 Brown, Kenneth S., 190-197  
 Brown, Marvin, \*356, \*535  
 Browne, Christina, 297-306  
 Bruckheimer, Sally M., \*318  
 Brugman, Thomas M., 397-403  
 Bruns, B., \*367  
 Bruns, Thomas W., \*357  
 Brunzell, John D., \*234-235  
 Bryant, M.G., \*474  
 Bryce, Graeme F., \*356  
 Buchanan, Bernard J., \*342

Buell, Donald N., \*1163-1164  
 Bukowiecki, L., \*346  
 Bunn, H.F., \*335  
 Burke, Gerald, \*536  
 Burke, V., 216-222  
 Burns, R.L., \*390  
 Burr, I.M., 216-222  
 Buse, Maria G., \*333  
 Buselmeier, T.J., \*349  
 Bush, M.A., \*357

## C

Cabijan, Tomislav, \*734  
 Cabral, Bienvenido V., 268-274  
 Cahill, George F., Jr., \*317, \*344  
 Caldwell, Jeanne, 72-74  
 Camerini-Davalos, R.A., \*383  
 Campbell, Robert G., \*315  
 Campiche, M., \*795-796  
 Canner, Paul L., \*369  
 Cantalamessa, L., \*538  
 Caras, J.A., \*325  
 Carpenter, A.M., \*357  
 Carroll, Ray, \*379  
 Carter, James R., Jr., 1110-1117  
 Cassetta, P., \*381  
 Cataland, Samuel, \*360, 931-935  
 Catania, A., \*538  
 Catellier, C., \*357  
 Cattaneo, R., 223-226  
 Cazzolato, Giuseppe, \*352  
 Cerami, Anthony, 1-5, 230-232  
 Cerasi, Erol, 949-954  
 Chai, S.Y., \*353  
 Chambers, A., \*347  
 Chan, S.J., \*343  
 Chance, R.E., \*326, \*329  
 Chang, A.Y., \*358  
 Chang, Peter H., \*358  
 Chao, T.T., \*352  
 Chappel, C.I., \*378  
 Charalambopoulos, D., \*369  
 Charles, M. Arthur, 256-259  
 Charters, A. Crane, II, \*797  
 Chase, G.R., \*378  
 Cheng, H., \*471-472  
 Chernicky, Cheryl, \*322  
 Cherrington, A.D., \*331  
 Cherrington, B.C., \*358  
 Chertock, H., \*380  
 Chhetri, M.K., \*539  
 Chiang, T.M., \*472  
 Chiasson, J.L., 283-291, \*331, \*358  
 Chick, William L., \*343, \*344  
 Chideckel, E.W., \*340  
 Chisholm, D.J., \*316  
 Chiumello, G., 550-553  
 Chochinov, Ronald H., 994-1004  
 Christacopoulos, P., \*358, \*368  
 Christacopoulos, P.D., 903-908  
 Christensen, Niels Juel, 6-10, \*235, \*1083, \*1084-1085  
 Christensen, Stig Engkjoer, \*235, \*538  
 Christlieb, A. Richard, 268-274, \*348, \*378, 820-825, 969-974  
 Chu, Chin-Pin, 566-573  
 Chute, Rosanna N., \*344  
 Clark, William R., 56-64, \*338, \*798  
 Clarke, James S., \*1004-1005  
 Claus, T.H., \*331  
 Clemens, Anton H., \*358  
 Clements, Rex S., Jr., \*337  
 Clifford, C., \*537  
 Cohen, Kenneth L., \*1005  
 Cohen, Margo P., \*349  
 Cohen, R.M., \*322  
 Cole, Harold S., \*359  
 Cole, Richard A., 984-988  
 Coleman, D.L., \*344  
 Colle, Eleanor, \*359, \*365  
 Colwell, John A., \*347, 826-831  
 Conant, Susan, \*380, 484-493  
 Conlay, L.A., \*359  
 Connolly, Daniel C., \*346, 566-573  
 Cook, Daniel, \*345  
 Cooperman, Jack M., \*359  
 Cooppan, R., \*359  
 Corbin, A., \*353  
 Cousineau, Daniel, \*1082  
 Coustan, D.R., \*384  
 Coy, D.H., 1031-1040  
 Crapo, Lawrence, \*337  
 Crapo, Phyllis A., \*156, 741-747  
 Craven, Patricia, \*535-536  
 Crespino, Stephen, 679-690  
 Crill, Wayne, \*345  
 Crockett, Samuel E., \*360, 931-935  
 Crofford, Oscar B., \*328, \*331  
 Crowley, Mary F., \*471  
 Crowther, R., 764-770  
 Crudup, James W., \*795  
 Cruz, A., \*367  
 Cryer, Philip E., \*347, 1071-1082, \*1083-1084, \*1085  
 Cudworth, A.G., \*236  
 Cuppers, H.J., \*354  
 Curnow, Randall T., \*332, \*383, 623-631  
 Curry, Donald L., \*360  
 Curtis, Guy P., \*535  
 Cutler, John, 1041-1051  
 Cutrona, D., \*366  
 Czech, Michael P., \*336, \*1164-1165  
 Czernik, A.J., \*380  
 Czyzyk, Artur, 717-718

## DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
 February, 81-160  
 March, 161-240  
 April, 241-320  
 Supplement 1, 321-396

May, 397-476  
 June, 477-544  
 July, 545-644  
 August, 645-740

September, 741-804  
 Supplement 2, 805-930  
 October, 931-1010  
 November, 1011-1090  
 December, 1091-1170



## D

Daane, T.A., \*384  
 Daffner, R., \*473  
 Dahms, William T., \*360  
 Daikos, G.K., \*369  
 Daly, S., \*389  
 Daughaday, William H., 994-1004,  
 \*1005, \*1006  
 Davidoff, Frank, \*316, \*360, \*797-798  
 Davidson, J.A., \*326  
 Davidson, Mayer B., \*154, \*235, \*361  
 Davidson, Paul C., \*324  
 Davis, B., \*328  
 Davis, E., \*349  
 Davis, John W., \*735  
 De Champlain, Jacques, \*1082  
 De Leiva, A., \*355, \*361  
 DeLellis, Ronald A., \*316, \*797-798  
 Del Guercio, M.J., 550-553  
 D'Elia, John A., \*367, \*378, 969-974  
 Delmez, J., \*333  
 DeLuca, K., \*635  
 De Meyts, Pierre, \*321, \*1163-1164  
 Dennin, H., \*375  
 Derojas, Juan F., \*362  
 DeRubertis, Frederick R., \*535-536  
 Deschamps, I., 505-508  
 Destro, Robert L., 459-462  
 Devereux, Dennis F., 650-660  
 Dixel, T., 914-919  
 Diakoumis, K., \*343  
 Dickerman, Richard M., \*795  
 Dillon, Richard S., \*361  
 di Natale, B., 550-553  
 Dippe, Stephen E., \*735  
 Dirgo, John A., \*387, 758-763  
 Ditzel, Jo  
 Doe, R.P., \*336  
 Doi, Kunihiro, \*327, 1018-1025  
 Doorenbos, H., 241-244, 245-249  
 Dorantes, L.A., \*362  
 Dorf, Arthur, 554-560  
 Dorio, Raymond J., 397-403  
 Doron, M., \*537  
 Downing, S. Evans, \*636  
 Doyle, A.E., \*1082  
 Drash, Allan, \*334, \*537, \*734  
 Drasin, H., \*363  
 Drejer, J., \*329  
 Dubuc, P.U., \*361  
 Du Caju, Marc V.L., \*1007  
 Duck, Stephen C., 111-115  
 Duckworth, William C., \*353, \*472  
 Dulin, W.E., \*384, \*390  
 Dunbar, J.C., \*377  
 Dunkley, W.L., \*537  
 Dunphy, T., \*387

Dupont, Andre, \*471  
 Dupre, John, 128-135, \*316, \*317, \*332  
 Duran, Tomas A., \*362  
 Dyer, Alan, 936-943  
 Dzoga, Katti Fischer, 207-215

## E

East, L.E., \*321  
 Eaton, R. Philip, 32-43, \*157, \*330,  
 \*535, \*536, 679-690, 978-983  
 Eder, Howard A., 509-515  
 Edgar, Paul J., \*539  
 Edmunds, Diana, 1118-1122  
 Efendic, Suad, 949-954  
 Eichner, Harvey L., \*157  
 Eisenbarth, George S., \*1006-1007  
 Eisenstein, Albert B., 51-55, \*327  
 Elahi, D., \*324  
 Elders, M. Joycelyn, \*1004-1005  
 Ellerman, Jeanette, \*156-157  
 Elveback, Lila R., 566-573  
 Engerman, Ronald, \*325  
 England, J.D., \*354, \*362, \*378  
 Ensink, John W., \*315, \*317, \*326,  
 \*340, \*536, 645-649  
 Erkelenz, D.W., 241-244, 245-249  
 Ertel, Norman H., \*325  
 Eschwege, Eveline, 463-469  
 Espinosa de los Monteros, A.M., \*362  
 Estep, Herschel L., \*538  
 Esterly, James A., 444-449  
 Eto, Sumiya, \*474  
 Even, S.E., \*334, \*378

## F

Faber, Ole K., \*329, \*362  
 Fabrykant, M., \*363  
 Fajans, S.S., \*330, \*634-635, 764-770  
 Falkner, Bonita, 101-103  
 Fan, A., \*537  
 Fanska, Rudolph, \*155  
 Farber, Bruce, 936-943  
 Farley, Lise, \*1082  
 Fedele, Domenico, 408-419  
 Felber, H.-P., \*367  
 Feldman, Jerome M., \*375, \*536  
 Felig, Philip, \*76, \*154, \*323, \*332,  
 \*539, 776-784, 944-948, 1091-1099  
 Felts, James M., \*363, \*385  
 Felts, P.W., \*331  
 Fenichel, R.L., \*353  
 Fernandes, G., \*356  
 Ferris, Robert K., \*315  
 Fettes, M.V., \*385  
 Field, James B., \*390  
 Filetti, S., 167-172

Filsell, O.H., \*635  
 Fineberg, S. Edwin, 297-306, \*341,  
 \*352  
 Finger, F.E., 283-291  
 Fink, J., \*75-76  
 Fink, William J., \*536, \*733  
 Finke, Edward H., 484-493  
 Fischer, Boguslav H., \*364  
 Fischer, L.J., \*343  
 Fisher, J.N., \*635  
 Fisher, Merrick, \*539  
 Flatau, E., \*537  
 Flatley, Margaret, 297-306  
 Flatt, Jean-Pierre, 494-504  
 Fleischer, Norman, \*474  
 Flender, Joan, \*334  
 Fletcher, T., 216-222  
 Flier, Jeffrey S., \*322, \*636, \*1165  
 Flock, Eunice V., \*384  
 Floyd, J.C., Jr., \*330, \*634-635  
 Fluker, G., \*316-317  
 Foa, P.P., \*234, \*377  
 Folse, D., \*349  
 Ford, Charles V., \*734-735  
 Forristall, Carvl A., \*374  
 Forsham, Peter H., 24-28, \*156, \*339,  
 \*340, \*735, 955-960  
 Forsman, Patricia J., \*537, \*734  
 Fort, Pavel, \*363  
 Foster, Daniel W., \*330  
 Foushee, Doretha B., \*1005  
 Frame, Carolyn M., \*154  
 Francis, M.J.O., \*1007  
 Frangipane, L., \*338  
 Frankel, Barbara J., \*315, \*364,  
 \*798-799  
 Fraser, E., \*357  
 Free, Alfred H., \*363  
 Free, Helen M., \*363  
 Freidberg, S., \*359  
 Freinkel, Norbert, \*317, \*324, \*346,  
 936-943  
 Friedman, Gerald J., \*364  
 Froesch, E. Rudolf, \*1006  
 Frohman, Lawrence, \*337  
 Fryklund, Linda, \*1006  
 Fujimoto, R.H., \*336  
 Fujimoto, Wilfred Y., \*472, \*536  
 Fujita, Yoshikuni, \*157  
 Fulop, Milford, 292-296

## G

Gabbay, K.H., \*335, \*635  
 Galbo, H., \*1084  
 Gallop, P.M., \*335  
 Galloway, J.A., \*325, \*326  
 Gammelfoht, Steen, \*1164

## DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
 February, 81-160  
 March, 161-240  
 April, 241-320  
 Supplement 1, 321-396

May, 397-476  
 June, 477-544  
 July, 545-644  
 August, 645-740

September, 741-804  
 Supplement 2, 805-930  
 October, 931-1010  
 November, 1011-1090  
 December, 1091-1170

## AUTHOR INDEX 1976

- Ganda, O.P., \*317, \*364, 595-603  
 Gander, R.E., 691-700  
 Gandhi, V.S., \*335  
 Ganong, W.F., \*155, \*385  
 Garber, Alan J., \*1083-1084  
 Gardiner, Robert J., \*351  
 Gargantini, L., 550-553  
 Garland, J.T., \*1006  
 Garlaschi, C., 550-553  
 Gastineau, C.F., \*373  
 Gauvin, B.R., \*328  
 Gavin, James R., III, \*315, \*1163-1164  
 Geiger, J.W., \*316  
 Genuth, Saul M., 1110-1117  
 George, David T., \*157  
 Gerich, John E., 24-28, 65-71, \*156, \*340, \*387, 955-960  
 Gerritsen, G.C., \*364, \*371, 477-483  
 Gersell, D.J., \*364  
 Ghazvinian, Sasan, 202-206  
 Gilbert, Marc, 1026-1030  
 Gingerich, R.L., \*329, \*364  
 Ginsberg, B.H., \*322  
 Ginsberg, Henry N., \*156, \*365  
 Giordano, N., \*381  
 Girard, Jean R., 1026-1030  
 Giron, B., 505-508  
 Giustina, G., \*538  
 Gladnikoff, Gila, 949-954  
 Glasgow, Joseph L., \*365  
 Gleason, Ray E., \*155, 268-274, \*335, \*370, 903-908  
 Gliemann, Jørgen, \*1164  
 Glinzmann, Walter H., \*539  
 Goetz, Frederick C., \*349, \*357, 709-712  
 Gold, Ernest M., \*388  
 Goldbourt, Uri, \*76  
 Goldfine, Ira D., \*154  
 Goldman, Hy, \*359, \*365  
 Goldman, Jack, \*373  
 Goldman, Jose, \*365  
 Goldner, Martin G., \*474  
 Goldsmith, P.C., \*155  
 Goldstein, H. Howard, \*367  
 Good, Thomas A., \*370  
 Goodman, A. David, \*328  
 Goodman, M., \*332, \*375  
 Goodner, Charles J., \*156, \*340  
 Gorden, Phillip, \*315, \*322, \*636, \*1163  
 Gordon, Edwin E., \*315  
 Gordon, Phillip, \*1165  
 Gorelkin, Leo, 623-631  
 Gorwitz, Kurt, 122-127  
 Goto, Yasuo, 961-968  
 Gottlieb, Barbara, 116-121  
 Gottlieb, Marise, \*155  
 Graham, Leonard A., \*153  
 Grambert, David E., \*797  
 Granholm, N., \*349  
 Grasso, S., \*366, 545-549  
 Gray, Thomas W., \*536, \*733  
 Green, O., \*375  
 Green, W., \*234  
 Greenberg, B.Z., \*355, \*361  
 Greenfield, Sheldon, \*235  
 Greenwood, M.R.C., \*389  
 Greider, M.H., \*329, \*364  
 Grgic, Ante, \*636-637  
 Gries, F.A., \*354  
 Griffin, Audrey J., \*367  
 Grisafe, J.A., 771-775  
 Grodsky, Gerold M., \*155, 256-259, \*364, \*381  
 Groth, Carl-Gustav, \*796  
 Grow, A.B., \*343  
 Grundleger, M.L., \*366  
 Grundy, Scott M., \*324  
 Grünekle, D., \*354  
 Grunt, Jerome A., 459-462  
 Gulli, R., \*385  
 Gunnarsson, Rolf, \*796  
 Guthrie, Diana W., \*350, \*378  
 Guthrie, Richard A., \*350, \*378  
 Guyot-Argenton, Claudine, 463-469  
 Gwinup, Grant, 29-31  
 Gylfe, Erik, \*315, \*798-799
- H**
- Haas, Darrell, \*360  
 Hadden, D.R., \*323  
 Hafken, Louis, \*734  
 Hagen, Thad C., \*351  
 Hagler, Louis, \*75  
 Haist, Reginald E., \*75  
 Hall, Kersten, \*1005-1006  
 Halter, Jeffrey B., \*323, \*1084  
 Halushka, P.V., \*347, 826-831  
 Hampshire, Jennifer, 116-121, \*330  
 Hamtil, Lawrence W., 459-462  
 Haney, D.N., \*335  
 Hann, Suhung, 101-103  
 Hansen, Aage Prange, \*235, \*538  
 Hansen, R.J., \*366  
 Hanssen, K.F., \*1006  
 Harding, H.R., \*328  
 Hardy, M.A., \*389, 944-948  
 Harker, Laurence A., \*156  
 Harris, Virginia, \*352  
 Harrison, Joy, \*338  
 Harrison, L.C., \*235-236  
 Hartman, Edzard, \*234  
 Hasell, Arieh, \*736  
 Hastings, Rochelle, \*339, \*386  
 Hasty, K., \*335  
 Hauch, T.W., \*234  
 Hauhart, Richard E., \*387, 758-763  
 Haunz, E.A., \*326  
 Hayashi, M., \*346  
 Haymond, Morey W., 111-115, \*349, \*733-734, \*1083-1084  
 Hayton, W.L., 771-775  
 Heber, D., \*366  
 Heding, Lise C., \*329, \*362  
 Hegre, O.D., 180-189, \*798  
 Heitz, P., \*474  
 Hellerstrom, Claes, \*796  
 Hellman, Bo, \*315, \*798-799  
 Hellrung, John M., \*636-637  
 Helton, D., \*368  
 Hender, Rosa G., \*76, \*323, \*332, \*539, 776-784, 1091-1099  
 Hendriksen, C., \*329  
 Henley, Walter L., 1106-1109  
 Henquin, J.C., \*345  
 Henry, David P., 198-201, \*317, \*1082-1083  
 Hepp, K. Dieter, \*370  
 Heptner, W., \*367  
 Herchuelz, Andre, \*345  
 Herington, Adrian C., \*1005  
 Herman, Joseph B., \*76  
 Herman, Robert H., \*75, \*153, \*734, \*735  
 Herold, A.A., Jr., \*359  
 Hetenyi, G., Jr., \*316-317  
 Hewett, J.E., \*378  
 Hill, D.W., \*471-472  
 Hobbs, R.K., \*537  
 Hoberman, Henry D., 292-296  
 Hodges, R.E., \*537  
 Hofeldt, Fred D., \*155, \*735-736  
 Hoffman, James, 72-74  
 Hoffman, Phyllis, 604-613  
 Hofmann, C., \*343  
 Hoganson, George, \*339  
 Hogle, Hugh, \*797  
 Hogles, Louis, \*735  
 Holder, G., 975-977  
 Holland, E., \*334  
 Hollands, Marjorie H., \*342  
 Holley, Daniel C., \*360  
 Holley, Keith E., \*796  
 Holm, Jan, \*236  
 Holst, J.J., 16-23, \*1084  
 Hope, Harriet, \*356  
 Hopwood, Nancy J., \*537, \*734  
 Horl, R., \*473  
 Horton, E.S., \*326  
 Horwitz, D.L., \*329, \*367  
 Hoskins, Beth, \*365  
 Houser, Harold B., 1110-1117  
 Hover, Barbara A., \*156-157

## DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80	May, 397-476	September, 741-804
February, 81-160	June, 477-544	Supplement 2, 805-930
March, 161-240	July, 545-644	October, 931-1010
April, 241-320	August, 645-740	November, 1011-1090
Supplement 1, 321-396		December, 1091-1170

Hoversten, Glen, \*339, \*386  
 Howard, Charles F., Jr., \*367  
 Howen, Genevieve G., 122-127  
 Hsu, T.H., \*157  
 Hubbell, J., \*637  
 Huckle, Samuel T., \*536, \*733  
 Hughes, Edwin R., \*1004-1005  
 Hulst, S.G. Th., 1052-1054  
 Hultquist, Gosta T., \*472  
 Humbel, Rene E., \*1006  
 Huss, Gregory, \*339

## I

Iamaguchi, Emi, 161-166  
 Icasas-Cabral, Esperanza A., 268-274  
 Idahl, Lars-Ake, \*315, 450-458, \*798-799  
 Ikeda, Masaki, 961-968  
 Ikeuchi, M., \*346  
 Imagawa, W., \*381  
 Imura, Hiroo, 961-968  
 Ingelfinger, Joseph A., 561-565  
 Irias, Julian J., 650-660, 661-666  
 Isaf, J., \*343  
 Issekutz, Bella, Jr., \*539  
 Issekutz, Thomas B., \*539  
 Isselbacher, K.J., \*318  
 Itterly, W., \*380  
 Iversen, J., \*538, \*1084  
 Iwamoto, Y., \*368  
 Izenstein, Barry, \*367  
 Izzo, J.L., \*368  
 Izzo, M.J., \*368

## J

Jackson, M.A., 11-15  
 Jackson, R.L., \*334, \*378  
 Jacobs, L.S., \*1006  
 Jacobson, Lester B., \*158  
 Jahrling, Peter B., 623-631  
 Jain, Adesh K., \*236  
 Janka, Hans-Uwe, 268-274, 914-919  
 Jansen, A., \*637  
 Jarett, Leonard, \*321, \*379  
 Jarrett, D., \*322  
 Jarrett, I.G., \*635  
 Jaspan, J.B., \*391  
 Javorski, W. Curtis, 673-678  
 Jeanrenaud, Bernard, \*636  
 Jefferson, Leonard S., \*333  
 Jenkins, P., \*153  
 Jensen, S. Lindkaer, 752-757  
 Jiang, N., \*529  
 Jintze, K.L., \*343  
 Job, Didier, 463-469  
 Johansen, Klaus, \*155

Johnson, David G., 198-201, \*317, 645-649, \*1082-1083  
 Johnson, M., \*329  
 Jonasson, Olga, \*339, \*386  
 Josefsberg, Z., \*537  
 Jost, Alfred, 1026-1030  
 Joy, Robert M., \*360  
 Juhn, Doojung D., \*318

## K

Kaestner, Elisabeth, \*390  
 Kahan, B., \*375  
 Kahn, C. Ronald, \*158, \*315, \*322, \*636, \*1006, \*1162-1163, \*1165  
 Kalant, N., \*316  
 Kaldany, Antoine, 969-974  
 Kalk, W.J., 11-15  
 Kalkhoff, R.K., \*368  
 Kalnasy, L.W., \*340  
 Kanazawa, Y., \*323, \*346  
 Kane, M., \*321  
 Kaneto, Akio, \*155-156  
 Kang, A.H., \*472  
 Kaplan, Edwin L., \*536  
 Kaplan, Sherrie H., \*235  
 Karakash, Clairette, \*636  
 Karam, John H., 24-28, 65-71, \*340, \*387, 580-585, 955-960  
 Karamanos, B., \*358, \*368  
 Karl, Irene, \*733-734  
 Karl, Richard C., \*236  
 Kastrup, K.W., \*1006  
 Kasuga, M., \*368  
 Katsilambros, N., \*369  
 Kaufman, I.A., \*537  
 Kaufmann, Robert L., \*155  
 Kawazu, S., \*323, \*346  
 Kaye, Robert, 101-103  
 Keller, Margaret A., \*537  
 Keller, Ulrich, \*331  
 Kelly, John, \*733  
 Kempner, Walter, \*472-473  
 Kenn, H., \*471-472  
 Kennedy, A., \*349  
 Kennedy, W.R., \*349  
 Kenny, Frederic M., \*537, \*734  
 Kerian, Alice, \*534  
 Kervran, Alain, 1026-1030  
 Kessinger, Anne, \*637  
 Khalifa, Ahmed, \*349  
 Khan, Farida, \*474  
 Kiehm, Tae G., \*369  
 Kiesow, L., \*351  
 Kile, J., \*361  
 Kilo, Charles, 230-232, 604-613, 925-927  
 Kim, H.-J., \*368  
 Kimmelstiel, P., \*349

Kimmerling, George, 673-678  
 King, Katherine C., 1118-1122  
 King-Roach, A.P., \*235-236  
 Kinney, J.M., \*316  
 Kipnis, David M., 679-690, \*733, 1041-1051, \*1083-1084  
 Kirsteins, L., \*328  
 Kitabchi, Abbas E., \*318, \*353, \*382  
 Kivirikko, Kari I., 1066-1070  
 Kjellstrand, C.M., \*349  
 Kleinfelder, J., \*347  
 Klimt, Christian R., \*369  
 Knight, P.J., \*355  
 Knopp, Robert H., 297-306, \*318, \*369  
 Knowlton, Stephen D., 275-282  
 Knox, Dale, \*797  
 Koenig, Ronald J., 1-5, 230-232  
 Koerker, Donna J., \*156, \*340  
 Koerner, Donald R., 1055-1065  
 Kohler, Elaine, \*370  
 Kohnner, Eva M., \*471-472, \*537-538, 839-844  
 Koivisto, Veikko A., 1066-1070  
 Kolb, Helmut J., \*370, 914-919  
 Komaroff, Anthony L., 297-306  
 Koncz, Lajos, \*316, \*370, \*797-798  
 Kono, Tetsuro, \*1164  
 Kopin, Irwin J., \*1083  
 Koren, Hillel, \*348  
 Kornhauser, D.M., \*328  
 Kosaka, Kinori, \*155-156, \*346, \*368  
 Koser, Majda, \*345  
 Koury, Mark, 890-896  
 Kowarski, Avinoam, 984-988  
 Kramer, Stuart, \*370  
 Kraus, Barbara, 268-274  
 Kreines, K., \*371  
 Krieger, D.T., \*383  
 Krolewski, Andrzej S., 717-718  
 Kronheim, S., \*75  
 Kuhl, C., 16-23, 752-757  
 Kuku, S.F., \*391  
 Kumar, Dinesh, \*371  
 Kumin, Selma, 420-427  
 Kupiecki, Floyd P., \*371  
 Kurland, Leonard T., 566-573  
 Kuzuya, H., \*329  
 Kwock, L., \*382  
 Kylo, Carole, \*372

## L

Labreque, A.D., \*343  
 Lacy, Paul E., \*75-76, \*345, \*346, 484-493, 667-672, \*796, 1041-1051  
 Lacy, W.W., 283-291, \*331, \*358  
 Lake, C. Raymond, \*1083  
 Lakshmanan, R., \*354

## DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
 February, 81-160  
 March, 161-240  
 April, 241-320  
 Supplement 1, 321-396

May, 397-476  
 June, 477-544  
 July, 545-644  
 August, 645-740

September, 741-804  
 Supplement 2, 805-930  
 October, 931-1010  
 November, 1011-1090  
 December, 1091-1170

# AUTHOR INDEX 1976

Lambert, A.E., \*345  
 LaMont, J.T., \*318  
 Lamusga, R.F., \*340  
 Landau, Bernard R., \*322  
 Landgraf, R., \*473  
 Landgraf-Leurs, M.M.C., \*473  
 Landsberg, Lewis, \*318, \*391  
 Lang, C. Max, \*377, 434-443  
 Lang, S., \*386  
 Langley, Paul E., \*357  
 Lerner, Joseph, 413-419  
 Laron, Z., \*537, \*1006  
 Larsson, Bo, \*236  
 Lasser, A., \*375  
 Laugharne, Elizabeth, \*342  
 Lauris, Vilma, \*343, \*344  
 Lauritzen, Torsten, \*362  
 Lavee, A., \*373  
 Lavine, R.L., \*372  
 Lavis, Victor, \*372  
 Lawecky, January, 256-259  
 Lawrence, Ann M., \*153, \*234, \*328, \*342  
 Layne, E.C., 81-89  
 Lazarow, A., 180-189, \*357, \*798  
 Lazes, Peter, \*343  
 Lebovitz, Harold E., \*355, \*1006-1007  
 Leclercq-Meyer, Viviane, \*473  
 Ledet, Thomas, 207-215, 1011-1017  
 Lee, H.B., \*372  
 Lee, J., \*373  
 Lee, John C., \*636  
 Lee, Sun, \*797  
 Lees, Robert S., \*154  
 Lefebvre, Pierre J., \*316, \*327, \*374  
 Leibell, B.S., \*325, \*333, 691-700  
 Leichter, Steven, \*734  
 Leitner, J. Wayne, \*386  
 Lemon, Henry M., \*637  
 Lengel, F., \*377  
 Leonard, R.J., 180-189, \*798  
 Leopold, Irving H., 1106-1109  
 Lerner, R.L., \*389, 944-948  
 Lestrade, H., 505-508  
 Levey, Gerald S., \*473-474  
 Levin, Seymour R., \*373, \*735  
 Levine, J.H., \*347  
 Levine, Jon, 826-831  
 Levine, Rachmiel, \*373  
 Lev-Ran, Arye, \*373  
 Levy, Robert I., \*154  
 Lewis, Charles E., \*235  
 Lewis, S.B., \*341, \*384  
 Li, Jeanne B., \*333  
 Liberti, J.P., \*1007  
 Libertino, John, \*367  
 Lickley, H.L.A., \*316  
 Ličko, Vojtech, 580-585

Liebow, Irving M., 561-565  
 Lifshitz, Fima, \*334, \*363  
 Like, Arthur A., \*344, \*378, 595-603  
 Lilienfeld-Toal, H.V., \*373  
 Liljenquist, John E., 283-291, \*331, \*341  
 Lin, Boniface J., \*75, 574-579  
 Lin, Hung-Jung, 650-660, 661-666  
 Lippe, B., \*379  
 Lippman, M.E., \*380  
 Lipson, Loren G., \*374  
 Livingston, J.N., \*321  
 Lloyd-Mostyn, R.H., 748-751  
 Lo, Hilda, \*473-474  
 Lockhart-Ewart, Robin B., 96-100  
 Lockwood, D.H., \*321, \*351  
 Loewenstein, J.E., \*359  
 Loken, Susan C., \*374  
 London, D.R., 975-977  
 Long, C.L., \*316  
 Lopez, Rafael, \*359  
 Lorenzi, Mara, 24-28, 65-71, \*156, \*340, \*387, 955-960  
 Louis, W.J., \*1082  
 Lowrey, George H., 650-660, 661-666  
 Lucchesi, Benedict R., \*535  
 Ludvigsen, Carl W., 667-672  
 Lufkin, Edward G., \*75, \*735  
 Luft, Rolf, 949-954, \*1005-1006  
 Lundbaek, Knud, \*235, \*538, 845-849  
 Lundgren, Goran, \*796  
 Lundquist, Ingmar, \*155  
 Lutwak, Leo, \*370  
 Lux, Samuel F., \*154  
 Luyckx, Alfred S., \*316, \*327, \*374  
 Lykke, C., \*537  
 Lynch, Almorris, \*539

## M

Macaron, C., \*375  
 Machina, Teresa, \*370, \*375  
 Mackes, K.G., \*373  
 Macmorine, H.G., \*339  
 Mahler, R.J., \*361  
 Mahmoud, Adel A.F., \*538  
 Mahony, Cheryl, \*375  
 Maizels, E., \*375  
 Majoor, C., \*637  
 Mako, Mary E., \*317, \*389, \*635  
 Malaisse, Willy J., \*345, \*473  
 Malaisse-Lagae, F., \*376  
 Malone, John I., \*636-637, 989-993  
 Malphus, Edward W., \*636-637  
 Mandel, Mark A., \*538  
 Mann, E., \*318  
 March, Wayne, \*325  
 Marchand, Jocelyne, \*472

Marchiori, Elisa, 408-419  
 Marcus, Robert, \*370  
 Margolis, Simeon, \*351, 984-988  
 Marinan, Barbara, \*348  
 Marks, Leon J., 202-206  
 Marks, Melvin, \*365  
 Marliiss, E.B., \*333, \*378  
 Marshall, Robert N., \*1005  
 Martin, A.L.A., \*376  
 Martin, Donald B., 275-282, \*331, \*389  
 Martin, Julio M., 96-100  
 Martin, Malcolm M., \*376, \*636, \*1165  
 Mason, D.T., \*537  
 Matas, Arthur J., \*349, \*376, 785-795, \*796, 1123-1128  
 Matin, S.B., \*359  
 Matschinsky, Franz M., \*156-157, \*346, \*391  
 Matsuyama, T., \*234  
 Mattson, James R., \*75  
 Mauer, S. Michael, \*349, \*356, 709-712, \*798, 850-857  
 Mayer, Kenneth H., 936-943  
 Mazzaferri, Ernest L., \*360, 931-935  
 Mazzarino, C., 545-549  
 McCorkle, K., \*326  
 McCulloch, E.L., \*342  
 McDaniel, Michael L., \*75-76, \*345, \*346, 667-672  
 McDonagh, P.F., \*537  
 McDonald, Hugh J., \*353  
 McDonald, T.J., \*332  
 McGarry, J. Denis, \*330  
 McGraw, C., \*355  
 McIntosh, Rawle, \*797  
 McKennan, Kevin X., 275-282  
 McMahon, F. Gilbert, \*236  
 McMillan, Donald E., \*374, 805-806, 858-864  
 McNatt, M. Loretta, \*1004-1005  
 Medalie, Jack H., \*76  
 Megyesi, Klara, \*315, \*1006  
 Meissner, H.P., \*377  
 Menez, M., \*343  
 Menke, D.R., \*334  
 Merkat, Irwin, 1110-1117  
 Messina, A., 545-549  
 Messina, D., \*366  
 Metzger, Boyd E., \*317, \*324  
 Meyer, J., \*340  
 Michael, Alfred F., 701-708, 709-712, \*798, 850-857  
 Michas, Constantine, \*388  
 Micossi, P., \*377  
 Mielke, C. Harold, \*156  
 Miki, Eishi, \*155-156  
 Milburn, Peter, \*399  
 Miller, Kenneth, 701-708, 709-712

## DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
 February, 81-160  
 March, 161-240  
 April, 241-320  
 Supplement 1, 321-396

May, 397-476  
 June, 477-544  
 July, 545-644  
 August, 645-740

September, 741-804  
 Supplement 2, 805-930  
 October, 931-1010  
 November, 1011-1090  
 December, 1091-1170

# AUTHOR INDEX 1976

Miller, Leon L., 865-871  
 Miller, Max, \*352, 404-407, 554-560, 561-565  
 Miller, Ralph E., \*387  
 Mincey, E., \*343  
 Mintz, Daniel, \*338  
 Mirkovitch, V., \*795-796  
 Mitchell, Marvin L., \*538-539  
 Mitsuhashi, O., \*316  
 Mitton, J., \*328  
 Mitzkat, H.J., \*354  
 Miwa, Ichitomo, 574-579  
 Miyamoto, S., \*383  
 Miyamoto, Yoshikatsu, 961-968  
 Mobley, P.W., \*361  
 Moeller, Ted, \*350  
 Mogensen, Carl Erik, 872-879  
 Mok, Ching, 96-100  
 Molenaar, Donald M., 880-883  
 Molitch, M.E., \*366  
 Molnar, I.G., 56-64, \*338, \*798  
 Monaco, M.E. \*380  
 Montes, A., \*369  
 Montgomery, D.A.D., \*323  
 Moore, Edward W., \*538  
 Moorhouse, J.A., \*372  
 Moossa, A.R., \*391  
 Morin, D., \*366  
 Morita, Soichiro, 1018-1025  
 Moss, Jonathan, 198-201, \*1082-1083  
 Mouratoff, George J., \*377  
 Moxley, Richard T., 128-135, \*317  
 Muggeo, Michele, 408-419  
 Mullen, Yoko S., 56-64, \*338, \*798  
 Munger, Bryce L., \*327, \*377, 434-443  
 Munichoodappa, C., \*378  
 Murphy, James J., \*796  
 Murphy, M., \*380  
 Murray, F.T., \*333  
 Murray, W.K., \*384  
 Murthy, D.Y.N., \*378  
 Murthy, V.K., \*378

## N

Nabarro, N.D.N., \*634  
 Naber, Stephen P., \*346, 484-493, 667-672  
 Nafz, Mary Ann, 173-179  
 Nagai, Katsuya, \*337  
 Nair, Raghavan M.G., \*347, 826-831  
 Najarian, John S., \*349, \*357, \*376, 709-712, 785-795, \*796, \*798, 1123-1128  
 Naji, A., \*338  
 Nakagawa, Sachiko, 420-427  
 Nakajo, Mona, 811-819  
 Nakhooda, A.F., \*378

Napoli, Elena, \*634  
 Neef, M.A., \*534  
 Neff, R., \*637  
 Nelson, D.M., \*379  
 Nelson, P.G., \*236  
 Nelson, R.L., \*325  
 Neubauer, B., 6-10, \*1083  
 Neufeld, N.D., \*379  
 Neuhaus, Günter A., 586-594  
 Neville, David M., Jr., \*158, \*315, \*1006, \*1162, \*1162-1163, \*1163-1164  
 Newborg, Barbara C., \*472-473  
 Newman, Timothy, \*324  
 Newton, William T., \*796  
 Ng, Frank M., 413-419  
 Nichols, William K., 614-622  
 Nielsen, O. Vagn, 752-757  
 Niki, Atsushi, 574-579  
 Niki, Hatsumi, 574-579  
 Nikkilä, Esko A., \*735  
 Nishi, Nozomu, \*471  
 Nissley, S. Peter, \*1005, \*1006  
 Nitowsky, Harold M., 420-427  
 Nizet, A.H., \*327  
 Noble, R.E., \*358  
 Noe, Bryan D., \*156  
 Nonpoggi, D., \*327  
 Noreen, H., \*336  
 Norwich, K.H., \*316-317  
 Nosadini, Romano, 408-419  
 Notkins, Abner Louis, 190-197  
 Nuttall, Frank Q., \*340, \*372  
 Nyhan, William L., \*537

## O

Oakley, Nigel W., \*537-538  
 Oase, Roger, \*536  
 Oates, J.A., \*328  
 O'Donnell, J.J., 24-28  
 O'Donovan, C.J., \*358  
 O'Dorisio, T.M., \*360  
 O'Gara, P., \*234  
 Ogasawara, Saburo, \*76  
 Ohgawara, Hisako, \*379  
 Okas, Sirje, 1106-1109  
 Olding, Lars B., \*472  
 Olefsky, Jerrold M., \*76, \*156, \*317, \*321, \*328, 673-678, 741-747, 1154-1162, \*1163, \*1165  
 Olson, Norman D., \*379  
 Onodera, Takashi, 190-197  
 Oppermann, W., \*383  
 Orawski, A.T., \*335  
 Orci, L., \*344  
 Orloff, Marshall J., \*797  
 Orskov, H., \*538, \*1085

Osborne, C.K., \*380  
 Ostman, Jan, \*796  
 Otto, H., \*370  
 Owen, O.E., \*341  
 Oyer, David, \*380

## P

Pace, C., \*380  
 Pace, W., \*360  
 Padula, R., \*349  
 Page, M. McB., 90-95  
 Pagliara, Anthony S., 111-115, \*156-157, \*391, 733-734, \*1083-1084  
 Pagurek, B., \*316-317  
 Palazzolo, Marjorie, \*386  
 Pallavicini, Maria G., 614-622  
 Pallotta, J., \*388  
 Palmer, Jerry P., \*315, \*317, \*326, \*340  
 Palotay, James L., \*367  
 Palumbo, G., \*366, 545-549  
 Palumbo, P.J., \*346, \*371, 566-573, 880-883  
 Pandolfi, Maurizio, 807-810  
 Papadimitriou, P., \*358  
 Papadopoulos, G., \*369  
 Papier, Cheri M., \*76  
 Park, Byung N., \*155  
 Partin, J.C., \*355  
 Parving, Hans-Henrik, 884-889  
 Patel, Dhanooprasad G., \*318  
 Patterson, Roy, \*75  
 Paulsen, Elsa P., \*334, 890-896  
 Paulshock, Bernadine Z., \*374  
 Pearse, C.T.E., \*474  
 Peavy, D., \*366  
 Peeler, Deenie, \*333  
 Pehlevanian, M., \*373, \*375  
 Pei, Eva, \*371  
 Pek, S., \*635, 764-770  
 Penhos, J.C., \*327  
 Peracchi, M., \*538  
 Perez, G., \*317-318  
 Permutt, M. Alan, \*333, 719-733, \*733  
 Perrino, P.V., \*372, 1031-1040  
 Perry, Helen R., \*350  
 Peschel, Ruth L., \*472-473  
 Peterson, Charles M., 230-232  
 Peterson, Gregory E., 650-660  
 Peterson, Lance, 72-74  
 Petrack, B., \*380  
 Pezzino, V., 167-172  
 Phelps, Richard L., \*317, \*324  
 Phillips, Lawrence S., \*335, 516-527, \*1005  
 Piccardo, M., \*381  
 Pictet, R., \*381  
 Pildes, Rosita S., 428-431

## DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
 February, 81-160  
 March, 161-240  
 April, 241-320  
 Supplement 1, 321-396

May, 397-476  
 June, 477-544  
 July, 545-644  
 August, 645-740

September, 741-804  
 Supplement 2, 805-930  
 October, 931-1010  
 November, 1011-1090  
 December, 1091-1170



# AUTHOR INDEX 1976

Pilkis, S.J., \*331  
Pimstone, B.L., \*75  
Pipeleers, Daniel G., 1041-1051  
Pipeleers-Marichal, Miriam A., 1041-1051  
Pi-Sunyer, F. Xavier, \*381  
Plonk, James W., \*536  
Podolsky, Stephen, \*381  
Podskalny, Judith M., 250-255  
Pohl, S.L., \*382  
Polak, J.M., \*474  
Polosa, P., 167-172  
Pommer, Ingeborg, 32-43  
Pontiroli, A.E., \*377  
Poole, Barbara L., \*337  
Popescu, I., \*316-317  
Porte, Daniel, Jr., \*234-235, \*323, \*345, \*534, \*1084  
Porter, John C., \*1082  
Posner, Norman A., \*157  
Potts, G.O., \*328  
Pozefsky, Thomas, 128-135, \*317, \*539  
Poznanski, N., \*382  
Poznanski, W.J., \*382  
Pozza, G., 223-226  
Prevot, Claude, \*1007  
Price, J. Wade, 1110-1117  
Prout, Thaddeus E., \*347, \*539  
Pupo, Armando A., 161-166  
Pykalisto, O.J., \*634  
Pyke, David A., \*236, \*318

## Q

Quickel, K.E., \*341  
Quigley, Carol, \*338

## R

Rabinovitch, A., \*316  
Rabinowitz, D., \*328  
Rabkin, Ralph, \*382  
Rabuzzo, Agata M., \*634  
Radziuk, J., \*332  
Rahemtulla, Firoz, 450-458  
Raizes, G.S., \*324  
Rannels, Stephen R., \*333  
Ranney, Helen M., \*318  
Rappaport, Raphael, \*1007  
Rasio, E., \*382  
Raskin, Philip, \*157, 227-229, \*341, \*352  
Ratner, Susan, \*381  
Ravazzola, M., \*323, \*376  
Rayfield, Elliot J., \*157, \*383, 623-631  
Read, Raymond C., \*536, \*733  
Reaven, Gerald M., \*76, \*156, \*328, \*383, 673-678, 741-747, \*1165

Recant, L., \*327, \*372, 1031-1040  
Rechler, Matthew M., 250-255  
Reckard, C.R., \*338  
Reddi, A.S., \*383  
Reddy, W.J., \*351  
Reemtsma, Keith, \*369, \*797, 944-948  
Reich, Theodore, \*734  
Reinhard, D., \*383  
Reinwein, D., \*354  
Reisner, Solomon, \*373  
Reitano, G., \*366, 545-549  
Reitsma, W.D., 241-244, 245-249  
Renner, Rolf, \*370  
Reschini, E., \*538  
Reuss, W., \*383  
Reynolds, W. Ann, \*386  
Rhodes, Buck A., 307-314  
Risteli, Juha, 1066-1070  
Ritts, Roy E., Jr., 880-883  
Rivier, Jean, \*535  
Robert, M., \*637  
Roberts, Mary, \*75  
Robertson, Giles M., Jr., \*538  
Robertson, R. Paul, \*323, \*384, \*1084  
Robinson, A., \*343  
Robinson, R.P., \*342  
Robison, G. Alan, \*357  
Robles-Valdes, Carlos, \*330  
Robolledo, Oscar, \*473  
Rodman, Harvey M., \*538  
Rodvein, Robert, \*156  
Roggeveen, A.E., \*366  
Roheim, Paul S., 509-515  
Roncone, A., \*368  
Root, Allen W., 989-993  
Root, M.A., \*326  
Rose, J.C., \*155  
Rosenbloom, Arlan L., \*636-637  
Rosenqvist, Urban, 580-585  
Rosensweig, Norton S., \*75  
Rosenthal, M., 24-28  
Rosenzweig, J., \*332  
Ross, Brian D., \*382  
Ross, Michael E., 190-197  
Rossini, Aldo A., 202-206, \*317, \*344, \*384, 595-603  
Roth, C., \*75-76  
Roth, Jesse, \*158, \*315, \*321, \*348, \*636, \*1006, \*1162, \*1163, \*1163-1164, \*1165  
Rowe, D.W., \*336  
Rowe, J.N., \*332  
Rowe K., \*371  
Rowold, Edwin, 604-613  
Rubenstein, Arthur H., \*317, \*318, \*329, \*365, \*536, \*635  
Rubinstein, D., \*332  
Rudd, B.T., 975-977

Ruderman, N., \*332, \*375  
Rushforth, Norman B., 404-407  
Ryan, Jerome R., \*236-237

## S

Saathoff, J., \*334, \*378  
Sacca, L., \*317-318  
Sagel, Julius, \*347, 826-831  
Saibene, V., 223-226  
Sakurai, Hideo, \*236  
Salel, A.F., \*537  
Sandborn, E., \*382  
Sanders, M.E., \*342  
Sandy, K.C., \*235-236  
Santiago, J.V., \*347, \*1083, \*1083-1084  
Sarji, Kay E., \*347, 826-831  
Sato, Haruko, \*471  
Savage, Peter J., \*384  
Savoie, J.-Y., \*357  
Sawin, Clark T., 202-206, \*538-539  
Sayler, D.F., 81-89  
Schade, David S., \*157, \*330, \*536, 978-983  
Schade, R., \*637  
Schally, Andrew V., \*471, 1031-1040  
Scharp, David W., \*796  
Schersten, Tore, \*236  
Schmid-Schönbein, H., 897-902  
Schmitt, R.V., 180-189, \*798  
Schneider, Bruce, 260-267  
Schneider, Stephen H., \*341, \*352  
Schneider, Victor, 955-960  
Schoenbaum, S., \*359  
Schubert, W.K., \*355  
Schucher, R., \*316  
Schultz, R.D., 81-89  
Schultz, T.A., \*340, \*384  
Schumacher, O. Peter, 1110-1117  
Schwartz, Alan L., 1118-1122  
Schwartz, Herbert C., 1118-1122  
Schwartz, Robert, 1118-1122  
Schwartzkopf, Wolfgang, 586-594  
Schwarz, Daniele, \*540  
Sclar, Elliott, \*381  
Scott, Edward M., \*377  
Scrimshaw, Nevin S., 494-504  
Searle, G., \*385  
Sehlin, Janove, 450-458  
Seino, Yutaka, 961-968  
Sekso, Mladen, \*734  
Selawry, Helena, \*70  
Selby, Mark, \*316, \*797-798  
Sener, Abdullah, \*345  
Senske, B., \*361  
Service, F.J., \*529  
Setchfield, James, \*535

## DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
February, 81-160  
March, 161-240  
April, 241-320  
Supplement 1, 321-396

May, 397-476  
June, 477-544  
July, 545-644  
August, 645-740

September, 741-804  
Supplement 2, 805-930  
October, 931-1010  
November, 1011-1090  
December, 1091-1170

- Seyer-Hansen, K., \*538  
 Shah, Suresh D., \*347, \*1083  
 Shakelford, R., \*385  
 Shapiro, Nadin, \*736  
 Shapiro, Shelley, \*474  
 Sharp, C., \*385  
 Sharp, Geoffrey W.G., \*374  
 Shaw, William A.S., \*539  
 Sheikholislam, Bagher M., 650-660, 661-666  
 Sherman, Herbert, 297-306  
 Sherman, Mindy, 494-504  
 Sherwin, Robert S., \*76, \*323, \*332, \*539, 776-784, 1091-1099  
 Sheth, K.J., \*370  
 Shibata, Atsumi, 667-672  
 Shimazu, Takahi, \*76  
 Shipp, J.C., \*378  
 Short, Patricia A., \*1005  
 Shroyer, L.A., \*387  
 Siegel, Barry A., \*733  
 Siegel, Michael E., 307-314  
 Sievers, Maurice L., 528-531  
 Sievertsson, Hans, \*1006  
 Silberberg, Ruth, 477-483  
 Silbert, Cynthia K., 202-206, \*538-539  
 Sill, Allan J., \*351  
 Silverberg, A.B., \*347  
 Silverstone, Felix, \*157  
 Simmons, R.G., \*349  
 Simmons, Richard L., \*349, 709-712  
 Sinclair-Smith, B.C., \*341, \*358  
 Singh, Harbhajan, \*348  
 Singh, Sant P., \*318, \*385  
 Siperstein, M.D., 24-28  
 Sirinek, K.R., \*360  
 Sizemore, Glen W., \*538  
 Sizer, Jack, 494-504  
 Sjostrom, Lars, \*236  
 Skyler, Jay S., \*472-473  
 Slama, G., 81-89, \*385  
 Slonim, A.E., 216-222  
 Slovik, D.M., \*326  
 Slowman, S.D., \*331  
 Sluiter, W.J., 241-244, 245-249  
 Smith, L.M., \*537  
 Smith, Phillip H., \*340  
 Smith, Robert M., \*321, \*379  
 Smith, S.S., \*327, 1031-1040  
 Smith, Stephen R., \*539  
 Smith, Ulf, \*236  
 Smythe, P., \*471  
 Sneed, D.S., \*1006  
 Snyder, Gary, \*386  
 Soeldner, J. Stuart, \*155, \*317, \*335, \*364, 903-908  
 Solano, Alberto, 268-274  
 Soll, Andrew H., \*158, \*1162-1163  
 Solomon, Solomon S., \*77, \*386  
 Soltes, Miljenko, \*734  
 Soman, V., \*332  
 Soret, M.G., \*390  
 Sorge, Franco, 586-594  
 Sparks, John W., \*539  
 Spaulding, Duane R., \*154  
 Specht, Bernd U. von, \*370  
 Spencer, E.M., \*339  
 Spencer, M., \*340  
 Spergel, Gabriel, \*474  
 Sperling, M.A., \*366, \*379  
 Spiro, Robert G., 909-913  
 Sprague, Randall G., 632-633  
 Spritz, Norton, \*348  
 Squatrito, S., 167-172  
 Srikant, C.B., \*326  
 Stacpoole, Peter W., \*328, \*363  
 Stadler, Jona, \*736  
 Stambaugh, John E., \*735  
 Stamler, Jeremiah, 936-943  
 Stamler, Rose, 936-943  
 Standl, E., 914-919  
 Staprans, Ilona, \*363  
 Starman, B.J., \*336  
 Starnes, Willard R., \*337  
 Starr, Jerome I., \*318, \*536  
 Stauffacher, W., \*376  
 Steffens, A.B., \*77  
 Steffes, Michael W., \*349, \*376, \*796, \*798, 850-857, 1123-1128  
 Steiner, Alton L., 256-259  
 Steiner, D.F., \*343, \*379  
 Stenger, Richard, \*327  
 Stenson, W., \*333  
 Stephenson, Steve R., 650-660  
 Stewart, M., \*348  
 Stifel, Fred B., \*75  
 Stober, J.A., \*342  
 Stolz, Kathleen, 307-314  
 Storck, L. Gunnary, \*797  
 Stout, C., \*349  
 Strack, Inge, 51-55  
 Stranahan, P., \*386  
 Straus, Eugene, 260-267  
 Stuhlman, Robert A., 444-449  
 Sturdevant, Richard A.L., \*154  
 Stutz, S., \*343  
 Sun, A.M., \*339  
 Sussman, Karl E., \*386  
 Sutherland, David E.R., \*349, \*376, 785-795, \*796, \*798, 1123-1128  
 Sweedloff, Ronald S., \*734-735  
 Sweeney, P.D., \*355  
 Switz, Donald M., \*538  
 Szabo, Andrew J., \*158  
 Szabo, Olga, \*158  
 Szakmary, Gary A., \*390  
 T  
 Taborsky, Gerald J., Jr., \*322  
 Tausch, H., \*637  
 Tai, T.-Y., 764-770  
 Takacs, Frank, \*367  
 Takoaka, Yoshiro, \*322  
 Täljedal, Inge-Bert, 450-458  
 Taminato, Tomohiko, 961-968  
 Tan, Meng H., \*155  
 Tancredi, Robert G., 128-135, \*317  
 Taradash, Michael R., \*158  
 Taskinen, Maya-Riltta, \*735  
 Taslitz, Norman, \*322  
 Taswell, H.F., \*371  
 Tato, Luciano, \*1007  
 Tattersall, Robert B., \*318, \*635  
 Taunton, O. David, \*75  
 Taylor, C.I., \*635  
 Taylor, Ruth, \*356  
 Tchobroutsky, Georges, 463-469  
 Terpstra, P., 245-249  
 Terry, Boyd, \*357  
 Thiene, P., \*383  
 Thomas, Katherine P., \*350  
 Thomas, L.J., 81-89  
 Thompson, Bernard W., \*536, \*733  
 Thompson, Theodore, 122-127  
 Thurston, Jean Holowach, \*387, 758-763  
 Tiengo, Antonio, 408-419  
 Tobin, Ellis H., \*157  
 Tobin, Jordan D., 128-135, \*317, \*324  
 Tobin, R.B., \*354  
 Tompkins, C., \*373  
 Toplick, Richard S., \*75  
 Tountas, C., \*358, \*368  
 Townsend, John F., 444-449  
 Traisman, H., \*375  
 Trus, M.D., \*346  
 Tsalikian, Eva, 24-28, 65-71, \*156, \*340, \*387, 955-960  
 Tucker, Dale C., \*735  
 Tucker, Thomas S., \*365  
 Turcotte, Jeremiah G., \*795  
 Turnell, D., \*471  
 Turner, John L., \*336  
 Turner, Ronald, \*386  
 Tuttlebee, J.W., \*471  
 Twiest, Melvin W., \*795  
 Tyler, Jean M., \*387  
 U  
 Underwood, Louis E., \*1005  
 Unger, Roger H., 136-151, \*157, 227-229, \*236, \*341, 404-407, \*539-540, \*637  
 Ursich, Milani J.M., 161-166

## DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
 February, 81-160  
 March, 161-240  
 April, 241-320  
 Supplement 1, 321-396

May, 397-476  
 June, 477-544  
 July, 545-644  
 August, 645-740

September, 741-804  
 Supplement 2, 805-930  
 October, 931-1010  
 November, 1011-1090  
 December, 1091-1170

Uthne, Knut, \*1006

## V

Vacchini, Marcos, \*352  
 Vale, Wylie, \*356, \*535  
 Valerio, David, \*474  
 Valverde, Isabel, \*539-540, \*637  
 Van Ameringen, Marie-Reine, \*1082  
 Vandenhoff, G.E., \*332  
 Van Obberghen, E., \*321  
 van't Laar, A., \*637  
 VanWyk, Judson J., \*1005  
 Varandani, Partab T., 173-179, \*387  
 Vasconcellos, Francisco G., 161-166  
 Vasselli, Joseph R., \*390  
 Veech, R.L., \*354  
 Velasco, C.A., \*383  
 Verspohl, E., \*337  
 Vidyasagar, D., 428-431  
 Vigneri, R., 167-172  
 Villalpando, Salvador, \*334  
 Villarreal, Arnold, 29-31  
 Vinicor, Frank, \*388  
 Vinik, A.I., 11-15  
 Vinten, Jørgen, \*1164  
 Vitiello, Michael V., \*390  
 Voina, Sandra J., \*1005  
 Volger, E., 897-902  
 Volk, Bruno W., 713-716  
 Volk, Thomas L., 650-660  
 Voyles, N.R., \*372, 1031-1040  
 Vranic, Mladen, \*327, \*333, 1018-1025

## W

Wahren, John, \*154, \*323, 1091-1099  
 Waid, Thomas H., \*388  
 Walike, B.C., \*340  
 Waller, B.F., \*346  
 Wallin, J.D., \*384  
 Walsh, M.F., \*377  
 Walter, Robert M., \*315, \*388  
 Wands, J.R., \*318  
 Wapnir, Irene L., \*363  
 Wapnir, Raul A., \*363  
 Warden, Glen, \*797  
 Warren, Kenneth S., \*538  
 Warren, Shields, \*344

Warth, M.R., \*369, \*388  
 Watkins, D., \*389  
 Watkins, P.J., 90-95, 748-751  
 Watson, Nancy M., \*342  
 Weaver, Daniel C., \*345  
 Weaver, J.A., \*323  
 Weber, C., \*389  
 Weber, C.J., 944-947  
 Weber, Collin, \*797  
 Weber, F. Thomas, \*636-637  
 Weigand, Dorothy A., \*333  
 Weil, Richard, III, \*797  
 Weinges, K.F., \*377  
 Weinkove, E., \*75  
 Weir, Gordon C., 275-282, \*326  
 Weiser, C., \*347  
 Weiss, Stuart, \*1085  
 Weldon, Virginia V., 111-115, \*733-734  
 Wellmann, Klaus F., 713-716  
 Wendorff, H., \*390  
 Wentworth, S.M., \*325, \*326  
 Weringer, Elora J., 811-819  
 Werner, P.L., \*326  
 West, K.M., \*342, \*389  
 Westberg, N. Gunnar, 920-924  
 Westermarck, Bengt, \*1096  
 Westman, Jan, \*796  
 Wexler, M., \*316  
 Wharton, C., \*355  
 Whedon, G.D., \*322  
 White, Robert L., 307-314, \*322  
 Whitefoot, R., \*538  
 Whorton, E., \*349  
 Widrich, Warren C., 202-206  
 Wiegelmann, W., \*354  
 Wieland, Ralph G., 1110-1117  
 Wiggan, Gloria, \*356  
 Wilkins, S.D., 1031-1040  
 Wilkinson, Jack S., \*355  
 Williams, G., \*389  
 Williams, G.R., \*349  
 Williams, J.W., 975-977  
 Williams, Robert H., \*1082-1083  
 Williams, T. Franklin, \*342  
 Williamson, Joseph R., 230-232, 604-613, \*635, 925-927  
 Willms, B., \*373  
 Wilson, Elizabeth T., \*350  
 Wilson, Walter R., \*371, 880-883

Wingfield, Barbara A., \*1004-1005  
 Winter, R., \*375  
 Wise, F., \*343  
 Wissler, Robert W., 207-215  
 Witters, Lee A., \*389  
 Wiznitzer, Theodor, \*736  
 Woodrow, J.C., \*236  
 Woods, John E., \*796  
 Woods, Stephen C., \*340, \*390  
 Wright, A.D., 975-977  
 Wright, R.L., \*390  
 Wyse, B.M., \*358, \*390

## Y

Yalow, Rosalyn S., 260-267, \*1005-1006  
 Yanaihara, N., \*329  
 Yardley, J.P., \*353  
 Yee, E., \*634  
 Yesus, Yohannes W., 444-449  
 Yingvorapant, N., \*390  
 Yip, Cecil C., \*327, 1018-1025  
 Yodaiken, Ralph E., 928-930  
 Young, Harvey S., 516-527  
 Young, James B., \*318, \*391  
 Younger, M.D., \*359  
 Yunis, E.J., \*336, \*356

## Z


Zachariou, N., \*368  
 Zahnizer, Lynne, \*384  
 Zamel, N., \*333  
 Zanoboni, Alberto, \*540  
 Zanoboni-Muciaccia, Wanda, \*540  
 Zarif, Mehr, 428-431  
 Zawalich, Walter S., \*391  
 Zeidler, A., \*391  
 Zelis, R., \*537  
 Zermatten, A., \*367  
 Ziegler, M.M., \*338  
 Ziegler, Michael G., \*1083  
 Zimmerman, Clarence E., \*316, \*797-798  
 Zimmermann, H., \*354  
 Zingg, W., \*325, \*333, 691-700  
 Zinman, N., \*333  
 Zjadic, Vanjo, \*734  
 Zuckerman, L., \*234

## DIABETES: VOLUME 25 (1976) PAGE NUMBERS BY ISSUE

January, 1-80  
 February, 81-160  
 March, 161-240  
 April, 241-320  
 Supplement 1, 321-396

May, 397-476  
 June, 477-544  
 July, 545-644  
 August, 645-740

September, 741-804  
 Supplement 2, 805-930  
 October, 931-1010  
 November, 1011-1090  
 December, 1091-1170









**American Diabetes Association, Inc.**

**600 Fifth Avenue**

**New York, N.Y. 10020**

